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Abstract  
A  phylogenetic  approach  combining  HIV  pol  sequences  with  laboratory  and 
clinical data was undertaken to explore HIV transmissions between men who 
have  sex  with  men  (MSM).   Combining  putative  transmission  events 
(reconstructed  through  phylogenetic  analyses  of  pol  sequences)  with  clinical 
(e.g.  viral  load)  and  diagnostic  (e.g.  recently-acquired  infection)  data  can 
enhance understanding of HIV transmission more than can be gleaned from 
each individual source. 
  
The thesis:  assessed the consistency of phylogenetic reconstructions of HIV 
transmission events; explored transmissions from recently HIV-infected MSM at 
diagnosis  and  critiqued  such  analyses;  and  ascertained  which  groups  of 
diagnosed HIV-infected MSM are generating HIV transmissions.         
  
Sensitivity  analyses  demonstrated  that  phylogenetic  reconstructions  of 
transmission  events  were  80%  consistent  as  sample  sizes  were  varied.   
Previous phylogenetic reconstructions overestimated transmission from recently 
HIV-infected  MSM  through  failing  to  recognize  that  this  infection stage  is 
transitory. Comparison of infection dates between recently HIV-infected MSM 
involved in transmission events revealed only half of the transmissions were 
generated during recent infection.  Through allowing infection stage (and other 
markers  of  transmission  risk)  to  reflect  the  course  of  HIV  infection  it  was 
established  that  the  recently  HIV-infected  have  a  transmission  risk  of  3.04 
(compared to the chronically HIV-infected population). Transmission rates were 
elevated among the untreated population; 72% (28/39) were generated from Alison Brown – 2009 
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treatment-naïve  MSM  and  23%  (9/39)  from  MSM  interrupting  treatment.  
Overall,  69%  (27/39) of  transmissions  occurred  from  MSM  with  CD4  counts 
>350 cells/mm
3. 
  
BHIVA guidelines recommend treatment discussions start when patients‟ CD4 
counts reach 200-350mm
3.  This work contributes to the debate on the public 
health  benefit  of  treating  all  HIV-diagnosed  individuals,  regardless  of  clinical 
need.   Behavioural  interventions  need  to  increase  awareness  of  recent  HIV 
infection,  and  the  elevated  transmission  risk  from  untreated  populations.  
Phylogenetics  has  enormous  potential  to  contribute  to  public  health,  but 
remains in its infancy;   methods need rigorous assessment and results require 
cautious interpretation.    Alison Brown – 2009 
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1. Chapter One: Introduction 
 
 
 
 
 
This chapter provides an introduction to HIV infection.   The UK HIV epidemic is 
then  described  alongside  a  summary  of  current  transmission  and  prevention 
strategies.      The  basic  concepts  of  phylogenetics  are  introduced  within  the 
context  of  how  they  can  be  applied  to  enhance  understanding  of  HIV 
transmission.  The gaps in the research are outlined.  The chapter ends with the 
research objectives and a description of the thesis structure.    
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1.1.  About HIV 
1.1.1  Human immunodeficiency virus 
Infection  with  Human  Immunodeficiency  Virus  (HIV)  is  fatal  if  left  untreated.   
HIV infection causes progressive deterioration of the host‟s immune system to 
levels that  make  an  individual  susceptible  to  the  development  of  a  range of 
opportunistic  infections  –  otherwise  known  as  AIDS  (Acquired  Immune 
Deficiency Syndrome) (Adler 1987).  HIV is transmitted from human to human: 
through sex (anal, vaginal and oral); vertically (from mother to child); through 
injecting drug use; and from blood contact with contaminated blood products.  
Without treatment, HIV-infected individuals typically survive for a median of 10 
years following infection (Porter, Babiker et al. 2003).    
 
Whilst antiretroviral therapy (ARV) treatment has transformed HIV from a fatal 
to a chronic infection, treatment is expensive and only effective provided an 
assiduous  routine of medication is followed indefinitely (Palella, Delaney et al. 
1998). ARVs suppress, but do not eradicate the virus. Viral resistance to ARVs 
can develop, increasing the risk of HIV-related death (Beinker, Mayers et al. 
2001; Zaccarelli, Tozzi et al. 2005).  Therefore HIV remains a serious, life-long 
infection. 
1.1.2  The global HIV epidemic 
The  first  AIDS  cases  were  recognized  in  the  early  1980s  (Berridge  1996) 
among men who have sex with men (MSM) in the United States (Brennan and 
Durack 1981) and Western Europe (Dubois 1981).  Further cases indicated that 
AIDS could also be acquired through injecting drug use (Masur, Michelis et al. Alison Brown – Chapter One 
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1981),  from  mother  to  child  (MMWR  1982)  and  through  heterosexual  sex 
(Clumeck, Sonnet et al. 1984).   Subsequently, AIDS was found within Africa 
(Kamradt, Niese et al. 1985; Mann, Bila et al. 1986).   HIV itself was isolated in 
1983 (Barre-Sinoussi, Chermann et al. 1983), and found to be the cause of 
AIDS (Blattner, Gallo et al. 1988).  
 
Almost  30  years  later,  an  estimated  33  million  people  are  living  with  HIV 
worldwide (Figure 1.1), with the virus responsible for approximately 25 million 
cumulative deaths (UNAIDS 2008).  In 2007, it was estimated that 2.7 million 
people  became  infected  with  HIV  and that  two  million  died from  HIV-related 
illnesses. Sub-Saharan Africa remains the focus of the global HIV epidemic.  
This region accounts for over two-thirds of the people living with HIV, and 75% 
of  HIV-related  deaths  (UNAIDS  2008).      Within  sub-Saharan  Africa,  HIV  is 
primarily transmitted heterosexually, although transmission between MSM also 
is becoming recognized (van Griensven, de Lind van Wijngaarden et al. 2009).  
Elsewhere, the key groups affected by HIV remain MSM, injecting drug users 
and  heterosexual  migrants  who  acquired  their  infection  within  sub-Saharan 
Africa. 
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Figure 1.1: Estimated global HIV prevalence among individuals aged 15-49 
 
 
Source: adapted from UNAIDS (UNAIDS 2008) Alison Brown – Chapter One 
14 
1.1.3  Genetic diversity of HIV  
Two types of HIV have been distinguished to date:  HIV-1 and HIV-2. HIV-1 
accounts  for  the  majority  of  infections  globally,  whilst  HIV-2  is  the  more 
prevalent in west African countries (Poulsen, Aaby et al. 1993).   HIV-1 can be 
further  categorized  into  three  groups:  M  (main),  N  (new)  and  O  (out-group) 
based  on  their  genetic  similarity  (Sharp,  Bailes  et  al.  2001).    Group  M  is 
responsible  for  the  most  global  HIV  infections.    Groups  O  and  N  remain 
restricted to West-Central Africa (Gurtler, Zekeng et al. 1996).  Group M viruses 
are further subdivided into nine subtypes (A-K) due to the substantial genetic 
diversity within this group (Louwagie, McCutchan et al. 1993).  There are also 
mosaics of subtypes in circulation, named as “circulating recombinant forms” 
(CRFs) and “unique recombinant forms” (URFs) according to their frequency.  
HIV subtypes are associated with geographic areas and specific risk groups. On 
a  global  scale,  the  most  prevalent  HIV-1  clades  are  subtypes  C  (47%),  A 
(27.2%), B (12.3%), and D (5.3%) (Osmanov, Pattou et al. 2002).  HIV infection 
has  long  been  associated  with  subtype  B  in  Western  Europe  and  North 
America,  and  most  frequently  found  among  MSM  and  injecting  drug  users 
(IDUs).     For the rest of this thesis, “HIV” refers to “HIV-1”. 
1.1.4  Life cycle of HIV 
This section describes the life cycle of HIV and is summarized in Figure 1.2.  
Once the virus has been transmitted into the host‟s body, HIV binds to CD4 
receptors on the host‟s CD4+ T-lymphocyte cells (hereafter called CD4 cells) 
(Turner and Summers 1999). These cells are a sub-class of T-lymphocytes and 
have  a  key  role  in  host  immunity.    Supplementary  interaction  with  two  co-Alison Brown – Chapter One 
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receptors allows the virus to fuse with host‟s cell membrane and enter the CD4 
cell.    The  HIV-RNA  (ribonucleic  acid)  is  converted  into  HIV-DNA 
(deoxyribonucleic  acid),  generating  a  provirus,  through  the  release  of  the 
reverse transcriptase enzyme.  
Figure 1.2: Life cycle of HIV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
    
Source: adapted from 
http://aidsinfo.nih.gov/contentfiles/HIVLifeCycle_FS_en.pdf)   Alison Brown – Chapter One 
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The HIV-DNA enters the host cell nucleus where it is integrated into the host‟s 
DNA (facilitated by the integrase enzyme). The provirus can then remain latent 
or be active, generating products for the generation of new virions.  Activation of 
the host cell results in the transcription of integrated viral DNA into messenger 
RNA (mRNA), which is then translated into viral proteins. Amongst these is HIV 
protease, which is required to process other HIV proteins into their functional 
forms. The viral RNA and viral proteins assemble at the cell membrane into a 
new virus, which is then released and capable of infecting another host cell.  
The originally infected host cell dies.   
1.1.5  HIV genome 
The HIV genome consists of approximately 9200 nucleotides of RNA.  The RNA 
contains nine genes encoding for 14 viral proteins (Figure 1.3).   Three of the 
genes are major: gag (encodes for internal structural proteins); env (encodes for 
transmembrane  proteins);  and  pol  (encodes  enzymatic  proteins  e.g.  reverse 
transcriptase (RT), protease (PR), and integrase). The remaining six genes are 
accessory, encoding for regulatory (tat and nef) and auxiliary (vif, nef, vpr and 
vpu) factors. 
 
Figure 1.3: Organization of the HIV-1 genome 
 
The three main genes are shaded: gag; pol; and env.  
Source: adapted from (Watts, Dang et al. 2009) Alison Brown – Chapter One 
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1.1.6  The course of HIV infection 
Following transmission, free virus is released which infect further CD4 cells, in 
turn leading to increased viral load (a measure of how much HIV is in the body). 
As more CD4 cells become targeted, the host‟s immune capability  gradually 
diminishes, leaving the individual susceptible to opportunistic infections.    From 
initial  infection  to  death,  the  course  of  HIV  infection  within  an  untreated 
individual can be summarized into four main stages (Figure 1.4):  
Recently-acquired HIV Infection 
Also known as primary, early or acute infection, recently acquired HIV infection 
(recent infection) describes the first few weeks following infection.  During this 
time,  HIV  is  present  in  blood  serum  and  plasma,  but  a  specific  antibody 
response  may  not  have  been  developed  (Pilcher,  McPherson  et  al.  2002) 
(section  2.3.1).    Consequently,  this period  is  characterized  by  high  levels of 
virus, reaching levels of up to 100 million copies of HIV (RNA/mL). At the same 
time CD4 cell counts temporarily decrease as a result of cell death following 
viral replication.  Blood virus levels are known to peak at around 17 days, with 
semen virus levels peaking at around 30 days following infection (Pilcher, Joaki 
et al. 2007).  Between 40-90% of patients experience symptoms of early HIV 
infection  (Kahn  and  Walker  1998).  Once  an  antibody  response  has  been 
generated by the host, HIV replication is restrained and CD4 cell counts return 
to normal levels.  
Asymptomatic infection 
Asymptomatic or chronic infection describes the period where viral replication is 
restrained  by  the  antibody  response.  The  infected  individual  will  not  usually Alison Brown – Chapter One 
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have clinical symptoms.  Viral replication and CD4 cell turnover remain active, 
but at low levels, and the immune system gradually weakens over time (Ho, 
Neumann et al. 1995).  The time interval between HIV infection to clinical AIDS 
has a median of 10 years, but varies considerably between individuals.  
 
Figure 1.4: Schematic diagram of the typical course of HIV infection    
 
Source: adapted from (Pantaleo, Graziosi et al. 1993) 
Symptomatic/late infection 
As CD4 cells reach very low levels (e.g. under 200 cells/mm
3) patients develop 
clinical  symptoms.  It  is  at  this  stage  that  individuals  become  vulnerable  to 
developing “opportunistic infections” – i.e. infections that do not cause illness in 
individuals with good immunity.  Patients diagnosed with CD4 counts under 200 
cells/mm
3  are described as being diagnosed with late stage infection  (Phillips 
and  Pezzotti 2004).  Such  groups  have  a  higher risk  of  HIV-related  mortality Alison Brown – Chapter One 
19 
(Chadborn, Baster et al. 2005; Chadborn, Delpech et al. 2006) compared with 
those diagnosed at an earlier stage of infection. 
AIDS 
The  host‟s  immune  system  fails  allowing  the  development  of  opportunistic 
infections  (Adler  1987)  –  eventually  leading  to  death.  In  the  absence  of 
treatment, survival time after diagnosis of AIDS is 10-12 months on average.   
The  definition  of  AIDS  includes  one  of  a  number  of  indicator  diseases  in 
persons  with  an  HIV  infection,  including  Kaposi‟s  sarcoma,  extra-pulmonary 
tuberculosis and Pneumocystis pneumonia: 
(http://www.eurohiv.org/reports/report_37/aids_euro_definition_eng.pdf 
accessed 12th August 2009). 
1.1.7  Monitoring disease progression 
Patients may be infected for many years before their HIV infection is diagnosed.  
This  is  because  of  the  long  duration  of  asymptomatic  infection.    The  host‟s 
immune response generates antibodies to HIV which are in sufficient quantity 
for HIV antibody tests to be positive about six weeks following infection (Busch 
and  Courouce  1997).      Recently,  other  diagnostic  tools  have  been  used  in 
conjunction  with  improved  antibody  tests  to  recognize  HIV  as  early  as  two 
weeks following infection (Busch, Glynn et al. 2005).  Diagnostic techniques and 
markers that can recognize HIV during recently acquired infection are described 
in more detail in section 2.3.2.    
 
Once  diagnosed,  two  main  clinical  markers  are  used  to  monitor  disease 
progression: blood CD4 cell counts and viral load.  CD4 cell counts per mm
3 of Alison Brown – Chapter One 
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the blood provide an indication of how well an individual‟s immune system is 
functioning,  since  CD4  cells  gradually  decline  over  the  course  of  an  HIV 
infection  (Figure  1.4).    In  2003,  guidelines  recommended  that  an  individual 
should  begin  ARV  treatment  once  the  CD4  cell  count  drop  to  under  200 
cells/mm
3 (Pozniak, Gazzard et al. 2003).  In 2008, guidelines were updated to 
recommend treatment discussions should start sooner, once CD4 counts reach 
between 200-350 cells/mm
3 (Gazzard 2008).     
 
Viral load measures how much HIV is in the body and increases as the host‟s 
immune  function  decreases  (Figure  1.4).  It  is  strongly  associated  with 
transmission risk: the higher the viral load, the higher the risk of transmitting 
virus per exposure (Castilla, Del Romero et al. 2005) (section 1.1.10).    
1.1.8  Antiretroviral therapy (ARVs) 
ARV  drugs  prevent  HIV  infection  causing  progressive  damage  to  the  host 
immune system through inhibiting viral replication and thus clinical progression.   
The drugs inhibit key stages of the HIV lifecycle and are classified accordingly: 
fusion  inhibitors;  reverse  transcriptase  inhibitors;  integrase  inhibitors;  and 
protease inhibitors (Zeniga 2008). 
 
Fusion  inhibitors  block  HIV  from  fusing  to  the  host  cell‟s  membrane.    RT 
inhibitors include  nucleotide  reverse  transcriptase  inhibitors (NRTIs)  and  non 
nucleotide  reverse  transcriptase  inhibitors  (NNRTIs).  Both  work  by  blocking 
reverse transcriptase from transcribing the viral RNA into DNA.  NRTIs compete 
with  nucleotide  analogues  for  incorporation  into  DNA  and  NNRTIs  inhibit 
replication by binding to the active site of reverse transcriptase.  Provirus is Alison Brown – Chapter One 
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prevented from integrating into the DNA of the host cell through the inhibition of 
integrase.    Protease  inhibitors  (PIs)  bind  to  the  active  site  of  PR,  thereby 
preventing the production of viral proteins for the final assembly of new virions.   
 
Since 1996, in North America and Western Europe, the provision of ARVs has 
been widespread.  Patients treated with ARVs have been shown to achieve 
reductions  in  viral  load  to  very  low  levels,  over  prolonged  periods  of  time, 
provided they have good adherence to treatment (Montaner, Reiss et al. 1998; 
Friedland  and  Williams  1999).        The  advent  of  treatment  has  substantially 
reduced  HIV-related  mortality  in  these  settings  (Mocroft,  Vella  et  al.  1998) 
(Palella,  Delaney  et  al.  1998;  Bhaskaran,  Hamouda  et  al.  2008).    However, 
such medication is only successful if followed indefinitely (Palella, Delaney et al. 
1998) and is not effective for all patients due to the adverse side effects (Lucas, 
Chaisson et al. 1999) and the presence of viruses resistant to the treatment 
(Beinker, Mayers et al. 2001).   
1.1.9  HIV drug resistant viruses 
HIV drug resistant viruses contain mutations that reduce the susceptibility of the 
HIV to ARV. ARV inhibits key stages of the HIV replication cycle (Zeniga 2008) 
delaying or even preventing disease progression (Hammer, Eron et al. 2008).  
Consequently, HIV-infected individuals with viruses resistant to ARVs are less 
likely to be treated successfully (Hirsch, Brun-Vezinet et al. 2003), and have an 
increased risk of HIV-related death (Beinker, Mayers et al. 2001), compared to 
those  with  viruses  that  did  not  contain  drug  resistant  mutations    (wild-type 
viruses).   
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Drug resistance to ARV can be “acquired” or “transmitted”. Acquired resistance 
develops following treatment failure in patients with suboptimal adherence to 
ARV.  Transmitted  drug  resistance  occurs  through  infection  with  a  resistant 
strain,  referred  to  as  TDR.    Both  acquired  and  TDR  have  adverse 
consequences for the success of treatment.  However, TDR has the potential to 
reverse the effectiveness of ARV more rapidly (Little, Holte et al. 2002).   The 
difficulties  associated  with  measuring  HIV  drug  resistance  and  definitions  of 
drug resistance are detailed in section 2.5.2. 
1.1.10 Transmission rates from HIV-infected patients. 
Transmission  rates  have  been  estimated  through  analyzing  transmission 
between  monogamous  serodiscordant  couples  (where  one  partner  is  HIV 
positive and the other HIV negative) followed up over time.  The probability of 
transmission per sexual act has been found to be closely correlated to the HIV-
infected partner‟s plasma viral load, and correspondingly, their infection stage 
and treatment status.  Such studies are summarized in Table 1.1. 
 
In  2000,  Quinn  et  al.  (Quinn,  Wawer  et  al.  2000)  first  demonstrated  the 
relationship between plasma viral load and HIV transmission.  Overall, 90 HIV 
negative partners of the 415 heterosexual serodiscordant couples became HIV-
infected over a period of 30 months.  The mean plasma viral load in the HIV 
positive  partner  was  found  to  be  significantly  higher  among  couples  whose 
initially  HIV  negative  partners  became  infected  during  the  study  period 
compared to those where partners remained negative (90,254 copies/mL vs. 
38,029 copies/mL, p=0.01).  Importantly, no transmission was observed within 
couples where the HIV positive partner had a plasma viral load under 1500 Alison Brown – Chapter One 
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copies/mL.  Similar results were later presented by Wawer et al.
 (Wawer, Gray 
et al. 2005) and Gray et al., (Gray, Wawer et al. 2001).  The latter found that, 
out of 43 serodiscordant couples where the HIV positive partner‟s plasma viral 
load was <1700 copies/mL, one initially HIV negative partner became infected. 
 
In  Thailand,  (Tovanabutra,  Robison  et  al.  2002)  it  was  found  that  each  log 
increment in plasma viral load was associated with an 81% increase in the risk 
of  transmission.    No  transmission  occurred  between  17  couples  where  the 
positive  partner  had  a  plasma  viral  load  <1094  copies/mL.    Castilla  et  al. 
(Castilla, Del Romero et al. 2005) studied 393 HIV serodiscordant heterosexual 
couples  between  1991-2003  to  identify  the  proportion  of  transmission  that 
occurred from  ARV-treated patients (specific regimen not detailed). While no 
transmissions occurred when the positive partner was ARV-treated, HIV was 
found to persist in genital secretions.   A review was undertaken of heterosexual 
transmissions  occurring  as  a  result  of  natural  pregnancies  among  62  HIV 
serodiscordant couples in Spain between 1998-2005 (Barreiro, del Romero et 
al. 2006).  All the HIV-infected partners received ARV and their median plasma 
viral load at around conception was <500 copies/mL.  None of the initially HIV 
negative partners became infected.   
 
While the studies indicate minimal transmission among the virally suppressed, it 
is important not to over interpret the results due to the small numbers of HIV 
serodiscordant  couples  followed  up;  this  is  reflected  in  the  upper  95% 
confidence  limits  (Table  1.1).    Additionally,  whilst  no  transmission  occurred 
where  the  positive  partner  was  treated,  the  viral  presence  within  genital Alison Brown – Chapter One 
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secretions  means  the  potential  for  HIV  transmission  cannot  be  discounted.  
Finally, patients fully adherent to ARVs may experience transient low-level viral 
rebound (blips) (Garcia-Gasco, Maida et al. 2008). The transmission risk from 
blips is not clear. 
 
However, the relationship between viral load, treatment and transmission is so 
strong that a recent report controversially suggested that HIV serodiscordant 
heterosexual  couples  may  have  unprotected  sex,  provided  the  HIV-infected 
partner  is  successfully  treated  with  plasma  viral  load  suppressed  to  <40 
copies/mL (Vernazza 2008).  The report has been criticized as inconclusive and 
dangerous,  jointly  by  the  World  Health  Organization  and  UNAIDS 
(http://data.unaids.org/pub/PressStatement/2008/080201_hivtransmission_en.p
df, accessed 12
th August 2009), and the American Centers for Disease Control 
(http://www.cdc.gov/hiv/resources/press/020108.htm,  accessed  12
th  August 
2009).    Additionally,  other  factors  can  increase  the  risk  of  transmission, 
including  the  presence  of  sexually  transmitted  infections  (STIs)  (Wasserheit 
1992) the type of sexual contact (anal, (Lane, Pettifor et al. 2006) vaginal or oral 
(Gilbart, Evans et al. 2004)).   Alison Brown – Chapter One 
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Table 1.1: Summary of studies examining the effect of viral load and/or ARV on sexual HIV transmission between serodiscordant couples 
Author,  year, 
reference 
Study aim  Setting: 
Country, 
Years 
sampled 
Number of HIV 
serodiscordant 
couples  
“Viral  load 
suppression” 
definition  
ARV 
details 
Total  proportion 
of  HIV  
transmissions  
Proportion  of 
transmissions  from  
virally  suppressed/ARV 
compliant  HIV+  partner 
(n/N*, 95% CI)) 
Comments 
Impact of viral load on HIV transmission 
Quinn,  2000,  (Quinn, 
Wawer et al. 2000) 
Examine impact of viral 
load  on  HIV 
transmission 
Rakai, Uganda, 
1994-1998 
415   <1500 copies/mL  Untreated  21.7% (90/415)  0% (0/51, 0-0.07)  76.7%  of  transmissions 
occurred  from  couples 
where  infected  partner 
had a viral load >10,000 
Gray,  2001,(Gray, 
Wawer et al. 2001)  
Calculate probability of 
HIV  transmission  per 
coital act 
Rakai, Uganda, 
1994-1998 
174   <1700 copies/mL  Untreated  21.8% (38/174)  2.3% (1/43, 0.0041-0.12)  Genital  ulceration  and 
viral  load  major 
determinates  of  HIV 
transmission 
Fideli,  2001,(Fideli, 
Allen et al. 2001)  
Compare  biological 
determinants  between 
transmitting  and  non-
transmitting 
serodiscordant couples 
Lusaka,  
Zambia,  1994-
2000 
311 
 
<10,000 copies/mL  Untreated  33.4% (104/311)  15.2% (8/52, 0.08-0.28)  Viral load more important 
determining  factor  in 
female  to  male 
transmission  than  vice 
versa 
Tovanabutra, 
2002,(Tovanabutra, 
Robison et al. 2002)  
Evaluate  association 
between HIV viral load 
and transmission 
Northern 
Thailand1992-
1998 
493  <1094 copies/mL  Untreated  44.2% (218/493)  5.9% (1/17, 0.011-0.27)  STI diagnosis and earlier 
first sex associated with 
transmission 
Wawer,  2005,(Wawer, 
Gray et al. 2005)  
Estimate  rates  of  HIV 
transmission  per  coital 
act 
Rakai, Uganda, 
1994-1999 
235   <3.45 log  Untreated  28.9% (68/235)  0% (0/57, 0-0.63)   Rate  of  transmission 
highest during early- and 
late-stage infection 
Impact of ARVs  on HIV transmission 
Musicco,  1994 
(Musicco,  Lazzarin  et 
al. 1994) 
Determine  effect  of 
ZDV  on  HIV 
transmission 
Italy,  1987-
1992 
436  Not collected  ZDV daily  6.2% (21/436)  9.4% (6/64, 0.044-0.19)  ZDV  used  more 
frequently  among 
patients  with  advanced 
disease 
Castilla,  2005(Castilla, 
Del  Romero  et  al. 
2005) 
Determine  if  ARV  can 
diminish  risk  of  HIV 
transmission  within 
serodiscordant couples  
Madrid,  Spain, 
1991-2003 
393  Not collected  a) No ARV 
1991-1995 
 
b)  ARV 
1999-2003  
a)  7.4  (29/393) 
1991-2003 
b)  0%  (0/52,  0-0.0069) 
1999-2003 
HIV  persisted  in  genital 
secretions  among  ARV 
treated 
Barreiro  (Barreiro,  del 
Romero et al. 2006) 
Review  natural 
pregnancies  among 
HIV  serodiscordant 
couples 
Spain,  1998-
2005 
62  <500 copies/mL  ARV 
(various 
regimens) 
N/A  0% (0/62, 0-0.058)  Length  of  follow-up  not 
specified Alison Brown – Chapter One 
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1.2. HIV in the UK 
1.2.1   The UK HIV epidemic  
In the UK, HIV infection remains a significant public health concern more than 
25  years after the first  AIDS  cases  were  reported  (O'Connor,  McEvoy  et  al. 
1983). An estimated 77,400 people were estimated to be living with HIV in the 
UK in 2007, of whom over one quarter were unaware of their infection (Figure 
1.5).  The largest groups living with HIV in the UK are MSM and heterosexuals 
born in sub-Saharan Africa (HPA 2008).  
Figure 1.5: Estimated number of adults (15-59) living with HIV, UK: 2007 
 
 
 
 
 
 
 
 
 
 
Source: (HPA 2008) 
The number of new HIV diagnoses reported in the UK continues to rise, with 
7,734 new diagnoses reported in 2007. While MSM are the group most affected 
by  HIV  in  the  UK,  over the  last  decade,  the  number of new  HIV  diagnoses 
reported among heterosexuals has exceeded the number reported among MSM 
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(Figure 1.6).  Of the 4260 diagnoses reported among heterosexuals in 2007, 
3300 are thought to have acquired their infection in Africa.  
 
Figure 1.6: Adjusted number of new HIV diagnoses by risk group, UK: 1998-2007 
 
Source: (HPA 2008) 
 
In the UK, ARVs have been widely available as an effective HIV treatment since 
1996 (Montaner, Reiss et al. 1998).  The late 1990s consequently saw a sharp 
decrease in the number of AIDS diagnoses and deaths
 (Figure 1.7). Since this 
time,  the  number  of  deaths  has  remained  stable,  and  the  number  of  AIDS 
diagnoses continued to decline.  This, combined with the rising number of new 
HIV  diagnoses,  means  an  increasing  number  of  people  are  living  with 
diagnosed  HIV  infection  in  the  UK.    In  2007,  there  were  56,556  diagnosed 
patients accessing care in the UK.  This is a three-fold increase since 1998.  
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Figure 1.7: HIV diagnoses, AIDS case reports and deaths in HIV-infected individuals, UK: 
1993-2007 
 
 
 
Of the 56,556 patients living with diagnosed HIV infection and attending, 70% 
(39,556) were prescribed antiretroviral therapy.  Those not receiving treatment 
are  likely  to  be  in  the  early  stages  of  infection  and  have  low  viral  loads.  
However,  in  2007,  among  those  with  severe  immunosuppression  (CD4  cell 
counts <200 per mm3) almost 20% (876/5004) were not on treatment.   
 
 
Source: (HPA 2008) 
1.2.2  Resistance to antiretroviral therapy 
Studies of drug resistance in the UK have found a wide range in the prevalence 
of transmitted (TDR) and acquired drug resistance. This is due to: differences in 
the  definitions  of  drug  resistance  used;  population  sampling,  and  the  time 
between infection and the time the sample was taken for resistance testing (see 
section 2.5.2).  
 
Estimates of the prevalence of TDR among drug naïve patients diagnosed in 
the  UK  have  varied  between  10-20%.  More  recent  data  suggest  that  the 
prevalence  of  TDR  may  be  declining  (Cane,  Chrystie  et  al.  2005; 
UKCollaborativeGroup  2007).    Prevalence  of  TDR  was  measured  at  8%  in 
2004.    However trends  are  difficult  to  interpret,  since  increasing  numbers of 
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patients have their virus tested for resistance mutations at around diagnosis due 
to national recommendations (Pozniak, Gazzard et al. 2003). Consequently, the 
decrease could be a consequence of the changing attributes of the population 
denominator.      
1.2.3  HIV diversity in the UK 
In the UK, subtype B is the most frequent HIV subtype, corresponding to that 
circulating  among  MSM  and  IDUs  in  Western  Europe  and  North  America.  
However, the increasing number of new HIV diagnoses among heterosexuals 
infected in Africa has led to greater subtype diversity within the UK.  Among 
HIV-infected heterosexuals attending sentinel STI clinics in England, Wales and 
Northern  Ireland  between  1997-2000,  subtype  C  accounted  for  the  majority 
(32%).    Subtypes  B  (29%),  and  A  (12%),  CRFs  (9%),  and  URFs  (8%)  and 
subtypes D-H (8%) were also detected.   Heterosexuals with non-B subtypes 
were more likely to have been infected within sub-Saharan Africa, reflecting the 
distribution of subtypes found outside the UK (Tatt, Barlow et al. 2004).   
 
More recently, a large scale phylogenetic analysis (see section 1.4) of HIV pol 
sequences  among  5675  patients  diagnosed  between  1996-2004  in  the  UK 
(Gifford 2007) found that 74% were infected with subtype B, with subtypes A 
and C occurring at 6% and 10% respectively (HIV exposure by subtype was not 
presented). 
1.2.4   HIV transmission in the UK 
It  is  unclear  whether  HIV  transmission  is  increasing  within  the  UK.    This  is 
because surveillance data are difficult to interpret.  For instance, the number of Alison Brown – Chapter One 
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new HIV diagnoses is determined not only by HIV transmission rates, but also 
the relative uptake of HIV testing among high risk populations and migration of 
individuals from high prevalence countries.  The relative contribution of these 
factors is difficult to disentangle (Dougan, Elford et al. 2007).  The annual HIV 
incidence among  MSM  attending  sentinel STI  clinics in  England, Wales and 
Northern  Ireland  has  been  estimated  at  around  3%  since  1995  (Murphy, 
Charlett  et  al.  2004).    However,  the  representativeness  of  this  high  risk 
population and its associated biases (e.g. people with recent risk behaviour are 
more likely to be included in the denominator of patients attending STI clinics 
(Burchell, Calzavara et al. 2003)) mean such data need to be interpreted with 
caution (see section 2.3.5).   Nevertheless, the continued high rates of STIs 
diagnosed among MSM, including among those with a diagnosed HIV infection, 
all suggest that if transmission is not increasing, it is certainly continuing even 
within the context of high uptake of ARVs. 
1.3. Preventing HIV transmission: the UK response 
1.3.1   Preventing HIV transmission 
Prevention has remained an essential component of the public health response 
to the UK HIV epidemic.  The sexual health strategy
  of 2001 (DH 2001) had two 
major initiatives: to increase HIV testing (to reduce undiagnosed HIV infection) 
and  to  change  sexual  risk  behaviour (to  prevent  transmission from  the  HIV-
infected population).  
 
Voluntary  confidential  HIV  testing  (VCT)  aims  to  reduce  HIV  transmission 
through reducing the proportion of HIV-infected individuals who are unaware of Alison Brown – Chapter One 
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their HIV infection.  An HIV diagnosis provides the opportunity for ARV for those 
with  low  CD4  counts  (which  reduces  viral  load  and  consequently  infectivity) 
(Vernazza,  Troiani  et  al.  2000),  partner  notification,  and  behaviour  change 
counselling.   Best practice guidance suggest VCT should be offered to all at 
their first attendance at a sexual health clinic, and subsequently according to 
risk (BHIVA 2006).  Updated guidelines in 2008  (BHIVA 2008) also suggest 
those  with  recent  risk  exposure  be  targeted  in  conjunction  with  testing  with 
fourth generation diagnostic tests.   
  
Prevention initiatives aim to reduce HIV transmission through promoting safer 
sex. This means reducing: unprotected sex; number of sexual partners; and 
concurrent partnerships.  Large scale health promotion campaigns have been 
launched by England‟s Department of Health and media focused such as: the 
“Don‟t die of ignorance” campaign in the 1980s (DH 1987) and more recently, 
the  Sex  Lottery 
(http://www.dh.gov.uk/en/Publicationsandstatistics/Pressreleases/DH_4025977 
accessed 17th August 2009). Other initiatives are commissioned at local levels 
within the NHS, or funded through charities or non-governmental organizations. 
1.3.2   Impact of HIV prevention initiatives in the UK  
Superficially, the promotion of VCT has been successful.  Between 1998-2007, 
the  proportion  of  MSM  attending  sentinel  STI  clinics  receiving  HIV  tests 
increased  from  46  to  86%.  However,  this  has  not  translated  directly  into  a 
prevention success.  Figure 1.8 plots the uptake of VCT against annual HIV 
incidence; the increase in VCT has not been mirrored by a significant decrease 
in HIV incidence.  This may be due to five reasons which are discussed in turn.    Alison Brown – Chapter One 
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Figure 1.8: The proportion receiving HIV tests and the annual HIV incidence among MSM 
attending sentinel STI clinics, England, Wales and Northern Ireland: 1998-2007 
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Source: Personal communication, Unlinked Anonymous STI survey. 
 
Firstly, those receiving HIV tests may not necessarily be those at highest risk of 
having an HIV infection.  Of HIV-infected MSM who arrived at sentinel STI clinic 
unaware of their infection in 2007,  30% (223/749) left the clinic without an HIV  
diagnosis because they were either not offered, or had declined an HIV test 
(Figure 1.9).    Importantly, an audit found that those arriving at clinics with a 
recent risk exposure were more likely to defer VCT due to concerns that testing 
soon  after  exposure  may  not  provide  accurate  results  (Munro  2007); 
reattendance rates were low.  The failure to pick up those most at risk limits the 
success of an overall increase in uptake, and is also largely unnecessary due to 
improvements in testing technology (section 2.3.2). 
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Figure 1.9: The proportion of MSM attending sentinel STI clinics receiving HIV tests and 
the fraction of HIV-infected MSM remaining undiagnosed, UK: 1998-2007 
 
 
 
 
 
 
 
 
 
 
Source: (HPA 2008) 
 
Secondly, VCT will only work as a prevention strategy if patients modify their 
sexual  behaviour  once  they  have  become  diagnosed.      However,  evidence 
suggests that the risk behaviour continues even after diagnosis.  For instance, 
Dodds et al (Dodds, Mercey et al. 2004) found approximately half of MSM with 
a diagnosed HIV infection had had unprotected anal intercourse (UAI) within the 
past 12 months.   Risky sexual behaviour among the HIV-diagnosed is thought 
to be facilitated by websites that allow MSM to seek partners for UAI (Elford, 
Bolding et al. 2007).  The continuation of STI diagnoses among diagnosed HIV-
infected men is further evidence that unprotected sex is continuing within this 
population (Simms, Fenton et al. 2005; Dodds, Johnson et al. 2007).  
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It is speculated that risk behaviour among the HIV diagnosed population may 
continue as a consequence of widespread ARVs (Elford and Hart 2005).   A 
meta-analysis found that while being on ARVs and achieving an undetectable 
plasma viral load did not increase sexual behaviour risk (Crepaz, Hart et al. 
2004), peoples‟ beliefs about ARV (e.g.  that it has changed HIV from a fatal 
disease to a chronic, treatable infection) may have facilitated the continuation of 
unprotected sex within this population. 
 
Thirdly, while patients with a diagnosed HIV infection have the opportunity to 
receive ARV treatment, which reduces their infectivity, ARV is prescribed on the 
basis of individual clinical need and not for public health benefit (section 1.3.1).  
It  was  recommended  that  patients  commenced  treatment  once  CD4  counts 
reached  under  200  cells/mm
3  in  2003  (Pozniak,  Gazzard  et  al.  2003),  and 
updated to  under 350 cells/mm
3 during 2008 (Gazzard 2008).  In 2007, it was 
estimated that 30% of the diagnosed HIV-infected UK population receiving care 
were not prescribed ARV (personal communication – SOPHID).  Therefore, HIV 
diagnosis does not necessarily lead to viral load reducing therapy, and many 
patients with diagnosed HIV infection may continue to have elevated levels of 
virus. 
 
Fourthly,  if  the  recently  HIV-infected  are  disproportionately  generating  HIV 
transmission, then the impact of VCT on reducing transmission will be limited.  
This is because those with recently acquired HIV infection will not yet have had 
the opportunity to receive an HIV test.    
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Finally, VCT promotion may not be implemented on a large enough scale.  The 
prevalence  of  an  infection  drives  onward  transmission,  and  increases  in  the 
prevalent pool of diagnosed and undiagnosed infection may limit the ability HIV 
testing to make an impact.  For instance while the proportion of HIV-infected 
MSM leaving the clinic remaining unaware of their infection has reduced, the 
increase in the number of MSM living with HIV has meant the absolute number 
has increased (Brown, Tomkins et al. 2006)
.  Therefore many more successfully 
targeted tests are needed to order to make an impact.
  
  
1.3.3  Improving interventions to prevent HIV transmission 
Whilst  the  promotion  of  VCT  remains  essential  for  the  clinical  outcome  of 
individual  patients,  its  potential  to  reduce  current  levels  of  HIV  transmission 
appears uncertain.   The potential barriers to VCT‟s success provide important 
clues as to why HIV transmission may be continuing in the UK.    
 
In  order  for  prevention  interventions  to  be  better  targeted,  it  is  important  to 
determine: 
  whether  individuals  with  recently-acquired  HIV  infection  are 
disproportionately driving new infections (including TDR); 
  the extent that new HIV infections are generated by the diagnosed 
HIV-infected population; 
  whether  reducing  the  viral  load  of  the  HIV  diagnosed  population 
through  treatment  could  substantially  impact  upon  population  level 
transmission.  
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This may be achievable through application of phylogenetic techniques that can 
reconstruct transmission events at the population level.  If such events can be 
linked to groups/risk factors that may be important in generating transmission 
(e.g.  the  recently  HIV-infected,  and/or diagnosed  population/viral load  and/or 
presence of STIs) then the groups/risk factors important in spreading HIV within 
the UK could be correctly identified and targeted for prevention initiatives. 
  
1.4.  Combining  phylogenetics  with  clinical,  diagnostic  and 
surveillance data for public health purpose  
Phylogenetic  analyses  involve  exploiting  small  differences  in  DNA  which  are 
combined with computational methods to calculate the degree of relatedness 
between organisms (see section 2.2). To date, phylogenetic analyses of HIV 
sequences have been conducted to: explore genetic diversity (Perrin, Kaiser et 
al.  2003);  to  aid  vaccine  development  (Novitsky,  Smith  et  al.  2002);  to 
supplement  evidence  in  criminal  investigations  of  HIV  transmission  (Leitner 
2000), (de Oliveira, Pybus et al. 2006); and to time calibrate phylogenies to date 
the introduction of specific HIV strains into populations or countries (Hue, Pillay 
et  al.  2005;  Drummond,  Ho  et  al.  2006)  through  calculating  the  rate  of 
mutations.  Phylogenetics  has  also  been  used  to  reconstruct  transmission 
events  between  HIV-infected  individuals  (Leitner,  Escanilla  et  al.  1996),  by 
assuming that sequences very closely related to each other may have been 
transmitted between those infected with these strains (thereby gauging “who 
infected who” (Leitner, Escanilla et al. 1996).  This thesis concentrates upon the 
latter application of phylogenetics.    
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Within the past decade, such analyses have become more frequent.  This is 
because since 2003, guidelines (Pozniak, Gazzard et al. 2003) recommended 
that  patients  newly  diagnosed  with  HIV  infection  have  their  virus  DNA 
sequenced  to  identify  drug  resistance  mutations  to  inform  treatment  options 
(Pozniak, Gazzard et al. 2003).  This has resulted in the accumulation of HIV 
pol  sequences,  which  are  believed  to  be  appropriate  for  phylogenetic 
reconstruction (Hue, Clewley et al. 2004).   
  
Phylogenetic  reconstructions  of  HIV  transmission  events  can  become  more 
powerful  when  they  are  combined  with  clinical  and  diagnostic  data. 
Demographic,  laboratory  and  clinical  data  are  collected  routinely  around  the 
time  of  HIV  diagnoses  for  medical  and  surveillance  purposes.  Demographic 
data  (e.g.  ethnicity,  age-group) and  clinical  data  (e.g.  sexual orientation,  co-
infection with sexually transmitted infections (STIs) etc) allow the ascertainment 
of  risk  factors  associated  with  infection.    Additionally,  recently-acquired  HIV 
infections among MSM can be distinguished through laboratory algorithms such 
as the Serological Testing Algorithm for Recent HIV Seroconversion (STARHS) 
(Janssen, Satten et al. 1998; Murphy and Parry 2008). The combination of such 
data has the potential to enhance our understanding of HIV transmission and its 
associated risk factors to a greater extent than can be gleaned from each data 
source when considered individually. This thesis combines HIV pol sequences 
with demographic, laboratory and clinical data to enhance understanding of HIV 
transmission  between  MSM  within  the  UK,  with  the  ultimate  aim  of  better 
targeting prevention interventions.  Alison Brown – Chapter One 
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1.5.   The current literature 
1.5.1   Studies  that  explore  transmission  from  patients  with  recently-
acquired infection 
Phylogenetic reconstructions of HIV transmission events have frequently been 
undertaken among populations of  MSM who were diagnosed soon after HIV 
infection.    This is because of the interest in this group with a high onward 
transmission  potential  (Pinkerton  2007).    Additionally,  such  datasets  are 
relatively easy to obtain since they are frequently generated as a by-product of 
studies  of  transmitted  drug  resistance  (Pozniak,  Gazzard  et  al.  2003;  Hue, 
Clewley et al. 2004) (section 1.5.3).  
 
Previous phylogenetic reconstructions of HIV transmission events using data 
exclusively from patients with recent HIV infection have concluded that such 
populations have an elevated transmission potential.    For instance, Pao et al. 
(Pao, Fisher et al. 2005) used phylogenetic analysis of HIV pol sequences to 
identify possible transmissions between recently HIV-infected MSM.  Out of 103 
individuals  with  recent  infection,  35  possible  transmission  clusters  were 
observed.    Yerly  et  al.  (Yerly,  Kaiser  et  al.  1999)  performed  an  exploratory 
phylogenetic  analysis  of  individuals  with  recent  HIV  infection  diagnosed 
between 1996-9 in Switzerland.  Of 197 sequences, 29% formed a transmission 
cluster with at least one other sequence. 
1.5.2  Analyses that “measure” the level of transmission  
Brenner et al. attempted to measure the extent that the recently HIV-infected 
were  generating  new  transmission  events  in  Canada  (Brenner,  Roger  et  al. Alison Brown – Chapter One 
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2007).  Phylogenetic analysis was performed to identify instances of possible 
transmission  events.    The  proportion  of  new  “transmission  events”  from  the 
recently  HIV-infected  (n=696)  and  the  chronically  HIV-infected  (n=795)  were 
compared: they concluded that 49% of transmission events were generated by 
the recently HIV-infected compared with 27% from the chronically HIV-infected.  
In contrast, the recently HIV-infected were estimated to make up 10% of the 
HIV-infected population.  This provided support that the recently HIV-infected 
are disproportionately generating transmission.   
 
1.5.3  Analyses of the transmission of drug resistant viruses 
The majority of phylogenetic explorations have focussed upon transmitted drug 
resistance  and  consequently,  the  recently  HIV-infected  populations.    This 
ensures that the study population is truly drug naïve and increases the detection 
of  resistant  viruses.    This  is  because  patients  are  infected  with  a  small 
population of viruses; resistant strains are rapidly outgrown by wild-type viruses 
shortly  following  infection  due  to  a  reduced  reproductive  fitness  of  resistant 
strains (section 2.5.2) (Devereux, Youle et al. 1999; Yerly, Junier et al. 2009).   
  
Phylogenetic analyses of sequences from recently HIV-infected individuals have 
been conducted to identify possible transmission events between persons with 
viruses that have identical drug resistance mutations – indicating transmission 
from  HIV-infected  individuals  with  drug  resistant  viruses.    Through  this 
technique, Pao et al. (Pao, Fisher et al. 2005) found two clustering sequences 
from recently HIV-infected MSM that shared the same drug resistance mutation.  
Yerly et al found that whilst 29% of sequences were phylogenetically linked to at Alison Brown – Chapter One 
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least one other sequence, and 8.8% (17) of individuals had a drug resistance 
mutation, none of the possible transmission events contained sequences with 
identical mutations (Yerly, Kaiser et al. 1999).   Later, Yerly et al (Yerly, Junier 
et al. 2009) found that patients whose sequences had drug resistant mutations 
were more likely to form transmission events than those without, and that the 
prevalence of NNRTI mutations increased between 2000-2008. 
 
However, the extent to which the acquired and transmitted resistant populations 
are generating onward infections is not known.  Leigh-Brown et al estimated 
through  modelling  methods  that  30%  of  those  with  acquired  resistance  may 
pass their infection onwards (Leigh Brown, Frost et al. 2003).   Kearney et al. 
(Kearney,  Maldarelli  et  al.  2009)  compared  the  spectrum  of  drug  resistance 
mutations  between  the  transmitted  and  acquired  populations  and  found  a 
greater distribution in the latter group; this may suggest that the populations 
with  acquired  resistance  are  not  the  only  source  of  TDR,  and  persistent 
mutations in the TDR population may continue to spread.   
 
More recently, studies have examined how transmission rates of specific drug 
resistance mutations vary.  Examining  pol sequences from patients recently 
HIV-infected  at  diagnosis,  Brenner  et  al.  (Brenner,  Roger  et  al.  2008) 
demonstrated that while the overall frequency of drug resistant viruses between 
non-clustered  and  clustered  transmission  was  similar  –  14.3%  and  16.5% 
respectively,  the frequency  of  specific classes  of mutations  differed  between 
clustering  sequences  and  non-clustering  sequences.  For  instance,  virus 
harbouring mutations to NRTIs were less like to cluster than those viruses with Alison Brown – Chapter One 
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NNRTIs.  This further illustrates that it may be the specific mutations, and not 
necessarily  the  infection  category  of  the  bearer  that  determines  onward 
transmission of TDR. 
1.6. Limitations 
Phylogenetic analyses that combine clinical, diagnostic, and demographic data 
are reliant on many assumptions that require further consideration.  
1.6.1  Accuracy of phylogenetics 
There is much debate about the suitability of phylogenetics for reconstructing 
HIV  transmission  events:  it  is  argued  that  phylogenetic  reconstructions  are 
insufficient to be used as evidence in criminal cases (Bernard 2007).  This is 
because viral genomes can be extremely similar, through parallel or convergent 
evolution, making it difficult to prove definitively that two viruses have a recent 
common origin.  Additionally, even if two individuals shared a closely related 
virus,   phylogenetic analysis could not verify the direction of transmission and it 
is difficult to rule out both individuals being infected via a third partner, or that a 
third  party  was  an  intermediary  partner between  the  two.  In  Leitner  et  al.‟s 
phylogenetic analysis of transmission events, one out of 13 transmission events 
was incorrectly reconstructed (Leitner, Escanilla et al. 1996).   
 
Epidemiological data on sexual partnerships between HIV-infected patients is 
rarely  available  to  validate  the  results  empirically  (and  if  available  would 
arguably  render  phylogenetic  analysis  unnecessary).  It  is  assumed  that 
phylogenetic  reconstructions  are  sufficiently  accurate  for  analyses  for  public 
health purposes, particularly if conservative cut-offs for possible transmission Alison Brown – Chapter One 
42 
events  are  applied  (e.g.  bootstrap  (a  measure  of  statistical  support  –  see 
section 2.2.7) support of 99% or more and a genetic distance of less than 0.015 
nucleotide substitutions per site (Hue, Clewley et al. 2004), see section 2.2.11).  
Studies  to  date  have  not  necessarily  used  such  conservative  cut-offs  (Pao, 
Fisher et al. 2005; Brenner, Roger et al. 2007).  
 
However, the robustness of phylogenetic methods for population level, public 
health applications has not been rigorously assessed.  Population level studies 
frequently  use  samples  derived  from  MSM  with  diagnosed  HIV  infection 
attending  a  particular  health  care  site for HIV  treatment  and  care  to  assess 
transmission events within an HIV-infected population (Pao, Fisher et al. 2005; 
Brenner, Roger et al. 2007).  By definition, these “samples” will not contain an 
HIV sequence from every single HIV-infected MSM in the population.  In the UK 
for example, approximately one third of individuals living with HIV are estimated 
to be undiagnosed (HPA 2008). Further reasons why MSM may only be partially 
represented  in  population-based  studies  include  HIV  diagnosed  MSM  being 
sexually  active  in  geographic  areas  where  they  do  not  attend  clinics  for 
treatment and care, HIV diagnosed MSM not attending clinics, or samples from 
HIV diagnosed MSM being unavailable (due to amplification problems etc).  The 
consequences of not including every sequence within a local population for the 
purposes of phylogenetic reconstructions are not known.  If the formation of 
robust clusters (section 2.2.11) is affected by the diversity, representativeness 
and completeness of the entire sample, these factors could be crucial.   
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It is possible that the identification of some transmission events may be affected 
by the relative genetic diversity of the population sample.  This means that any 
observed  phylogenetic  clusters  may  reflect  relative  relationships  between 
sequences  rather  than  demonstrate  absolute  relationships.  Brenner  et  al 
(Brenner,  Roger  et  al.  2007)  undertook  a  phylogenetic  reconstruction  of 
transmission events using sequences entirely obtained from patients diagnosed 
during  recent  infection  and  found  75  possible  phylogenetic  relationships 
according to cut-off criteria described above.  A second phylogenetic analysis 
included  an  additional  number  of  sequences  from  patients  chronically  HIV-
infected  at  diagnosis;  they  found  that  several  of  the  original  “transmission 
events” between individuals with recent HIV infection were disrupted.   Sample 
size was found to be an important determinant of accuracy in a study (Wiens 
and Servedio 1998) that compared the results from parsimony, likelihood and 
distance  based  phylogenetic  methods  (see  section  2.2.6).  Assessment  is 
therefore required of the extent that phylogenetic reconstructions can produce 
reproducible and consistent results.    
1.6.2   Diversity of pol 
The  pol  region  of  the  HIV  genome  (section  1.1.5)  is  generally  used  for 
phylogenetic analyses out of convenience, since it is a by-product of the routine 
HIV  drug  resistance  testing.  There  are  relatively  few  full  length  (i.e.  entire 
genome)  HIV  sequences  available  from  patients  involved  in  a  known 
transmission event, and large scale phylogenetic analyses would be restricted 
by the sequencing costs of producing such a dataset and the computing power 
needed to analyse it. 
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However, there are concerns that the pol region is too conserved since it codes 
for  regulatory  genes  involved  in  viral  replication  and  consequently  has 
insufficient  genetic  variability  (Palmer,  Vuitton  et  al.  2002).    This  has  led  to 
debate about its suitability for phylogenetic reconstructions (Palmer, Vuitton et 
al. 2002; Sturmer, Preiser et al. 2004).  While gag and env genes have been 
preferred due to their greater genetic variability, pol remains attractive due to its 
greater accessibility through routine drug resistance testing.  Hue et al (Hue, 
Clewley et al. 2004) demonstrated that phylogenetic analyses of 140 HIV pol 
sequences  produced  the  same  results  as  analyses  using  HIV  env  and  gag 
sequences from the same patients.   
1.6.3  Sampling considerations 
It is likely that the specific selection of HIV-infected individuals from whom the 
sequences were obtained for phylogenetic analysis will affect the likelihood of 
recognizing transmission events.  For instance, sequences collected from one 
geographical region and taken around the same date may be more likely to be 
drawn from individuals within the same transmission network.   
 
Brenner et al. selected three populations within Canada (Brenner, Roger et al. 
2007): a Quebec cohort of recently HIV-infected MSM (n=215) and a provincial 
genotyping programme (n=502).  A chronically HIV-infected population was also 
taken entirely from the provincial genotyping programme (n=660). The presence 
of  individuals  drawn  from  the  Quebec  cohort  increases  the  chance  that 
individuals will be selected from the same transmission networks compared to 
the provincial sample.  This generates a bias; more transmission events will be 
identified  between  the  recently  HIV-infected  sample  from  Quebec  compared Alison Brown – Chapter One 
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with  the  sample  of  chronically  infected  individuals.  Furthermore,  while  the 
chronically  HIV-infected  were  sampled  between  2001-2005;  the  dates  of 
infection for these sequences were not known.  The interval between infection 
dates within this population may span tens of years, increasing the likelihood 
that  they  had  been  obtained  from  different  transmission  networks.  
Consequently  it  is  essential  that  population  samples  used  for  phylogenetic 
analyses are selected with the consideration that no group under investigation 
has an increased likelihood of being involved in transmission networks.    
1.6.4  Infection stage considerations 
Interpretation  of  and  comparison  between  phylogenetic  studies  of  HIV 
transmission  using  datasets  derived  from  patients  with  recent  infection  is 
problematic.  This is due to the definitions of recent HIV infection employed. 
Importantly,  if  generous  definitions  of  the  latter  are  applied,  it  may  serve  to 
overestimate the extent that this population are generating transmission events.  
Viral load is known to peak less than a month following infection, but remains 
elevated for approximately 10 weeks  (Fiscus, Pilcher et al. 2007).  However, 
definitions of recent infection and the laboratory techniques used to identify it 
vary  (Pilcher,  Fiscus  et  al.  2005;  Fiscus,  Pilcher  et  al.  2007),  and  those 
frequently adopted mean that patients can be so categorized  up to (Pao, Fisher 
et al. 2005)  or even more than six months after infection (Pao, Fisher et al. 
2005; Brenner, Roger et al. 2007).    
 
Moreover,  infection  stages  do  not  remain  static  over  the  course  of  an 
individual‟s infection (section 1.1.6).  However, many studies do not consider 
the  transient  nature  of  recent  infection.    Phylogenetic  analyses  frequently Alison Brown – Chapter One 
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categorize patients as being recently or chronically  HIV-infected according to 
their infection stage at diagnosis (Pao, Fisher et al. 2005; Brenner, Roger et al. 
2007).  However, all patients will experience recent and chronic infection, and 
the  observation  of  possible  transmission  events  (ascertained  through 
phylogenetic reconstruction) between patients diagnosed during recent infection 
does  not  necessarily  mean  transmission  occurred  while  the  patients  were 
recently HIV-infected.   
 
To illustrate this, the mean time interval between infection dates in Brenner‟s 
“transmission  events”  identified  between  patients  recently  HIV-infected  at 
diagnosis was 15 months ( 9.5 months) – indicating the transmissions could 
have  occurred  many  months  after  HIV  acquisition.    Specifically,  27  of  the 
phylogenetically  linked  sequences  from  recently  HIV-infected  individuals  had 
time  intervals  of  over  two  years  between  their  infection  dates.    These  were 
interpreted as transmissions occurring from patients with recent HIV infection.  It 
is  similarly  difficult  to  interpret  possible  transmission  events  found  between 
sequences  taken  from  individuals  with  chronic  infection:  all  individuals  with 
chronic  HIV  infection  were  once  “recently  HIV-infected”.    For  studies  that 
explore  the  impact  of  infection  stage  on  transmission  risk,  it  is  essential  to 
account for the transient nature of the risk factor.      
1.6.5  Sexual behaviour  
While factors such as viral load, STIs and infection stage are likely to affect 
population level HIV transmission, the sexual behaviour of patients from whom 
a sequence was derived will also be important.  A phylogenetic reconstruction 
revealing many transmission events close together in time and geography may Alison Brown – Chapter One 
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reflect  the  action  of  one  or two  individuals with  high  rates  of  sexual partner 
change.   This would produce results that it would be difficult to extrapolate to 
the  population  level.      It  is  extremely  challenging  to  include  these  data  in 
phylogenetic analyses since such data are hard to capture, and difficult to link 
with reconstructed transmission events.  While Pao et al captured indicators of 
unsafe sex (Pao, Fisher et al. 2005) with their reconstruction, the method could 
not  precisely  match  behaviour  to  actual  transmission  events.    Consequently 
results need to be interpreted with caution. 
1.6.6     Analyses of transmitted drug resistance  
Studies that measure the prevalence of TDR and transmission from patients 
with drug resistance mutations are difficult to interpret (section 1.2.2 and 2.5.2).  
Studies  of TDR  have found a  range  of  prevalence  levels  (Little,  Holte et al. 
2002)  (Grant,  Hecht  et  al.  2002;  Cane,  Chrystie  et  al.  2005).  However,  it  is 
impossible  to  exclude  the  possibility  that  phylogenetically  linked  sequences, 
sharing  identical  mutations  were  generated  by  one  individual  with  acquired 
resistance, rather than onward transmission between individuals with TDR.  
1.7. Gaps in the research 
 Phylogenetic analyses to date have highlighted the  heightened  transmission 
potential of the recently HIV-infected.  However, such studies have remained 
exploratory, and have focused almost exclusively on sequences from patients 
diagnosed during recent HIV infection.  While Brenner et al. (Brenner, Roger et 
al. 2007) attempted to measure the extent that the recently HIV-infected cause 
new transmission events relative to the chronically HIV-infected, their methods 
lacked rigour.  Differences between the sample populations of the recently and Alison Brown – Chapter One 
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chronically  HIV-infected,  and  the  failure  to  recognize  the  transient  nature  of 
infection  stage,  mean  that  the  extent  that  the  recently  HIV-infected  are 
generating transmission has not been measured with adequate precision. 
 
 Phylogenetic  analyses  conducted  for  public  health  purposes  require  more 
rigorous  design,  application  and  interpretation.    From  an  epidemiological 
perspective,  appropriate  consideration  should  be  given  to  sample  selection 
(especially with regard to geography and diagnosis dates).  In order to obtain a 
measure  of  HIV  transmission  at  the  population  level  from  certain  groups, 
datasets should be extended to include sequences from individuals who were 
chronically HIV-infected at diagnosis.     The latter group needs to be broadly 
comparable with the population of the recently HIV-infected with regard to their 
likelihood of being included in transmission networks (as far as is possible).  It is 
also important in analyses that infection stages are considered to be transient 
properties that change over the course of an individual‟s infection.  
 
The published evidence that indicates individuals with recent HIV infection have 
a high risk of transmission per sexual act (Wawer, Gray et al. 2005).  This and 
the relative ease with which this population can be studied may mean that other 
groups that have potentially important roles in generating HIV are insufficiently 
investigated.    Phylogenetic  analyses  need  not  be  restricted  to  studying  the   
recently HIV-infected; analyses can be extended to integrate other relevant risk 
factors, such as concurrent STIs, and chronically-infected (both the ARV-treated 
and untreated individuals). 
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The prevalence of TDR has been studied and its transmission reconstructed 
through  phylogenetic  analyses.    However,  the  extent  that  acquired  and 
transmitted  drug  resistant  populations  are  generating  TDR  is  not  known.  
Additionally, the sources of TDR have not been explored in relation to viral load 
and infection stage.   
 
There  are  uncertainties  with  regard  to  the  ability  of  phylogenetic  analysis  to 
identify  accurate  transmission  events  to  be  used  for  public  health  purposes.  
The  concerns  include:  whether the  variability  of  pol  is sufficient for accurate 
reconstructions;  the  effect  of  the  overall  genetic  diversity  of  the  population 
samples have on the likelihood of recognizing phylogenetic relationships; the 
inability  to  determine  the  direction  of  transmission;  and  the  possibility  that 
observed  phylogenetic  linked  relationships  could  have  been  generated  or 
mediated through an unsampled third party. While it is not possible to verify the 
transmission  events  identified  through  phylogenetic  reconstructions  through 
linkage  to  sexual  histories  at  a  population  level,  it  is  possible  to  perform 
sensitivity analyses to assess the consistency of phylogenetic approaches. 
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1.8. Research objectives 
This thesis uses a phylogenetic approach that combines clinical, diagnostic and 
demographic data to enhance understanding of HIV transmission events among 
MSM.  Specifically,  it  uses  combined  datasets  to  perform  phylogenetic 
reconstructions of HIV transmission events to:  
1)  assess the consistency of results from phylogenetic reconstructions of 
HIV transmission events; 
2)  explore  transmissions  from  the  recently  HIV-infected  population  and 
critique the methods used in such analyses; 
3)  ascertain  the  risk  factors  associated  with  transmission  using  a  novel 
approach; 
4)  explore the transmission sources of patients diagnosed with TDR. 
 
1.9. Thesis outline 
Chapter  two  outlines  the  concepts,  methods  and  definitions  applied  to 
phylogenetics, and sequence-based, clinical, diagnostic and demographic data.  
Chapter  three  describes  and  compares  the  datasets  used  in  the  thesis.  
Chapter  four  explores  the  consistency  of  phylogenetic  approaches  in 
reconstructing  HIV  transmission  events.      Chapter  five  explores  the 
transmission events from the recently HIV-infected and critiques the methods 
used  in  such  analyses.    Chapter  six  ascertains  the  sources  of  new  HIV 
transmissions and the factors associated with these sources.  Chapter seven 
explores  the  sources  of  TDR.    Chapter  eight  describes  how  the  thesis 
contributes to research and links it with the current literature.  It also outlines the 
thesis  limitations  and  describes  the  future  research  needed  in  this  field.    Alison Brown – Chapter Two 
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2. Chapter Two: Sequence-based, diagnostic and clinical HIV 
data: principles and definitions 
 
 
 
 
 
Sequence-based, laboratory and clinical data are collected routinely around the 
time of HIV diagnoses for medical and surveillance purposes. The data sources 
available and the techniques used to obtain them are described in this chapter.  
The chapter also outlines how the sources can be combined and used for public 
health analyses, and their limitations.  Finally, the definitions used throughout 
this thesis are provided.   Alison Brown – Chapter Two 
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2.1. Introduction  
Sequence-based, laboratory and clinical data are collected routinely around the 
time of HIV diagnoses for medical and surveillance purposes. The combination 
of  such  data  has  the  potential  to  enhance  our  understanding  of  HIV 
transmission  (section  1.4).    This  chapter  aims  to  describe  the  data  sources 
available  and  the  techniques  used  to  obtain  them.    It  also  outlines  how  the 
sources can be combined and analysed, and their limitations.   The specific 
data sources used in the thesis are detailed in chapter three. 
2.2.  Phylogenetic analysis of sequence-based data 
The principles of phylogenetics are outlined.  The applications of phylogenetic 
analysis to HIV sequences are then described. Phylogenetic methodologies are 
explained and the techniques used in this thesis are defined. 
2.2.1  Phylogenetic principles 
Phylogenetic  analyses  investigate  the  evolutionary  relationship  between 
organisms.  Over  time,  through  successive  generations,  changes  occur  in 
genetic  make-up  of  organisms.  Phylogenetic  reconstructions  exploit  the 
changes that have accumulated between these organisms. The technique is 
derived  from  evolutionary  theory,  which  states  that  the  genetic  similarity 
between species is attributable to a descent from common ancestry. It assumes 
the more similar the genetic make up of two organisms is, the closer they are in 
time to having a common ancestor (Page 1998).   Alison Brown – Chapter Two 
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2.2.2  DNA, nucleotides, amino acids and proteins 
Genetic  material  is  contained  within  DNA  (deoxyribonucleic  acid).  DNA 
comprises two long strands of nucleotides arranged into a double helix. The 
nucleotides  consist of  two  purines  (Adenine  (A),  and  Guanine  (G)),  and  two 
pyrimidines  (Thymine  (T),  and  Cytosine  (C)).  Phylogenies  are  routinely 
reconstructed from nucleotide, or amino acid sequences which are aligned so 
that homologous bases are compared. In this thesis, only evolutionary changes 
between nucleotide sequences are considered, since this contains the highest 
resolution of genetic variability. 
2.2.3  Nucleotide sequence alignments 
Before  phylogenetic  analyses  can  be  conducted,  the  sequences  need  to  be 
aligned.  This  is  because  the  analyses  exploit  differences  found  at  specific 
nucleotide positions. In order for these analyses to be meaningful, it is essential 
that comparisons are made between equivalent (homologous) positions.  The 
nucleotide sequences are aligned in-frame i.e. as triplets of three nucleotides 
(codons) coding for specific amino acids.  
 
A representation of a nucleotide sequence alignment is shown in Figure 2.1a.  
Differences that accumulate between sequences over time can take the form of 
point  mutations/substitutions  (whereby  the  nucleotide  has  been  replaced  by 
another base), insertion (one or more nucleotides have been added into the 
sequence), or deletion (one or more nucleotides have been removed). During a 
sequence alignment, each nucleotide position will be compared at equivalent 
positions  and  categorized  as  either  a  “match”  (where  the  nucleotides  are 
identical), a “mismatch” (where the nucleotides differ), or a “gap” (where one or Alison Brown – Chapter Two 
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more of the sequences has had an insertion/deletion) (Figure 2.1b). Sequence 
alignments work to take account of insertions or deletions (Figure 2.1c). It is 
important to limit the number of gaps so that the resultant alignment makes 
biological  sense.  Provided  the  sequences  are  sufficiently  similar,  sequence 
alignments  can  be  performed  manually  using  software  such  as  Sequence 
Analyzer  (SE-AL).  Otherwise,  programmes  such  as  Clustal-X  (Thompson, 
Gibson  et al. 1997)  can be used  to  align  sequences  crudely  according  to a 
scoring system based on the frequency and extent of gaps. A heuristic search is 
then  conducted  to  find  the  best  alignment  according  to  the  scoring  system, 
which should then be checked manually before phylogenetic reconstruction.     
2.2.4  Evolutionary models 
The majority of phylogenetic methods are dependent on the user defining an 
explicit evolutionary model. These are necessary since the rate of substitutions 
that accumulate between two sequences over time is not linear (Yang 1996). 
Some  substitutions  occur  more  frequently  than  others  (Kimura  1980).  For 
instance transitions (substitutions between purines, or between pyrimidines) are 
more  frequent  than  transversions  (substitutions  between  purines  and 
pyrimidines) (Kimura 1980). Additionally, multiple substitutions may occur at the 
same nucleotide  position,    with  the  saturation  of  specific positions  making  it 
difficult to ascertain the true evolutionary distance (Holmes 1998). Evolutionary 
models  convert  the  genetic  distances  that  exist  between  sequences  into 
measures of estimated evolutionary distance. 
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Figure 2.1: Graphical representation of sequence alignments 
 
Several  models  of  molecular  evolution  have  been  developed.  Each  model 
varies in its complexity and the extent to which it incorporates biochemical and 
evolutionary knowledge. Models can include three parameters: nucleotide base 
i) Unaligned sequences: Alison Brown – Chapter Two 
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frequency, base exchangeability and the rate of heterogeneity between sites. 
Examples of common models of evolution are given in Table 2.1. 
 
The base frequency parameter accounts for the respective frequency of the four 
nucleotides throughout the sequences being compared. Base exchangeability 
describes the relative tendency of bases to be substituted for one another.  
Table 2.1: Summary of the main evolutionary models 
Evolutionary model  Description 
Jukes Cantor (JC  (Jukes 1969)  Assumes an equal frequency  of the four bases 
and that all substitutions are equally likely.    
Kimura‟s two parameter model (K2P  (Kimura 
1980) 
 
Assumes  base  frequency  is  equal,  but  that 
transitions  occur  more  frequently  than 
transversions. 
Felsenstein (F81  (Felsenstein 1981)  This model allows an unequal frequency of base 
substitutions. 
Hasegawa,  Kishino  and  Yano  (HKY85  
(Hasegawa, Kishino et al. 1985) 
Allows  both  the  base  frequency  and 
transition/transversion rate to differ. 
General  Time  Reversible  Model  (GTR  
(Lanave, Preparata et al. 1984) 
Allows all substitutions to occur at a different rate 
and  permits  the  user  to  define  initial  base 
frequency  rate  of  heterogeneity  between  sites.  
Also allows substitution rates to be reversible. 
 
Substitutions  are  not  equally  likely  between  the  four  bases.    The  rate  of 
heterogeneity summarises the difference in substitution rates across the DNA 
sequence,  typically  described  by  a  gamma  distribution.  The  rate  variation 
among sites is described by the shape parameter ( ). Small values of   will 
result  in  L-shape  distributions,  indicating  extreme  rate  variation  across  the 
sequences,  whereas  high  values  of    will  reflect  a  bell  shape  distribution, 
demonstrating that most of the sites remain invariable (Holmes 1998). Models 
featuring a gamma distribution of rate heterogeneity are conventionally given 
the suffix +  . 
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The  simplest  model  is  the  Jukes  Cantor  model  since  it  only  includes  one 
parameter,  the  base  substitution  rate,  and  considers  the  rate  to  be  equal 
between  all  four  bases.    The  most  complex  is  the  GTR  model  since  it 
encompasses all three parameters and allows these to be user-defined.     
 
Software  such  as  ModelTest  can  identify  the  most  appropriate  evolutionary 
model, which is informed by the sequence data itself. The ModelTest algorithm 
with  the  program  PAUP  calculates  the  hierarchical  likelihood  ratios  of  56 
evolutionary models using a chi-square distribution and selects the model that 
best  fits  the  sequence  data  (i.e.  that  with  the  highest  likelihood  score)  and 
estimates the corresponding parameters.  
2.2.5  Phylogenetic trees 
A  phylogenetic  tree  is  a  graphical  representation  of  the  evolutionary 
relationships that exist between aligned sequences. Examples of different types 
of tree representations are given in Figure 2.2. A tree consists of branches and 
nodes.  Each  branch  represents  one  sequence  (or  taxa),  and  branches  are 
joined  together  by  nodes  that  represent  theoretical  ancestors.  Two  or  more 
sequences  that  share  a  node  are  referred  to  as  a  “cluster”.  The  branching 
pattern, (the order of the nodes and branches), is referred to as the “topology”.   
 
Trees can either be rooted or unrooted.  A rooted tree has a node defined as 
the root from which all other nodes have originated.  It provides a scale; the 
branch lengths indicate the extent of genetic divergence between the two taxa 
connected by a common node.   The further away a specific node is from the 
root of the tree, the more recently the node occurred in time.  An unrooted, or Alison Brown – Chapter Two 
58 
unscaled, tree shows the common ancestry of the sequences, but not the extent 
of genetic divergence.  
Figure 2.2: Schematic diagram of a rooted phylogenetic tree 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.6  Tree building methods 
There are different methods of creating phylogenetic trees.  These vary in their 
complexity, computational demands and their assumptions about evolutionary 
theory. There is no “one-fit” method to suit all data and no tree is guaranteed to 
find  the  true  evolutionary  relationships  between  sequences.  The  most 
appropriate tree building method (and, where relevant, the evolutionary model 
upon  which  it  is  created)  is  informed  by  the  specific  data  set.  Tree-building 
methods are generally categorized into “distance-based” and “character-based” 
methods. These are summarized in Table 2.2. 
Internal node 
Tree root 
Branches/taxa - each  
represents one DNA sequence 
Branch length - represents evolutionary  
distances between nodes 
Tree scale - evolutionary distance given  
as nucleotide (nt) substitutions per site 
0.05  0.1  0.15  0.2  0.25 Alison Brown – Chapter Two 
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Distance-based methods 
Distance-based methods involve two steps. Firstly, the evolutionary distance is 
calculated  between  every  possible  sequence  pair  in  the  given  alignment, 
creating a distance matrix. The proportion of nucleotide positions in which the 
two  sequences  differ  is  calculated,  creating  a  measure  of  dissimilarity. 
Secondly, the tree is constructed on the basis of the relationship between the 
distance values. There are two main distance based methods: the Unweighted 
Pair  Group  Method  with  Arithmetic  Means  (UPGMA)  and  Neighbour-joining 
(NJ). 
 
UPGMA  
This method identifies the  two sequences with the smallest genetic distance 
between them, and then halves that distance to define the branching patterns. 
These two sequences are then combined and considered as one unit. A new 
distance matrix is computed, calculating the distance from the newly formed unit 
to each of the remaining sequences. The process is repeated until there is only 
one entry in the matrix. A tree is then built on the basis of the distance matrix 
obtained.   
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Table 2.2: Summary of phylogenetic tree construction methods 
Method  Description  Advantages  Disadvantages 
Distance-based  
UPGMA  Tree  constructed  through  pair-
wise distance matrix. 
Quick.  Assumes  rate  of  molecular 
evolution is constant. 
Neighbour-
joining 
As above, but distances can be 
adjusted  through  application  of 
appropriate evolutionary model. 
Quick,  allows 
application  of 
evolutionary 
model. 
Has  been  known  to  build 
trees incorrectly. 
Character-based 
Maximum 
likelihood 
Uses  Maximum  Likelihood  to 
calculate the probability of a tree 
by describing the patterns of the 
sequence  alignment,  given  a 
specific  model  of  nucleotide 
substitution.  The  method 
calculates  the  likelihood  of  all 
possible  trees  for  the  specified 
alignment,  and  selects  the  one 
associated  with  the  maximum 
likelihood. 
Exhaustive.  Computationally demanding. 
Bayesian  Uses Bayesian theory and a user 
defined  evolutionary  model  to 
calculate “posterior” probabilities 
of  all  possible  trees  for  the 
specified alignment, and selects 
the  one  with  the  highest 
probability. 
Allows  genetic 
distances 
obtained  to  be 
time calibrated.    
Fairly time intensive. 
Parsimony  Tree  constructed  on  the  basis 
that  the  minimum  number  of 
evolutionary differences between 
sequences is the most likely. 
Quick.  Two  or  more  trees  can  be 
selected as best tree.  Does 
allow  for  substitutions 
occurring  at  same  site 
multiple times.  It only uses a 
small  fraction  of  nucleotide 
positions to inform tree. 
 
The UPGMA method assumes that the rate of evolution is linear (i.e. that there 
is a global molecular clock). Consequently all taxa are equidistant to the root. 
However, this assumption is no longer accepted; this is a frequent criticism of 
this method‟s reliability (Li 1993). 
 
Neighbour-joining 
The NJ method works in the same way as the UPGMA method, but rather than 
assuming the rate of evolution is constant, it permits the adoption of a specific 
evolutionary model.  Alison Brown – Chapter Two 
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Like  the  UPGMA  method,  it  is  quick,  and  computationally  undemanding. 
However, it cannot guarantee to find the right tree: cases have been reported 
where the true phylogeny was known, and the NJ tree building algorithm has 
provided inaccurate reconstructions (Hillis D 1996).  It has been found to have 
inferior robustness compared to character based methods (Huelsenbeck 1995).  
 
A further criticism of distance methods is that they do not make use all of the 
available  information.  Through  constructing  distance  matrices,  information 
about individual sites is lost, and only an overall estimate of relative distances 
between  the  sequences  is  given.  Additionally  the  branch  lengths  are  not 
necessarily biologically meaningful. Programmes that can be used to build NJ 
trees include ClustalW (Thompson, Gibson et al. 2002) and PAUP (Swofford 
2001). 
Character-based methods 
Character-based methods are informed directly from the sequences, rather than 
from the proportion of nucleotide differences. There are two main character-
based methods: Maximum likelihood and Bayesian analysis.  
 
Maximum likelihood 
Maximum likelihood (ML) tree construction exploits the concept of the statistical 
theory  of  likelihood  probabilities  (Felsenstein  1996).  In  the  context  of 
phylogenetic  reconstructions,  maximum  likelihood  methods  calculate  the 
probability of a tree by describing the patterns of the sequence alignment, given 
a specific model of nucleotide substitution. The method calculates the likelihood Alison Brown – Chapter Two 
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of all possible trees for the specified alignment, and selects the one associated 
with the maximum likelihood.  
 
Specifically, the likelihood (L) that the constructed tree represents the actual 
evolutionary relationship is given by: 
 
L=P (D|H) 
 
Where P is the probability that the observation D (the sequences) is true, given 
the hypothesis, H (the phylogenetic tree).  
 
The ML approach is rigorous, makes use of each nucleotide position, allows the 
user  to  adopt  a  specific  evolutionary  model  that  fits  the  specified  data  and 
permits statistical testing of evolutionary hypotheses (Holmes 1998). However, 
it is computationally demanding, particularly as the number of taxa increases. In 
order to reduce the time used to build the trees, often an initial NJ tree is used 
as  a  starting  topology,  and  likelihood  scores  are  computed  for  each 
rearrangement of the initial topology. Programs that can be used for ML tree 
construction include PAUP (Swofford 2001) and Phylip. 
 
Bayesian Analysis 
Bayesian phylogenetic analysis is based on Bayes‟ theorem. Like the Maximum 
likelihood method, the Bayesian method incorporates an explicit  evolutionary 
model, and looks for trees that correlate best to the sequence alignment under 
the specified model.  However, unlike the ML method, it calculates the so-called Alison Brown – Chapter Two 
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“posterior probability” of distribution of trees, i.e. the probability of a tree, given 
the observed data (Drummond and Rambaut 2007). The most frequently used 
software for phylogenetic Bayesian analysis is called Mr.Bayes (Ronquist and 
Huelsenbeck 2003). 
 
Bayesian analysis is becoming more popular (Lewis, Hughes et al. 2008) due to 
computational  advances.  Specifically,  a  simulation  technique  called  Markov 
Chain  Monte  Carlo  (MCMC)  has  increased  the  method‟s  efficiency.  This 
algorithm  searches  at  random  for  the  tree  with  the  highest  probability.  It 
constructs a random tree “T1”, and compares it to another randomly generated 
tree “T2”. If the likelihood of T1 is lower compared to the likelihood of T2, then 
T2 replaces the current T1. If not T1 is held in memory. The number of times a 
particular tree is held in memory is proportional to its likelihood, each tree being 
given a likelihood score on the basis of how often it was held during the MCMC 
simulation (Mau, Newton et al. 1999). 
 
This method is more efficient than the ML method since it permits simultaneous 
independent searches that can exchange information. Also, the MCMC method 
provides a measure of statistical support for each tree constructed, negating the 
need  for  techniques  to  check  tree  robustness,  such  as  bootstrapping  (see 
section 2.2.7). Bayesian analysis also permits the calibration of phylogenies, 
allowing the introduction of specific lineages to be dated (Hue, Pillay et al. 2005; 
Lewis, Hughes et al. 2008).  
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2.2.7  Tree robustness 
It is impossible to guarantee that phylogenetic reconstructions will represent the 
true  evolutionary  relationship  between  sequences  (Hillis  D  1996). 
Consequently, it is important to obtain a measure of tree robustness: this is 
frequently estimated through a process called bootstrapping (Efron, Halloran et 
al. 1996). Bootstrapping is a statistical resampling method that works through 
repeated,  random  sampling  of  columns  of  nucleotide  positions  of  sequence 
alignments.  A  new  tree  is  created  on  the  basis  of  each  randomly  sampled 
column.  This  process  is  repeated  many  times  (usually  up  to  1000).  The 
proportion of times the original tree matches the reconstructions of the randomly 
sampled  columns  is  expressed  as  a  percentage,  or  the  bootstrap  value. 
Bootstrap values are shown on the branches of the tree. A bootstrap value of 
100%  on  a  particular  branch  would  demonstrate  that  it  was  present  in  all 
sampled trees. 
2.2.8  Applications of HIV phylogenetics 
The applications of phylogenetic analyses of HIV sequences are described in 
section 1.4.    
2.2.9  Reconstructing  HIV  transmission  events  through  phylogenetic 
analysis   
For the purposes of reconstructing “who infected who” phylogenetic methods     
have  tended  to  use    maximum  likelihood  (Brenner,  Roger  et  al.  2008)  and 
Bayesian (Lewis, Hughes et al. 2008) approaches.  Those that use maximum 
likelihood approaches frequently use neighbour joining methods to identify an 
initial topology (Pao, Fisher et al. 2005; Brenner, Roger et al. 2007), and use it Alison Brown – Chapter Two 
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as the starting tree. Since the actual transmission histories are not known, it is 
difficult to validate whether reconstructions represent true transmission events, 
and  efforts  have  focused  upon  developing  a  definition  of  what  may  be 
considered a “robust” indicator of such a transmission event. 
 
The  cut-offs  used  to  identify  a  possible  transmission  event  comprise  the 
observation of a cluster with a bootstrap of at least 99% and a genetic distance 
<0.015 nucleotide substitutions per site (Hue, Clewley et al. 2004). These cut-
offs are conservative and have been shown to reduce the proportion of false-
positive clusters among a phylogenetic analysis of UK HIV sequences derived 
from individuals with a known transmission history (Hue, Clewley et al. 2004).   
The need for such definitions to be interpreted with caution remains since these 
cut-offs are not absolute indicators of transmission. 
2.2.10 Limitations  of  phylogenetic  reconstructions  of  HIV  transmission 
events 
The limitations of using phylogenetic reconstructions of HIV transmission events 
for public health purposes are described in section 1.6.1 and 1.6.2.  
2.2.11 Thesis methods and definitions 
Phylogenetic methods 
The phylogenetic methods and definitions used in this thesis are summarized in 
Figure 2.3. The sequences were aligned manually in Se-Al (Sequence Analyzer 
version  2.0).  The  nucleotide  positions  associated  with  drug  resistance  were 
deleted to prevent bias arising from convergent evolution (Shafer, Rhee et al. 
2007)  (whereby  organisms  have a  similar range  of  mutations due  to  shared Alison Brown – Chapter Two 
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environmental  pressures  rather  than  a  shared  ancestry).  A  NJ  tree  was 
constructed  using  the  General  Time  Reversible  model  with  gamma  rate 
heterogeneity  estimated  at  0.5.  The  alignment  was  then  run  through  PAUP 
(version 4.0b10) with ModelTest (version 3.7) to select the best fitting model. 
 
If there were fewer than 250 sequences in the sample, a maximum likelihood 
tree was constructed using the initial NJ tree as the starting tree, and the best 
fitting model and the parameters derived through PAUP with ModelTest. The 
resultant tree was then bootstrapped with 500 replications.  
 
If  there  were  more  than  250  sequences  in  the  sample,  a  NJ  tree  was 
constructed  using  the  most  appropriate  model  selected  by  PAUP  with 
ModelTest  and  the  parameters  derived.  This  is  because  the  computational 
demands  of  constructing  a  maximum  likelihood  tree  for  larger  sample  sizes 
were not feasible. Sequences that formed a cluster within the NJ tree were then 
selected, along with a random sample of sequences that did not form a robust 
cluster. This smaller sample of sequences  was then treated as a sample of 
fewer  than  250  sequences  and  re-run  through  PAUP  with  ModelTest  and  a 
maximum  likelihood  tree  was  constructed  accordingly  and  bootstrapping 
analysis repeated. The topology and relationship between the sequences that 
clustered  in  the  original  NJ  tree  were  then  compared.  Provided  that  the 
sequences formed the same relationship as in the original NJ tree, they were 
interpreted as a robust cluster. 
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Figure 2.3: Schematic diagram of the phylogenetic methods used throughout thesis 
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Definitions 
In all instances, a cluster was defined as two or more sequences that shared a 
common node, a bootstrap support of 99% or more, and a genetic distance of 
under 0.015 nucleotide substitutions per site (Hue, Clewley et al. 2004). This 
was interpreted as a “robust cluster” and also a “possible transmission event”  
2.3. HIV diagnostic data and identifying recent infection 
HIV infection is characterized by an extended asymptomatic period that can last 
10-12  years  (Figure  1.4).  While  a  proportion  of  patients  may  experience 
“seroconversion  illness”  shortly  after  infection,  which,  in  combination  with  a 
recent  risk  exposure  may  prompt  them  to  come  forward  for  testing  (Remis, 
Alary et al. 2000) others may remain unaware of their infection for many years.   
Many  epidemiological  studies  of  HIV  infection  are  consequently  dependent 
upon HIV-infected patients coming forward for HIV diagnostic tests. In addition 
to identifying antibodies to HIV, viral proteins, or the virus itself, diagnostic tests 
have also been adapted so that patients who acquired their infection recently 
can be distinguished from those with long-standing infection.    
 
These diagnostic markers,  and  their  application  in  ascertaining HIV  infection 
stage and calculating HIV incidence, are described below.  First the immune 
response to HIV is outlined.  Secondly, the diagnostic markers that relate to the 
specific stages of the immune response are described.   Thirdly, methods used 
to  identify  recent  infection  are  summarized  (including  diagnostic  markers, 
laboratory  algorithms  and  testing  histories).    Fourthly,  the  public  benefits  of 
linking infection stage to population-level data are summarised.  The limitations Alison Brown – Chapter Two 
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of measuring recent infection and incidence estimates at the population level 
are described.  The definitions of recent infection used in the thesis are outlined. 
2.3.1  The HIV immune response 
The HIV immune response following exposure is shown in Figure 2.4.  
Figure 2.4: Schematic diagram of viral load and immunological markers during the first 
weeks of HIV infection 
 
 
 
 
 
 
 
Source: adapted from (Murphy and Parry 2008) 
The very early stages of HIV infection are characterized by local viral growth, 
followed by viral spread two-three weeks after infection (Busch and Courouce 
1997; Busch, Glynn et al. 2005).   Approximately 10 days after infection, HIV-
RNA and the p24 antigen (a protein component of the virus core) may become 
detectable (Busch, Glynn et al. 2005), peaking at around 16 days post infection 
and declining over the following 10 weeks as the antibody response develops.    
 
The antibody response to HIV normally occurs between three to twelve weeks 
following an HIV transmission. This period, describing the change from antibody 
negative to antibody positive, is called “seroconversion”. There is considerable 
variation in the time of seroconversion between individuals (Busch, Glynn et al. Alison Brown – Chapter Two 
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2005).    The  initial  immune  response  is  typically  characterized  with  a  virus 
specific  IgM  response  (Gaines,  von  Sydow  et  al.  1988).    It  generally  peaks 
within  1-2  weeks  after infection falling  back  to background  levels 1-2  weeks 
later.  Shortly afterwards the IgG response is developed – this response is long 
lived with IgG antibody levels detectable at a high level throughout infection.   
2.3.2  Diagnostic tests 
The period of time from HIV infection to that when diagnostic tests can detect 
HIV infection, is characterized in Figure 2.5.  This period is referred to as the  
“diagnostic window” (Busch and Courouce 1997).  
 
Figure 2.5: Schematic diagram showing what stage of infection diagnostic markers can 
detect HIV infection 
 
 
 
 
 
 
 
 
 
 
 
 
Source: adapted from (Le Vu, Pillonel et al. 2008) 
Key:
1) HIV-RNA detectable
2) p24 detectable
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Most patients are diagnosed with HIV through the detection of virus specific 
antibodies to HIV (anti-HIV IgG) (Gurtler 1996). The HIV enzyme immunoassay 
(EIA  or  ELISA)  exploits  the  binding  of  the  patients‟  antibodies  against  HIV 
protein to antigens immobilized typically on the surface of the wells of microtitre 
plates. Patient serum, which may contain HIV antibodies, is added to the plate. 
Non HIV antigen binding antibodies are washed free of the plate. A second 
antibody, a conjugate, is then added to determine whether the human serum 
contains  antibodies.  Excess  conjugate  is  then  washed  from  the  plate.    A 
substrate (chromagen) is added, and the enzyme of the conjugate acts on the 
substrate to give a colour change if the serum sample contained anti-HIV. The 
intensity  of  the  colour  is  calibrated  against  a  scale  known  as  Standardized 
Optical  Density  (SOD).  A  SOD  score  greater  than  1.0  is  interpreted  as  a 
positive reaction. Confirmatory testing follows before HIV infection is diagnosed, 
using methods such as the western blot (see below).  
 
The western blot is a method of detecting specific host protein products and is 
often  used  as  a  confirmatory  HIV  test  following  a  reactive  EIA.  It  uses  gel 
electrophoresis to separate denatured HIV proteins on the basis of their relative 
molecular mass. The proteins are then transferred to a nitrocellulose membrane 
where they are probed with the patient serum that is suspected of containing 
HIV antibodies. For HIV, the antigens detected are derived from gag (p53/55, 
p24/5  p17/18,)  pol  (p31/32)  and  env  (p160,  p41  p45).    HIV  can  also  be 
diagnosed through nucleic acid testing (Pilcher, Fiscus et al. 2005) conducted 
through amplification techniques such as the polymerase chain reaction (PCR) 
and through identifying the virus through cell culture.  Alison Brown – Chapter Two 
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The diagnostic window can be reduced through combining HIV antibody tests 
with  other  diagnostic  markers.  Recent  improvements  in  HIV  test  sensitivity 
mean the latest (“4
th generation” tests) can detect both anti-HIV and HIV p24 
antigen  within  four  weeks  of  infection  (Brust,  Duttmann  et  al.  2000;  Parry, 
Mortimer et al. 2003; Perry, Ramskill et al. 2008). 
2.3.3  Identifying recent infection 
Recent  HIV  infection  can  be  ascertained  in  three  ways:  through  diagnostic 
markers;  through  laboratory  algorithms;  and  through  clinic  records  of  HIV 
testing history.    
Diagnostic markers 
Specific diagnostic markers are capable of identifying very early stages of HIV 
infection.  These include detection of p24 antigen and HIV-RNA approximately 
10 days after infection, declining over the following 10 weeks as the antibody 
response develops.   Additionally, if a western blot detects high p24 and low 
p41  levels,  this  also  indicates  early  infection.  Conversely  if  a  western  blot 
detects high pol protein products, this may indicate long standing infection.  
Laboratory algorithms 
Laboratory algorithms have been developed that exploit the early immunological 
response  to  HIV  infection  in  order  to  identify  recent  infection.    Such 
developments have been necessary because while p24 antigen and western 
blots  are  capable  of  identifying  early  stage  infection,  the  extremely  short 
duration  of  these  markers  serves  to  under-detect  recent  infection  among 
individuals recently exposed.  Alison Brown – Chapter Two 
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The Serological Testing Algorithm of Recent HIV Seroconversion, or STARHS, 
(Janssen, Satten et al. 1998) works through taking advantage of the gradual 
increase  in  anti-HIV  over  the  first  few  months  of  recent  HIV  infection  and 
assumes this increase occurs at a similar rate between individuals.    Three 
main  assays  can  be  integrated  into  STARHS;  the  detuned  assay;  the  BED 
assay; and the avidity assay. 
 
A detuned, (a less sensitive assay), can be applied to samples that were found 
to  be  anti-HIV  positive  using  a  more  sensitive  EIA.  Through  deliberately 
combining highly sensitive tests with weakly sensitive tests, these strategies are 
able to estimate the proportion of patients who have only recently undergone 
seroconversion (Parekh, Pau et al. 2001). An anti-HIV negative test in the less 
sensitive EIA indicates the sample was derived from someone who acquired 
their infection within an average of 170 days (95% confidence interval 162-183 
days) prior to the specimen collection.  
 
Alternatively,  the  detuned  assay  can  be  replaced  by  the  BED-CEIA  assay 
(Parekh, Kennedy et al. 2002).  This is a class-specific EIA that detects and 
compares the level of anti-HIV-IgG to total IgG.  It works on the assumption that 
the ratio of anti-HIV IgG to total IgG increases after infection. If a specimen is 
positive on the sensitive EIA, but has a SOD of <0.8 on the BED assay it is 
considered  to  be  recently  infected.  Avidity  assays  measure  the  strength  of 
bonding between IgGs and the corresponding antigens (Chawla, Murphy et al. 
2007). This increases over a period of months following infection.   Alison Brown – Chapter Two 
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The STARHS technique used the detuned assay up until fairly recently, but due 
to concerns about its appropriateness for non-B subtypes, its application was 
restricted to MSM populations.  The BED and avidity assay were developed as 
an alternative that could be used for both B and non B subtypes, with the avidity 
assay being most successful (Suligoi, Butto et al. 2008). 
Testing histories  
As a patient‟s HIV testing pattern is often well documented in clinic notes, an 
alternative to laboratory markers can be obtained from testing histories.  For 
instance, a short time interval (e.g. three months or less) between the date of 
the  last  HIV  negative  test  and  the  date  of  the  HIV  positive  can  be  used  to 
indicate recently acquired HIV infection.    However, this is more likely to identify 
recent HIV infection among those with frequent HIV testing patterns.  
2.3.4  Applying recent infection markers to population level data 
The development of techniques to ascertain recent HIV-infection has facilitated 
epidemiological  studies  including  the  monitoring  of  HIV  incidence  (Murphy, 
Charlett et al. 2004) and partner notification exercises (Pilcher, McPherson et 
al. 2002). They can also be used for assessment of transmitted drug resistance 
(TDR  (for  instance,  patients  recently  HIV-infected  at  diagnosis  are  almost 
certainly drug naïve)). Before the advent of STARHS, HIV incidence estimates 
were limited to calculating rate of HIV diagnoses occurring among a cohort of 
HIV negative individuals followed up over many years.  Current techniques have 
many advantages.  They are quicker and cheaper than following large scale 
cohorts,  and  tests  can  be  applied  both  to  diagnostic  samples  and 
retrospectively to stored samples.   Alison Brown – Chapter Two 
75 
 The  ability  to  ascertain  whether  a  patient  was  diagnosed  during  recent  or 
chronic infection from a single diagnostic sample has enabled the categorization 
of  viral  sequences  as  being  from  patients  who  were  recently  or  chronically 
infected at diagnosis.  In turn this has enabled phylogenetic reconstructions of 
HIV transmission events by patients with recent HIV-infection at diagnosis (see 
section 1.5.1 and 1.5.2). 
2.3.5   Limitations  associated  with  applying  markers  that  can  identify 
recent infection to population level data   
There are two issues that require consideration when applying techniques to   
identify  recent  HIV-infection  at  a  population  level.    These  relate  to  the 
techniques  themselves  and  the  selection  of  the  population  to  which  the 
techniques are applied.      These will be discussed in turn. 
  
The specific markers or techniques used to identify recent HIV infection vary   
between  studies,  making  it  difficult  to  draw  comparisons  (section  2.3.3).  
Frequently, the markers of choice are the STARHS, or utilizing testing history, 
data  due  to  the  short  window  of  opportunity  that  other  techniques  have  to 
recognize recent infection (e.g. HIV RNA and the p24 antigen).     However, the 
selection of these more inclusive markers may serve to over-estimate the length 
of  “recent  infection”.        Consequently,  a  sample  from  a  patient  ascertained 
through  STARHS  as  being  recently  HIV-infected  does  not  necessarily  mean 
that the patient was experiencing elevated viral load at the time the sample was 
taken.   
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Variation  exists  in  the  immune  response  to  HIV  between  individuals; 
consequently  there  is  also  variation  between  individuals  in  the  time  interval 
between infection and the time specific markers can detect recent HIV infection. 
(Busch and Courouce 1997; Fiebig, Wright et al. 2003). The number of days 
following infection that each test can define a recent HIV infection is not an 
absolute measure, but represents a population average.   
 
There  have  been  attempts  to  measure  the  extent  of  this  variation  for  each 
marker.  However, these have tended to focus on the markers that identify very 
early infection for purposes of accurate screening for blood donation  (Fiebig, 
Wright et al. 2003; Busch, Glynn et al. 2005). Fewer studies have focused on 
the variation for markers that identify later stages of recent HIV infection (e.g. 
STARHS  etc).    One  study  (Reed  2004)  examined  the  extent  variation  from 
infection  to  the  time  STARHS  could  identify  recent  HIV  infection,  between 
individuals.  Nearly 400 follow-up specimens were collected from 60 individuals 
with  recently  acquired  infection.    The  specific  time  interval  within  which  the 
STARHS algorithm would define a recent infection was ascertained.  Whilst the 
mean window period was 183 days following infection for the 60 individuals, the 
range  of  window  periods  extended  from  63  to  404  days,  demonstrating 
considerable variation between individuals.   Consequently laboratory markers 
and techniques need to be interpreted with caution when they are applied to 
individual samples, for instance, to calculate an infection date from a diagnostic 
sample. 
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There are a number of other factors that can affect the accuracy of algorithms 
such as STARHS.   These include late stage infection and treatment with ARV 
(Janssen, Satten et al. 1998). Whilst most infection stage tests are carried out 
on diagnostic sera, within anonymised datasets, the treatment status of patients 
from which the samples were derived cannot be known definitively; this may 
increase the risk of inadvertently including false-positive results.   Finally, the 
tests  can  be  affected  by  virus  subtype.    Algorithms  were  developed  using 
assays for use on patients with sub-type B (Janssen, Satten et al. 1998) which 
give inconsistent results for non-B subtypes.   
 
The application of algorithms to patient‟s diagnostic samples may not produce 
results  representative  of  the  populations  at  risk  of  HIV  infection.    This  is 
because  HIV  test  seeking  behaviour  may  bias  results  (Remis  and  Palmer 
2009).  The resultant bias can go in either direction.   For instance, recently 
HIV-infected  patients  may  experience  symptoms  of  seroconversion  illness, 
prompting  them  to  come  forward  for  testing  (Schacker,  Collier  et  al.  1996).  
Those with recent risk exposure may also be more likely to present for testing  
(Remis, Alary et al. 2000).  Conversely, those with lower sexual risk behaviour 
may also be more likely to seek regular health check ups.      Such biases have 
been  studied  using  modelling  techniques  in  order  to  enable  adjustment  of 
population-based HIV incidence measurements (Remis and Palmer 2009). 
2.3.6  Thesis methods and definitions  
“Recent infection” is the term used throughout the thesis, since the methods 
used to identify it in each of the datasets vary depending on the available data. 
Since  some  datasets  use  STARHS,  labels  such  as  “primary”  and  “acute” Alison Brown – Chapter Two 
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infection or “seroconverters” are inappropriate.  Recent infection will not refer to 
a  period  of  more  than  six  months  from  infection  throughout  the  thesis.  
However,  the  specific  methods  used  to  ascertain  recent  infection  are  made 
explicit throughout the thesis, and are defined for each data set in chapter three.  
2.4. Clinical and demographic data 
In the UK, laboratory and clinical reports of HIV diagnoses, and patients living 
with diagnosed HIV infection, are collected routinely on a voluntary basis by the 
Health  Protection  Agency  and  Health  Protection  Scotland  for  surveillance 
purposes (HPA 2008). Clinical and demographic data are usually collected at 
clinical consultation around the time of diagnosis.  Data include: exposure (likely 
transmission  route);  age;  country  of  infection;  country  of  birth  and  (where 
applicable) year of arrival in the UK; ethnicity; injecting drug use; plasma viral 
load and CD4 count nearest to the time of diagnosis.  
2.4.1  Geographic region of infection 
The UK has a voluntary reporting system for new diagnoses of HIV, AIDS and 
deaths.  This system attempts to ascertain the country of HIV infection through 
the  follow  up  of  likely  HIV  exposure  events  in  conjunction  with  patient 
travel/migration  history  (Dougan,  Gilbart  et  al.  2005).  However,  for  many 
studies,  the  country,  region  or  city  of  infection  is  not  always  possible  to 
ascertain: often the clinic or country of diagnosis is taken as a proxy for “region” 
of infection (Masquelier, Bhaskaran et al. 2005).  
2.4.2  Risk group and age-group  
Data  concerning  risk  group  (transmission  route) and  age  (or  age-group)  are 
routinely collected at the clinic consultation around the time of diagnosis.  Alison Brown – Chapter Two 
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2.4.3  Sexually Transmitted Infections 
STI diagnostic data are usually collected around diagnosis and for subsequent 
attendances post diagnosis. However, the specific STIs may not be reported, 
and such reports may be categorized as “acute STI” or “other” with definitions of 
these categories varying between studies.    
2.4.4  Viral load 
The quantitative detection of HIV RNA in plasma can be used as a prognostic 
marker  to  monitor  the  success  of  therapy  (Berger  et  al  2002)  and  estimate 
infectiousness. Various commercial and in house methods are available with 
the  most  sensitive  tests  capable  of  detecting  approximately  50  copies/mL. 
These are based on polymerase chain reaction (PCR), branched DNA (b-DNA) 
nucleic  acid  sequence  based  amplification  (NASBA),  ligase  chain  reaction 
(LCR) or real time PCR measurements.  
2.4.5  CD4 count 
CD4 counts provide a measure of how many CD4 cells are present and are 
consequently  used  as  an  indicator  of  the  functioning  of  the  host‟s  immune 
system  (section  1.1.7).     CD4  counts  are  consequently  collected  routinely 
around  diagnosis  and  at  subsequent  clinic  attendances.  They  are  used  to 
monitor infection progression and inform decisions on when it is appropriate to 
begin therapy.  Up until recently, treatment has commenced once CD4 cells 
counts  reached  below  200  cells/mm
3  (Pozniak,  Gazzard  et  al.  2003).    In 
Autumn  2008,  guidelines  were  revised  to  recommend  treatment  discussions 
commence when CD4 counts reached between 200-350 cells/mm
3  (Gazzard 
2008).  
 Alison Brown – Chapter Two 
80 
2.4.6  ARV treatment 
Patients  are  very  likely  to  be  drug  naïve  at  diagnosis  (exceptions  include 
patients treated with pre- and post-exposure prophylaxis before and after a risk 
exposure respectively, and those not reporting previous treatment).  Treatment 
related  data  collected  for  HIV  diagnosed  patients  at  each  clinic  visit  can 
document the occurrence and length of treatment interruptions. The treatment 
regimen may not be specified. In 2003, BHIVA guidelines recommended that 
patients without drug resistance mutations initially commence therapy with two 
nucleotide  reverse  transcriptase  inhibitors  (NRTIs),  plus  either  a  protease 
inhibitor (PI) or a non-nucleotide reverse transcriptase inhibitor (NNRTI).     
2.4.7  Limitations associated with linkage to phylogenetic analysis 
Phylogenetic  reconstructions  of  HIV  transmission  have  linked  sequences  to 
clinical and demographic data to see which patient groups have an important 
role in generating HIV transmission.  Most studies to date have used clinical 
and demographic data obtained at diagnosis to permanently categorise patients 
by risk group. For data concerning transmission route, ethnicity and, to a lesser 
extent,  age-group,  this  is  reasonable  practice.  For  other  variables  (e.g.  STI 
presence, viral load, CD4 count), this may be less appropriate, since the risk 
factors vary considerably over the time of infection.   The presence of an STI, 
(or  viral  load,  CD4  count,  treatment  status  or  infection  category)  at  around 
diagnosis will not necessarily reflect the status of that patient at the time of an 
HIV transmission event (section 1.6.4).   With reference to STI presence, it is 
not always specified whether patients were screened for STIs. If not, there is 
likely  to  be  an  underestimation  of  STI  reporting,  and  a  bias  towards 
symptomatic infections being recognized.  If data are also collected on whether Alison Brown – Chapter Two 
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patients were screened for an STI during the clinical consultation, this gives a 
better denominator for the calculation of prevalence.  
 
The treatment history of a population used in phylogenetic analysis is important.  
Sequences from patients who have experienced treatment may have altered 
considerably  to  the  sequences  present  within  the  same  patient  at  around 
diagnosis.    Consequently, for the purposes of phylogenetic reconstructions, it 
is  important  that  sequences  are  obtained  from  drug  naïve  patients,  and  are 
taken as soon as possible following diagnosis. 
2.4.8  Thesis methods and definitions 
The  clinical  and  demographic  data  available  varies  considerably  between 
datasets used in this thesis. Consequently, the specific data used are described 
in chapter three. 
2.5. Drug resistant viruses 
2.5.1  About HIV drug resistance 
HIV drug resistance is described in brief in section 1.1.9. 
2.5.2  Limitations  associated  with  monitoring  prevalence  and 
transmission of drug resistant viruses 
Measuring  the  prevalence  and  monitoring  the  transmission  of  drug  resistant 
viruses is difficult for several inter-related reasons: the complex dynamics of 
viral populations; differences in the sampling strategies; and varied definitions of 
drug resistance.   These will be discussed in turn.  Alison Brown – Chapter Two 
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Dynamics of viral populations 
Within  an  HIV-infected  individual  a  number  of  slightly  different  viral  species 
(quasi-species) exist. These variants are generated as random errors during the 
HIV life cycle. Replication errors that generate mutations can occur throughout 
the HIV genome (the most usual or common variant is known as “wild-type”). 
Each viral species may have a different level of fitness (i.e. the measure of the 
virus  ability  to  survive  and  replicate)  which  will  depend  on  two  factors:  the 
specific mutations it contains and its current environment.   
 
Whilst some mutations are “neutral” and will not affect the ability of the virus to 
survive and replicate, others are not. By chance, some mutations generated as 
replication  errors  will  confer  resistance  to  ARV  (HIV  drug  resistant  species): 
such  species  will  be  better  able  to  replicate  within  a  patient  taking  ARV. 
However, in a selectively neutral environment (for instance, untreated patients), 
wild-type variants generally have a higher reproductive fitness and will become 
the dominant strain (Devereux, Youle et al. 1999).  
 
For prevalence and transmission studies of drug resistance, the likelihood of 
finding  drug  resistance  mutations  in  the  virus  from  a  patient‟s  blood  sample 
depend  upon  the  time  elapsed  between  HIV  infection,  and  the  nature  and 
duration of ARV.  Among drug naïve patients, if a substantial amount of time 
has elapsed since infection, then the likelihood that a drug resistance mutation 
is found is decreased due the reduced fitness of the resistant strain. This will 
cause an underestimation of the prevalence of TDR. Similarly, the likelihood of 
finding drug resistance mutations among patients with acquired resistance will Alison Brown – Chapter Two 
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depend  upon  whether  the  patient  is  currently  treated  and,  if  not,  the  time 
elapsed  since  treatment  was  interrupted.      However,  all  viral  variants  are 
archived  within  the  host  and  have  the  potential  to  re-emerge  as  selective 
pressures change.   
Sampling strategies 
The  selection  of  populations  for  studies  examining  TDR  requires  careful 
consideration.  The  majority  of  studies  use  samples  taken  from  patients  at 
around the time of diagnosis: this population is likely to contain a relatively high 
but  uncertain  proportion  of  patients  with  recently  acquired  HIV  infection 
(Burchell, Calzavara et al. 2003). Additionally, some studies use populations 
exclusively drawn from patients with recent infection to facilitate comparison, 
and  to  increase  the  chance  that  drug  resistance  mutations  are  recognized 
(Yerly, Kaiser et al. 1999; Masquelier, Bhaskaran et al. 2005) – the selection of 
such populations can contain inherent biases (Remis and Palmer 2009). 
Definitions of HIV drug resistance 
There is no unambiguous definition of HIV drug resistance mutations. This is for 
several  reasons.  Firstly,  drug  resistance  mutations  arise  as  a  response  to 
circulating ARV drugs: consequently new mutations appear as new drugs are 
introduced. Secondly, drug resistance mutations require different definitions for 
different purposes. Some are needed to inform clinical treatment options and 
others for surveillance purposes.  However, some clinically relevant mutations 
are  also  polymorphic  (i.e.  the  nucleotide  position  has  two  or  more  variants 
circulating at a high frequency in the population). Consequently, the inclusion of 
polymorphic mutations (that also confer drug resistance) in definitions used for Alison Brown – Chapter Two 
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surveillance purposes will lead to an overestimation of the prevalence of drug 
resistance  mutations.    Thirdly,  the  definitions  have  to  be  derived  from  the 
sequences that are available.  The majority of definitions have been derived 
from subtype B viruses. Preliminary observations suggest that mutations that 
cause drug resistance in subtype B viruses are also the main mutations that 
cause drug resistance in non-B viruses (Kantor, Katzenstein et al. 2005).   
 
There are at least five expert lists of HIV drug resistance definitions: ANRS drug 
resistance  interpretation  algorithm;  HIVdb  drug  resistance  interpretation 
algorithm (Rhee, Gonzales et al. 2003); IAS-USA Mutations Associated With 
Drug  Resistance  (Johnson,  Brun-Vezinet  et  al.  2008);  Los  Alamos  National 
Laboratories HIV Sequence database (Clark 2003) and the Rega Institute Drug 
Resistance Interpretation Algorithm (Van Laethem, De Luca et al. 2002).  Each 
varies to the extent that they list polymorphic mutations and/or mutations that 
are associated with reduced response to ARV.   The complete list of mutations 
associated  with  each  of  these  lists  can  be  found  on  the  Surveillance  Drug 
Resistance  Mutation  (SDRM)  worksheet  (http://hivdb.stanford.edu/cgi-
bin/AgMutPrev.cgi accessed 20th August 2009). 
 
In 2007, Shafer et al. defined a list of mutations suitable for epidemiological 
studies (Shafer, Rhee et al. 2007). Mutations are included provided they meet 
the  following  criteria:  commonly  recognized  as  causing  or  contributing  to 
resistance;  non-polymorphic  in  untreated  persons;  applicable  to  all  HIV 
subtypes.  However, the list does not include all clinically relevant mutations.  
This list has recently been updated (Bennett, Camacho et al. 2009). Alison Brown – Chapter Two 
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2.5.3  Thesis methods and definitions 
The list of mutations deemed appropriate for surveillance purposes were used 
to define drug resistance mutations (Shafer, Rhee et al. 2007). These mutations 
are described in Table 2.3. 
 
Table 2.3: HIV drug resistance mutations suitable for use for surveillance purposes 
Drug 
class 
Drug resistance mutations for surveillance 
PI  L24I, D30N, V32I, M46I, I47A, I47V, G48V, I50V, I50L, F53L, I54V, I54L, I54M, I54A, 
I54T, I54S, G73C, G73S, G73T, G73A, V82A, V82F, V82T, V82S, V82M, I84V, I84A, 
I84C, N88D, N88S, L90M 
NRTI  M41L, K65R, D67N, D67G, D67del, T69D, T69ins, K70R, L74V, V75A, V75M, V75T, 
V75S, F77L, Y115F, F116Y, Q151M, M184V, M184I, L210W, T215Y, T215F, T215C, 
T215D, T215E, T215S, T215I, T215V, K219Q, K219E, K219R 
NNRTI  L100I,  K101E,  K103N,  K103S,  V106A,  V106M,  Y181C,  Y181I,  Y188L,  Y188H, 
Y188C, G190A, G190S, G190E, G190Q, P225H, M230L, P236L 
 
Source: (Shafer, Rhee et al. 2007) 
The  drug  resistance  mutations  were  identified  directly  from  the  HIV  pol 
sequences.  After  identification  of  specific  drug  resistance  mutations,  the 
nucleotide  positions  associated  with  drug  resistance  were  deleted  prior  to 
phylogenetic analysis to prevent bias from convergent evolution. 
 
All patients with drug resistance mutations who were also recently HIV-infected 
at  diagnosis  and/or  drug  naïve  were  categorized  as  having  TDR.    All  other 
patients  with  drug  resistance  mutations  were  categorized  into  “acquired”  or 
“transmitted” drug resistance using relevant clinical and diagnostic data. Where 
data  were  not  available  to  categorize  patients  in  this  way,  this  is  explicitly 
stated. Alison Brown – Chapter Two 
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2.6. Conclusion 
This  chapter  has  described  the  principles  of  phylogenetic  analysis.    It  also 
summarized  the  laboratory  and  clinical  data  that  can  be  linked  to  HIV  pol 
sequences  for  the  phylogenetic  reconstruction  of  transmission  events.  The 
methods and limitations of obtaining, linking, analyzing and interpreting these 
data  sources  have  been  described  and  thesis  definitions,  where  applicable, 
have been outlined.   
  
In summary, a range of data sources are available that can be combined with 
HIV  pol  sequences  to  interpret  phylogenetic  reconstructions  of  transmission 
events.  Combining  data  sources  creatively  has  the  potential  to  enhance  our 
understanding about different aspects of HIV transmission. Specifically, it can 
help identify which groups are generating HIV transmission, the role of infection 
stage, viral load and other risk factors, and the transmission of drug resistant 
viruses. The availability of such datasets is likely to enhance the targeting of 
public  health  interventions  to  reduce  HIV  transmission.    However,  two  main 
considerations  are  apparent:  the  likely  biases  resulting  from  accessing  a 
sequence-based  dataset  and  the  appropriateness  of  linking  laboratory  and 
clinical  data  to  interpret  phylogenetic  reconstructions  of  HIV  transmission 
events. Alison Brown – Chapter Three 
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3. Chapter Three: Four datasets 
 
 
 
 
 
This chapter describes and compares the four data sets used in the thesis and 
outlines the specific considerations in interpreting the data from each.   Alison Brown – Chapter Three 
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3.1.  Introduction 
This thesis uses datasets derived from four populations: the Concerted Action 
on  Seroconversion  to  AIDS  and  Death  in  Europe  (CASCADE)  study;  the 
Unlinked  Anonymous  Survey  of  Sexually  Transmitted  Infection  (STI)  Clinic 
Attendees (the UA STI survey); a population of men who have sex with men 
(MSM) attending the Brighton HIV clinic; and a random selection of anonymised 
HIV  pol  sequences  taken  from  MSM  attending  clinics  in  Manchester  and 
London.    The  first  two  datasets  were  derived  from  subsets  of  established, 
ongoing surveys.  The third population was created for a phylogenetic study on 
transmission  potential  of  the  recently  HIV-infected  in  2005  (Masquelier, 
Bhaskaran et al. 2005; Pao, Fisher et al. 2005), but was updated and extended 
for this thesis.  The fourth is an extract taken from an established dataset. This 
chapter aims to describe and compare the four datasets used in the thesis.  It 
also outlines the specific considerations in interpreting results from each source. 
3.2.  CASCADE 
3.2.1  Background 
Established  in  1997,  CASCADE  is  an  international  multi-centre  study  that 
monitors events among over 17,000 HIV-infected individuals with well estimated 
infection dates, throughout the course of their infection (Porter, Babiker et al. 
2003).  Its aims
 are to (CASCADE 2009):   
1)  “Estimate the survival expectations and assess changes over time;  
2)  Examine  the  characteristics  of  recently  acquired  HIV  infection  in  the 
population and changes over time; 
3)  Assess the impact of adverse drug reactions on survival, particularly if Alison Brown – Chapter Three 
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therapy is started close to seroconversion, and monitor changes in the 
cause of death over time; 
4)  Examine any changes in the characteristics of the HIV virus over time; 
5)  Determine the impact of transmitted resistance, virus subtype, and host 
genetic factors on response to therapy and clinical outcome; 
6)  Characterise the foci of recent HIV epidemics in Eastern Europe; 
7)  Characterise initial disease progression in new epidemic areas; 
8)  Examine the effect of co-infection on HIV disease and response to 
therapy; 
9)  Develop new techniques to facilitate the co-ordination of HIV clinical 
research across European cohorts." 
 
There  are  23  cohorts  collaborating  in  CASCADE,  taken  from  15  European 
countries,  and  Australia  and  Canada.  HIV-infected  patients  are  eligible  for 
inclusion provided they are over 15 years old and have a reliably estimated date 
of infection. Patients are enrolled locally and nationally, and submitted to the 
CASCADE  database,  which  is  maintained  in  the  UK.    Patients  are  typically 
followed-up throughout the course of their infection.  For this thesis, a subset of 
data was provided comprising drug naive HIV-infected patients with accessible 
HIV pol sequences. 
3.2.2  Demographic and clinical data 
Clinical  and  demographic  data  are  collected  locally,  and  submitted  to  the 
CASCADE  dataset.    Clinical  data  available  in  the  thesis  included:  exposure 
category;  estimated  infection  date;  and  diagnosis  date.    Demographic  data 
included  age; sex; and country of HIV diagnosis.     Alison Brown – Chapter Three 
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3.2.3  Infection stage 
For CASCADE, definitions of recently HIV-infected patient included: a) an HIV 
positive test within three years of an HIV negative test; b) an antibody negative 
test with polymerase chain reaction (PCR) positivity; or c) an evolving antibody 
response (Masquelier, Bhaskaran et al. 2005). The estimated infection date was 
taken as the midpoint between the diagnosis date and the last HIV negative test 
date.  For the laboratory marker, the date the sample was taken was used as a 
proxy.    
3.2.4  Sequences 
In  each  participating  cohort,  the  first  plasma  sample  available  after  the 
estimated  infection  date  was  taken  for  genotypic  resistance  testing.  The 
sequencing  methodology  has  been  described  previously  (Masquelier, 
Bhaskaran  et  al.  2005).  Participating  centres  were  asked  to  provide  pol 
nucleotide sequence data (the entire protease (PR) gene and at least codons 
41-236 of reverse transcriptase (RT)).   
3.2.5  Ethics 
Ethics approval for cohorts contributing to CASCADE is maintained according to 
the respective national regulations in the countries concerned. 
3.2.6  Dataset specifics 
From data pooled in December 2004, 8993 patients from 10 European cohorts, 
with  a  reliably  estimated  date  of  infection  (ranging  from  1989-2004)  were 
submitted  to  the  CASCADE  dataset.  Of  these,  677  had  complete  pol 
sequences, and were from drug naïve patients, taken fewer than 18 months 
after the estimated date of infection.    Alison Brown – Chapter Three 
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In order to ensure the definitions of recent infection were broadly consistent 
between  the  three  datasets,  for  the  purposes  of  this  thesis,  the  CASCADE 
definition for recent infection using the date algorithm was modified.  The date 
of the last negative test and the date of the HIV positive test were available, so 
it was possible to select a sub-sample for which the interval between the two 
dates was shorter.  Unless stated otherwise in this thesis, patients were defined 
as being recently infected provided they had an HIV positive test within 90 days 
of an HIV negative test.  Using this definition, the sample size was reduced from 
677 patients defined as seroconverters using the CASCADE definition to 165 
patients with recent infection. Thirty four sequences were anti-HIV negative, but 
PCR positive, and 131 had fewer than 90 days between their HIV positive test 
date and their last HIV negative test date.  
3.3. Unlinked Anonymous Survey of STI clinic attendees 
3.3.1  Background 
The UA survey (Catchpole, McGarrigle et al. 2000) is part of a family of surveys 
that  make  up  the  Unlinked  Anonymous  Prevalence  Monitoring  Programme 
(Nicoll, Gill et al. 2000).  This programme measures the prevalence of HIV using 
samples  left-over  from  tests  undertaken  for  clinical  purposes  in  accessible 
population groups.  The residual samples are unlinked and anonymised from 
any patient identifiers before HIV testing.  It is impossible to link back an HIV 
test result to the patient from whom the sample was derived.  
 
Specifically, the UA STI survey has been continuing from 1989 (Gill, Adler et al. 
1989)  and  measures the prevalence of  HIV  infection  (including  undiagnosed Alison Brown – Chapter Three 
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HIV  infection)  among  attendees  at  sentinel  STI  clinics.  It  also  monitors  the 
uptake  of  voluntary  confidential HIV  testing  (VCT) in  this population  (Brown, 
Tomkins et al. 2006).  
 
Sentinel  clinics  participate  in  the  survey  in  England,  Wales  and  Northern 
Ireland.  In each clinic, all attendees undergoing a blood test for syphilis are 
included in the survey.  Patients can be included in the survey up to four times 
per  year,  but  only  once  during  each  calendar  quarter.  Blood  left  over  from 
syphilis testing is irreversibly unlinked from patient identifiers and anonymously 
anti-HIV tested.  Limited demographic and clinical data are retained with the 
sample to assist with interpretation. 
  
Demographic and clinical data 
Clinical  data  consisted  of:  STI  diagnosis;  known  HIV  positive;  and  VCT 
received.  Demographic data consist of: age-group; world region of birth; year 
and quarter of attendance. 
 
Using clinical data, patients are categorized by diagnosis status.  Samples from 
patients found to be anti-HIV positive through UA testing are categorized as 
“previously diagnosed” (diagnosed before the clinic attendance) or “previously 
undiagnosed”.    Samples  from  “previously  undiagnosed”  patients  are  further 
subdivided into “newly diagnosed” (diagnosed during the clinic attendance) and 
“undiagnosed” (left clinic attendance unaware of their HIV infection).  Alison Brown – Chapter Three 
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3.3.2  Infection stage 
Since 1995, samples from MSM found to be HIV-infected with an undiagnosed 
or newly diagnosed HIV infection have undergone further laboratory testing with 
the  Serological  Testing  Algorithm  for  Recent  HIV  Seroconversion  (STARHS) 
(Janssen, Satten et al. 1998).  This has been conducted to provide an annual 
measure  of  incidence  among  this  population  (Murphy,  Parry  et  al.  2001; 
Murphy, Charlett et al. 2004). 
3.3.3  Sequences 
A  subset  of  samples  obtained  during  1999-2002  from  MSM  ascertained  as 
recently HIV-infected through STARHS were genotyped for the pol gene for a 
study on transmitted drug resistance (unpublished).  The PR region of pol was 
sequenced, along with the first 230 codons of RT (Tatt, Barlow et al. 2004).  
3.3.4  Anonymisation 
The anonymous nature of the UA technique means no patient identifiers are 
retained with the sample or the sequence.  
3.3.5  Ethics 
The  UA  survey  has  had  ethical  approval  since  its  inception  in  1989  and  is 
compliant with the Human Tissue Act (2004).  
3.3.6  Dataset specifics 
A  flow  diagram  showing  how  data  were  obtained  for  this  thesis  is  given  in 
Figure  3.1. While  the  UA  survey  has  been  continuing  since  1989,  only  the 
years for which sequences are available (1999-2002) are included in this thesis.   
Between 1999 and 2002, 28530 MSM attending the sentinel STI clinics were Alison Brown – Chapter Three 
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included in the UA survey (Figure 3.1).  Of these, 3692 were found to be HIV 
positive,  of  whom  1072  had  a  previously  undiagnosed  HIV  infection  (newly 
diagnosed or undiagnosed HIV infection).  Among this group, 21% (229) were 
found to have been recently-infected through STARHS. Complete PR and RT 
sequences were obtained for 127 recently HIV-infected patients (samples from 
the remaining 102 could not be amplified).   
Figure 3.1: Flow diagram showing collation of UA STI survey data 
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3.4. Brighton 
3.4.1  Background 
Between 2000-2007, the Brighton HIV/STI clinic managed over 90% of the local 
diagnosed HIV-infected population (personal communication, SOPHID, HPA).  
The  population  of  clinic  attendees  therefore  represents  a  relatively 
comprehensive insight in to a local sexual network.   
 
Since 2000, samples from MSM newly diagnosed with HIV have been referred 
to  be  tested  for  recent  infection  and  sequence-based  antiretroviral  therapy 
(ARV) resistance testing. This has enabled the creation of a large pol sequence 
database linkable to information on patient infection stage.   This data set was 
created for a study of the transmission among the recently infected population 
in 2005 (Pao, Fisher et al. 2005).  For this thesis, the database was updated to 
also include patients attending between 2004-6 and clinical data extended to 
include plasma viral load and CD4 counts. 
3.4.2  Demographic and clinical data 
Clinical  data  were  obtained  through  clinic  case  notes  and  electronic  patient 
records. The fields included: evidence of an STI; plasma viral load; CD4 counts; 
treatment;  drug  resistance  mutations;  date  of  diagnosis.  Demographic  data 
collected included: age-group; ethnicity; world region of birth. 
 
Brighton  HIV/STI  clinic  is  a  collaborator  of  the  UK  Collaborative  HIV  Cohort 
Study  (UK  CHIC)  (UK-CHIC  2004).  This  is  a  UK  research  programme  that 
follows up clinical details of HIV-infected individuals attending key HIV clinics Alison Brown – Chapter Three 
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over the course of their infection.    Clinical details for each diagnosed HIV-
infected  patient  attending  Brighton  HIV/STI  clinic  are  submitted  to  UK  CHIC 
annually.  Consequently, clinical details were available through linkage to UK 
CHIC  for  the  vast  majority  of  the  HIV-infected  attendees  at  diagnosis  and 
subsequent attendances.  This allowed the creation of a longitudinal database 
capable of following up HIV diagnosed MSM attending the clinic, throughout the 
study  period.    Data  were  updated  for  patients  for  each  calendar  quarter 
following diagnosis (Figure 3.2). 
3.4.3  Infection stage 
All patients newly diagnosed with HIV since 2000 were referred for laboratory 
testing:  p24  antigen;  western  blot;  and  STARHS.    STARHS  testing  was 
performed using the bioMerieux Vironostika HIV assay as previously described 
(Pao, Fisher et al. 2005).  From clinic notes, HIV testing history was available: 
patients with 183 days or fewer between their last HIV negative test date and 
their HIV positive test date could therefore be identified. The precise method for 
estimating infection dates for each patient from whom a sample was obtained is 
detailed in section 6.2.1.    
3.4.4  Sequences 
Brighton HIV/STI clinic collaborates with and submits HIV pol sequence data to 
UK  HIV  drug  resistance  database  (MRC-Resistance-Database  2009).    This 
national  database  collates  HIV  pol  sequence  data  annually  to  estimate  the 
prevalence of drug resistant viruses within untreated patients, and describes the 
pattern of drug resistance among treated patients.  Sequences submitted to the 
MRC HIV drug resistance database from patients who attended Brighton clinic Alison Brown – Chapter Three 
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between 2000-2006 were extracted for this study. Patients for whom complete 
sequences were initially unavailable were actively followed up for sequences 
from  the  laboratory  where  the  sequence  was  originally  obtained.   Where no 
sequence was available, stored RNA samples taken from the patients around 
diagnosis  were  sent  to  collaborating  laboratories  for  HIV  pol  sequencing.  
Where no stored RNA sample was available, for the purposes of this study, 
fresh  samples  were  collected,  with  patient  consent,  during  routine  clinical 
consultation and sent to collaborating laboratories for sequencing. 
 
For each patient, details were available on the timing of treatment history in 
relation  to  the  date  that  the  sample  was  taken  for  drug  resistance  testing.  
Patients with viruses resistant to ARV therefore could be categorized as having 
acquired or transmitted drug resistance.   
3.4.5  Anonymisation 
Patient  identifiers  were  used  initially  to  link  clinical  records  from  Brighton 
HIV/STI clinic to longitudinal clinical and demographic data from UK CHIC study 
and to sequences stored at the UK HIV drug resistance database.  The patient 
identifiers were then removed and replaced with anonymous ID labels by a third 
party prior to phylogenetic analysis. 
3.4.6  Ethics 
The  project  obtained  LREC  approval  in  November  2006  (06/Q1907/93). 
Patients from whom a fresh DNA sample was sought for the study had written 
consent obtained.  The leaflet and consent letter are given in appendix B. 
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Figure 3.2: Flow diagram showing collation of Brighton data  
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3.4.7  Data set specifics 
Between 2000 and 2006 1144 HIV-infected patients attended Brighton HIV/STI 
clinics with clinical and demographic data available.  Complete sequences were 
linkable to 859 of the 1144 HIV-infected patients.  Of these, 431 were newly 
diagnosed during the study period. 
 
In total 159 of 859 HIV-infected patients linkable to sequences were found to be 
recently infected.  Of these 21, were found to be recently infected through p24 
antigen, three through western blot, 119 through STARHS and 16 through the 
date algorithm. 
 
For each patient, data were also available on treatment history, viral loads, CD4 
count  and  any  AIDS  defining  illnesses.    These  data  were  updated  for  each 
quarter, for each patient, following diagnosis.  Where data were not available for 
a specific quarter, data from the previous quarter were carried forward.   Where 
a patient did not attend for 12 consecutive months, they were considered lost to 
follow-up and excluded from subsequent calendar quarters. 
3.5. HIV sequences from MSM diagnosed in London and Manchester 
An extract of 500 pol subtype B sequences from MSM diagnosed at a London 
and 500 from a Manchester clinic were selected at random from an existing 
dataset  (Lewis,  Hughes  et  al.  2008).   This  dataset  has  London  Multicentre 
Research  Ethics  Committee  approval  (MREC/01/2/10).  These  data  were 
selected  to  explore  the  consistency  of  the  phylogenetic  approach  in  chapter 
four.   Consequently, no additional data were linked to the sequences. Alison Brown – Chapter Three 
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3.6. Comparison of the datasets 
The  key  characteristics  of  the  datasets  are  summarized  in  Table  3.1.    This 
section compares the attributes of the first three datasets: CASCADE; UA STI 
survey;  and  Brighton  only.  The  fourth  dataset  is  not  included  because  no 
additional data were linked to the sequences. 
 
While the three datasets are each comprised of HIV-infected patients linkable to 
infection  stage  information  and  pol  sequences,  there  are  considerable 
differences between them.     
3.6.1  Geographical coverage 
Each  dataset  has  a  different  level  of  geographical  coverage:  European 
(CASCADE); national (UA STI); and local (Brighton).   In terms of phylogenetic 
analyses,  this may  mean  there  is  a  higher  probability  of  identifying  possible 
transmission events in the Brighton dataset, since there is a greater chance that 
patients from the same sexual networks will be included within the population 
sample.    Consequently,  comparing  the  number  of  transmission  events 
reconstructed between sequences within each dataset will not be meaningful. Alison Brown – Chapter Three 
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Table 3.1: Key characteristics of the four datasets  
Data 
source 
Geographical 
coverage 
Number of pol 
sequences 
Years 
sampled 
Sample 
characteristics 
Additional data  Method use to 
ascertain recent 
infection 
Estimation of 
infection date 
CASCADE  11 European 
cohorts. 
677 or 165*  1989-2004  Exclusively 
recently HIV-
infected. Mainly 
MSM/IDUs. 
Risk group, age-
group, country 
P24 antigen, 
western blot and 
interval of <90 
days between 
last negative test 
and HIV 
diagnosis. 
Midpoint of HIV 
negative and positive 
test is used.  For 
laboratory evidence, 
sample date is taken. 
UA survey  15 clinics in 
England Wales 
and Northern 
Ireland. 
127  1999-2002  Exclusively 
recently HIV-
infected MSM.  A 
proportion are 
undiagnosed 
Undiagnosed or 
newly diagnosed. 
VCT uptake. STI 
diagnosis, age-
group, attendance 
quarter, world 
region of birth. 
STARHS  Quarter of 
attendance is taken 
as a proxy. 
Brighton 
HIV/STI 
clinic 
One local 
HIV/STI clinic. 
859  2000-2006  Both recently and 
chronically HIV-
infected MSM 
attending 
Brighton HIV/STI 
clinic 
Infection stage, 
STI, age-group, 
WRB, diagnosis 
quarter, treatment 
history. 
P24 antigen, 
western blot, 
STARHS and 
interval of <90 
days between 
last negative test 
and HIV 
diagnosis. 
See section 6.2.1 
Randomly 
selected 
sequences 
MSM 
diagnosed in 
clinics in 
London 
/Manchester. 
500 from 
London and 
500 from 
Manchester. 
N/A  Subtype B and 
from MSM 
None.  N/A  N/A 
* depending on the definition of recent HIV infection used (see section 3.2.6). Alison Brown – Chapter Three 
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3.6.2  Demographic data 
The datasets have different demographic variables available.  All three datasets 
included  age-group  and  exposure  group.  While  CASCADE  includes  data  on 
country  of  diagnosis,  it  does  not  contain  data  on  world  region  of  birth  or 
ethnicity.  The UA survey and the Brighton data set contain data on world region 
of birth, with the Brighton dataset also containing data on ethnicity. 
3.6.3  Clinical data 
The level of clinical data available also varies between the datasets.  Only the 
diagnosis date and exposure group is available for CASCADE (all patients are 
treatment naïve).   The UA survey and Brighton both contain data on diagnosis 
date, and STI diagnosis.  The UA survey is likely to be more comprehensive in 
terms of the STI data since the majority of patients are likely to be screened for 
an STI.  For Brighton, only evidence of an STI diagnosis is available,  since 
patients may not be screened at every attendance.   The UA survey is able to 
categorize HIV-infected patients into the undiagnosed and the newly diagnosed. 
It also contains information on which patients received VCT.  
 
The  Brighton  data  set  contains  comprehensive  data  for  markers  of  disease 
progression  and  treatment  (plasma  viral  load,  CD4  count,  AIDS  defining 
illnesses, and treatment (treatment native, treated and treatment interruption)).  
Additionally, unlike the UA survey and CASCADE, these variables are updated 
for each patient, by calendar quarter throughout the study period. Alison Brown – Chapter Three 
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3.6.4  Infection stage 
The  methods  used  to  ascertain  recent  infection  vary  between  the  three 
datasets, and are  shown  in  Table  3.1.    Since  each  method for ascertaining 
recent infection is different, comparing “recently HIV-infected patients” between 
data sets may not be entirely valid.    
 
The UA survey is the only study for which the marker used to identify recent 
infection is consistent within the dataset.  Both CASCADE and Brighton use a 
mixture of techniques to identify recent infection. This has implications for the 
accuracy and consistency of ascertaining “infection dates” for individuals within 
datasets,  and  the  extent  to  which  overall  comparisons  can  be  made  both 
between and within studies. 
3.6.5  Sequences 
The number of sequences available for each data set varies (Table 3.1).  In 
order  that  phylogenetic  analysis  is  not  biased  by  convergent  evolution,  it  is 
important that the sequences are taken from the drug naïve.   For CASCADE, 
only sequences from the drug naïve were provided.  For the UA survey, only 
samples  from  patients  who  were  undiagnosed,  or  newly  diagnosed  were 
included  –  consequently  all  sequences  should  be  from  the  treatment  naïve.  
However, there is a possibility that patients with a diagnosed HIV infection may 
have  attended  one  of  the  participating  clinics  for  STI  screening,  and  not 
revealed their HIV status.  For Brighton data, information was available on the 
date the sequence was obtained, and the date the patient initiated treatment.  It 
is therefore possible to verify which sequences are from the treatment naïve.  
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Since sequences are not available for every patient, it is important to consider 
whether patients with complete pol sequences differ in any substantial way to 
patients for whom no HIV sequence data are available (Table 3.2).  For the UA 
STI survey, the demographic make up between the 127 recently HIV-infected 
MSM  with  HIV  pol  sequences  and  the  1072  previously  undiagnosed  HIV-
infected MSM without HIV pol sequences were similar: the median age-group 
for both groups was 25-34 years and the proportion of non-UK born MSM was 
40% (51) and 38% (407) respectively.   
 
Table 3.2: Differences between HIV-infected patients with and without HIV pol sequences, 
UA survey and Brighton  
Attributes  UA survey (previously 
undiagnosed) 
Brighton 
  Sequence 
available 
N= 127 (%) 
Sequence not 
available 
N= 1072 (%) 
Sequence 
available 
N= 859 (%) 
Sequence not 
available 
N= 285 (%) 
Median age/age-group 
  25-34  25-34  38  39 
Non-UK born/non UK 
national  51 (40.2)  407 (38.0)  239 (27.8)  76 (26.7) 
London clinic  109 (87.2)  836 (78.0)  -  - 
STI  47 (27.6)  501 (36.3%)  66 (7.6%)  13 (4.6) 
Proportion 
undiagnosed  70 (55.2)  639 (59.7)  -  - 
Recently HIV-infected  -  -  159 (18.5)  30 (10.5) 
Median plasma viral 
load copies/mL  -  -  41,180  11,425 
Median CD4 count 
(cells/mm
3)  -  -  392  404 
 
For  the  Brighton  data,  the  demographic  attributes  between  the  MSM  at 
diagnosis  with  (n=859)  and  without  (n=285)  HIV  pol  sequences  were  also 
similar:  for  instance  median  age  was  38  vs.  39  respectively.    However,  the 
clinical  markers  at  diagnosis  varied  between  the  two  groups.    A  higher 
proportion of MSM with HIV pol sequences had an STI (7.6%) and a higher 
average  plasma  viral  load  at  diagnosis  (41,180  copies/mL).    The  equivalent Alison Brown – Chapter Three 
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figures for MSM without HIV pol sequences were 4.5% and 11,425 copies/mL.  
The  elevated  plasma  viral  load  at  diagnosis  is  likely  to  reflect  the  higher 
proportion  of  this  population  who  were  recently  HIV-infected  at  diagnosis: 
18.5% vs. 10.5% among MSM with and without HIV pol sequences respectively.  
This is because the proportion of patients with a recent infection at diagnosis 
increased between 2000-2006 (section 6.3.4); a time when the proportion of 
newly diagnosed MSM who had samples taken for HIV drug resistance testing 
also increased. 
3.7. Conclusion 
Four data sources are used in this thesis.  Of these, three contain clinical and 
demographic  data  linkable  to  HIV  pol  sequences  and  are  either  entirely 
constituted  from  individuals  with  “recent  infection”  or  have  data  on  infection 
stage.    Despite  the  similarities,  substantial  differences  remain  in  relation  to 
geographic distribution, the number of sequences and the availability of data.    
The fourth dataset contains no other data than subtype B pol sequences.   The 
specific attributes of each dataset require consideration during study design and 
interpretation,  and  when  making  comparisons  within  and  between  datasets.   Alison Brown – Chapter Four 
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4. Chapter Four: The consistency of phylogenetic 
reconstructions of HIV transmission events. 
 
 
 
 
 
This  chapter  assesses  the  accuracy  of  HIV  transmission  reconstructions  in 
relation to their consistency.  It uses two anonymous datasets of pol sequences 
from  men  who  have  sex  with  men,  one  from  London  and  the  other  from 
Manchester.  For  each  data  set  an  initial  phylogenetic  reconstruction  was 
undertaken, and the number of possible transmission events recorded.  The 
phylogenetic reconstruction was repeated for each dataset with the sample size 
and evolutionary models used to construct the tree varied.  In each instance, 
the  number  of  initial  transmission  events  retained,  and  novel  transmission 
events created, were identified and described. Alison Brown – Chapter Four 
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4.1.  Introduction  
The assumption that phylogenetic reconstructions of HIV transmission events 
are accurate is critical to this thesis and the increasing number of phylogenetic 
analyses  of  HIV  pol  sequences  conducted  for  public  health  purposes  (Pao, 
Fisher et al. 2005; Brenner, Roger et al. 2007; Lewis, Hughes et al. 2008).  The 
suitability of phylogenetics for public health purposes has not been investigated 
thoroughly, and inaccurate reconstructions have been reported (section 1.6.1). 
 
It  is  not  possible  to  verify  the  transmission  events  identified  through 
phylogenetic  reconstructions  through  linkage  to  sexual  histories  on  a  large 
scale.    However,  it  is  possible  to  perform  sensitivity  analyses  to  assess  the 
consistency  of  the  phylogenetic  approach.    This  chapter  takes  HIV  pol 
sequences  from  two  population  samples:  MSM  diagnosed  in  London  and  in 
Manchester.    It assesses the consistency of the phylogenetic clusters formed 
within each dataset and describes how clusters change under varied sample 
sizes and models of evolution. 
4.2. Method    
This chapter used two anonymised datasets:  HIV pol sequences taken from 
500 MSM diagnosed with HIV in London, and 500 MSM diagnosed with HIV in 
Manchester (section 3.5).  Whilst the specific sequence sources are not known, 
the datasets were derived from the data utilized in Lewis et al. (Lewis, Hughes 
et al. 2008).   Drug resistance mutation sites (Shafer, Rhee et al. 2007) were 
deleted prior to reconstruction. Initial phylogenetic trees were constructed for 
both the London and Manchester datasets using a neighbour joining tree with Alison Brown – Chapter Four 
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gamma rate heterogeneity set at 0.5 and 500 replicates of bootstrapping. The 
two sequence alignments were each run through ModelTest to ascertain the 
sample heterogeneity. 
  
Using  the  initial  neighbour  joining  trees,  possible  transmission  events  were 
identified and categorised as robust, medium or weak.  The definitions were as 
follows - two or more sequences that share a common node and: 
  Robust: bootstrap support of =>99% and an average genetic distance of 
<0.015  nucleotide  substitutions  per  site  (this  is  the  definition  used 
throughout the thesis – section 2.2.11); 
  Medium: bootstrap support of >95% and <99% and a genetic distance of 
>0.015 and <0.03 nucleotide substitutions per site; 
  Weak: bootstrap support of >90% and <95% and a genetic distance of 
<0.05 and >0.03 nucleotide substitutions per site. 
Where the bootstrap and genetic distance value would have placed the cluster 
into different categories (e.g. a bootstrap support of 97% and a genetic distance 
of 0.014), the "weaker” marker was used to categorise the cluster (e.g. in the 
example above, the cluster would be categorised as “medium”). 
 
Phylogenetic reconstruction was repeated with each of the two datasets, each 
time varying the sample size or evolutionary models applied. The number of 
original transmission events identified in the initial tree was noted, and in each 
subsequent  reconstruction,  the  number  of  original  transmission  events  that 
were  maintained  in  the  subsequent  analyses,  and  any  novel  transmission 
events added, were recorded.   Alison Brown – Chapter Four 
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The variations were as follows (see Figure 4.1): 
   Analysis A: Number of sequences included in each population sample 
reduced by a fifth at random (sequence labels were sorted numerically, 
and every fifth sequence deleted); 
  Analysis B: Number of sequences included in each population reduced 
by half at random (sequence labels were sorted numerically and every 
other sequence was deleted); 
  Analysis C: Number of sequences included in each population sample 
reduced  non  randomly  (one  sequence  from  each  initial  robust  cluster 
deleted); 
  Analysis D: Number of sequences included in each dataset reduced non 
randomly (half of the initial sequences that did not form a robust cluster 
deleted); 
  Analysis E: Neighbour joining tree constructed under different models of 
evolution:  General  time  reversible  model  (GTR);  Jukes  Cantor 
(JC)(Jukes 1969); Kimuras 2 parameter (K2P)(Kimura 1980); Felsenstein 
(F81)(Felsenstein  1981),  and  Hasegawa  Kishino  and  Yano 
(HKY85)(Hasegawa, Kishino et al. 1985); 
  Analysis F: Combining the sequences from Manchester and London.  
 
The  sample  sizes  were  reduced  in  order  to  replicate  the  effect  of  partial 
representation of an HIV-infected population on phylogenetic reconstructions of 
transmission events within a population.    The initial tree was used as a proxy 
for the entirety of sequences circulating in the population, and the reductions in 
sample size undertaken to mimic the effect of sampling within this population.   Alison Brown – Chapter Four 
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The random reduction was used to mimic the effect of random sampling.  The 
non-random reduction (i.e. deleting one sequence from each cluster) was used 
to assess the potential effect of not including sequences that were part of actual 
transmission chains (i.e. when robust clusters are disrupted by the deletion of 
one sequence, does the remaining sequence “erroneously cluster” with another 
sequence?).  The non-clustering sequences were deleted to see if the formation 
of the “true clusters” were dependent on the presence of other sequences in the 
sample, or whether the transmission events were absolute. 
 
Figure 4.1: Flow diagram outlining phylogenetic analyses undertaken in chapter four 
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4.3.  Results 
4.3.1  Initial trees 
London 
An initial neighbour joining tree was constructed using the London dataset and 
subsequently  run  through  ModelTest  (Figure  4.2).    ModelTest  calculated  a 
London  kappa  score 7.57  and  gamma  shape 0.76.   Out  of  the 500  London 
sequences, 50 sequences formed 23 robust clusters (numbered L1-23), (Figure 
4.2).   Twenty  clusters  consisted  of  sequence  pairs, two  of  sequence triplets 
(L14 and L18) and one cluster made from four sequences (L12).  The clusters 
are summarised in Table 4.1. 
 
The criteria were relaxed to identify clusters that formed under the definition of a 
medium cluster (>95% and <99% bootstrap, and <0.03 and >0.015 nucleotide 
substitutions per site).   This resulted in an additional five clusters (numbered 
L24-7 and L35).   Three consisted of sequence pairs (L25, L26 and L35) and 
one triplet (L24) and one comprised eight sequences (L27).   
 
Under the definition of a weak cluster (>90% and <95% bootstrap and between 
0.05-0.3,  nucleotide  substitutions  per  site)  an  additional  four  clusters  were 
added (numbered L28-L31).  Three clusters consisting of sequence pairs (L28, 
L29 and L31), and one cluster consisting of five sequences (L30). 
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Table  4.1:  Robust,  medium  and  weak  clusters  ascertained  through  phylogenetic 
reconstruction, London 
Cluster type  Cluster ID  Number of sequences per cluster 
Robust clusters  L1  2 
  L2  2 
  L3  2 
  L4  2 
  L5  2 
  L6  2 
  L7  2 
  L8  2 
  L9  2 
  L10  2 
  L11  2 
  L12  4 
  L13  2 
  L14  3 
  L15  2 
  L16  2 
  L17  2 
  L18  3 
  L19  2 
  L20  2 
  L21  2 
  L22  2 
  L23  2 
Total = 23    Total=50 
Medium clusters  L24  3 
  L25  2 
  L26  2 
  L35  2 
  L27  8 
Total=5    Total=17 
Weaker clusters  L28  2 
  L29  2 
  L30  5 
  L31  2 
Total=4    Total=11 
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Figure 4.2: Phylogenetic reconstruction of HIV transmission events, initial tree, London  
 
Clusters L1-23 highlighted in bold. Alison Brown – Chapter Four 
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Figure  4.3:  Phylogenetic  reconstruction  of  HIV  transmission  events:  initial  tree, 
Manchester  
 
Clusters M1-12 highlighted in bold. Alison Brown – Chapter Four 
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Table  4.2:  Robust,  medium  and  weak  clusters  ascertained  through  phylogenetic 
reconstruction, Manchester  
Cluster type  Cluster ID  Number of sequences per cluster 
Robust  M1  2 
   M2  2 
   M3  2 
   M4  2 
   M5  2 
   M6  2 
   M7  2 
   M8  2 
   M9  2 
   M10  2 
   M11  2 
   M12  2 
Total=12    Total=24 
Medium  M13  2 
   M14  2 
   M15  2 
   M16  2 
   M17  7 
   M18  2 
   M19  2 
   M20  2 
Total=8    Total=21 
Weak  M21  2 
   M22  2 
   M23  2 
   M24  2 
Total=4    Total=8 
 
Manchester 
An initial neighbour joining tree was constructed for the Manchester dataset and 
run through ModelTest.  ModelTest calculated the Manchester kappa score to 
be  7.18  and  the  gamma  shape  to  be  0.35.    Out  of  the  500  Manchester 
sequences,  24  sequences  formed  12  robust  clusters  (numbered  M1-M12) 
Figure 4.3.  They all consisted of sequence pairs and are summarised in Table 
4.2.  
 Alison Brown – Chapter Four 
116 
Under  the  definition  of  medium  clusters,  eight  clusters  were  apparent  (M13-
M20).   Seven clusters consisted of sequence pairs and one consisted of seven 
sequences  (Cluster  M17).      Under  the  weak  cluster  definition  a  further  four 
clusters  were  added  (clusters  M21-24).    Cluster  M22  comprised  three 
sequences, with the remainder of clusters consisting of sequence pairs.    
4.3.2  Reducing sample sizes 
An overall summary of results from analyses A-F is presented in Table 4.3. 
London 
Analysis A 
The number of sequences within the dataset was reduced by a fifth at random. 
Overall, 100 sequences were deleted, seven of which had been part of robust 
clusters in the initial tree (clusters L11, L12, L13, L15, L16, L20, and 21) (Table 
4.4).  Of  the  400  remaining  sequences,  30  formed  15  robust  clusters,  14  of 
which were identical to the original tree (Table 4.4).   Excluding the 7/23 robust 
clusters that were affected by the deletion, 87.5% (14/16) of the robust clusters 
found in the initial tree were also found in the analysis A (Table 4.3).  
 
Clusters L1  and  L18,  robust  clusters in  the  initial tree  appeared  as  medium 
clusters in analysis A.     Cluster 32 appeared as a novel robust cluster (i.e. it 
did not appear as a robust, medium or weak cluster in the initial analysis). 
 
Analysis B 
The number of sequences within the dataset was then randomly reduced further 
so  that  half  of  the  original  500  sequences  were  deleted.    A  further  150 Alison Brown – Chapter Four 
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sequences were deleted, so that 13 of the robust clusters in the initial tree had a 
sequence within that cluster, deleted.  Overall, of the 250 sequences deleted, 
22 had formed 14 robust clusters in the initial tree (clusters L2, L5, L6, L8, L11, 
L12,  L13,  L15,  L16,  L19,  L20,  L21,  L22,  and  L23)  (Table  4.4).  While  one 
sequence making up cluster 18 was deleted, the initial robust cluster contained 
three sequences in the initial tree, consequently two of the original sequences 
remained.   
 
Of  the  remaining  250  sequences,  nine  robust  clusters  were  identified, 
comprised of eighteen sequence pairs.  Of these, eight were identical to robust 
clusters found in the initial tree (clusters L3, L4, L7, L9, L10, L14, L17, and L18).  
Excluding 14/23 robust clusters affected by the deletions, 88.9% (8/9) of the 
robust clusters found in the initial tree were also found in analysis B (Table 4.3).   
 
Robust  cluster  L32  was  novel,  but  also  had  appeared  in  analysis  A.      One 
robust cluster present in the initial tree (L1) was apparent as a medium cluster 
in analysis B.  L18, appeared as a robust cluster in this analysis, but was a 
medium cluster in analysis A.         
 
Analysis C 
One  sequence  from  each  of  the  initial  clusters  was  deleted.    In  total,  24 
sequences were deleted, one from each robust cluster, leaving 476 sequences 
remaining.   Of the remaining 476 sequences, four robust clusters were formed, 
comprising 13 sequences (Table 4.4). Excluding 21/23 robust clusters affected 
by the deletions, 100% (2/2) of the robust clusters found in the initial tree were Alison Brown – Chapter Four 
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also found in analysis C (Table 4.3) – clusters L12 and L18.     Both of these 
clusters had more than two sequences within the cluster in the initial tree, and 
the  remaining  sequences  had  clustered.    Cluster  L27,  a  robust  cluster  in 
analysis C, was a medium cluster in the initial analysis.  Cluster L33 was a 
novel robust cluster in analysis C. 
 
Analysis D 
Half of the sequences that did not form a cluster in the initial tree were deleted.  
In total 214 sequences were deleted, leaving 286 sequences.    Twenty three 
robust  clusters  were  found  in  this  analysis.  No  robust  clusters  in  the  initial 
analysis  were  affected  by  deletions  and  91%  (21/23)  of  the  robust  clusters 
found in the initial tree was also found in analysis D (Table 4.3). 
 
The remaining two robust clusters (L28 and L29) in analysis D were found as a 
weak and a medium cluster in the initial tree respectively.    The two robust 
clusters in the initial tree not found in analysis D were L1 and L11.  For analyses 
A-D L1 had not been present as a robust cluster, and L11 had been affected by 
deletions  in  analyses  A-C.    In  all  instances,  where  a  sequence  had  been 
deleted  that  had  been  part  of  a  robust  cluster  in  the  initial  analysis,  the 
remaining sequence did not form a cluster (robust, medium or weak) with any 
other sequence in subsequent analyses.   
Manchester 
Analysis A 
The Manchester dataset was reduced by a fifth at random.     Overall, 100 
sequences were deleted, including seven sequences that had originally formed Alison Brown – Chapter Four 
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a robust cluster in the initial tree (clusters M2, M3, M5, M6, M7, M8, and M12).  
Of the 400 remaining sequences, ten formed five robust clusters, four of which 
were identical to the initial tree (Table 4.5).    Excluding the 7/12 robust clusters 
that were affected by the deletion, 80% (4/5) of the robust clusters found in the 
initial tree were also found in analysis A. Cluster M9, a robust cluster in the 
initial reconstruction did not appear as a robust cluster in the present analysis.  
Robust cluster M25 appeared as a novel cluster in this analysis (Table 7.4). 
 
Analysis B 
The number of sequences within the dataset was then randomly reduced further 
so that half of the original sample was deleted.  In total 250 sequences were 
deleted, of which ten had formed a robust cluster in the initial tree (clusters M2-
8,  10-12).    Of  the  remaining  250  sequences,  three  robust  clusters  were 
retained, both consisting of sequence pairs.  Excluding the 10/12 robust clusters 
that were affected by the deletion, 100% (2/2) of the robust clusters found in the 
initial tree were also found in the analysis B (Table 4.3).    One novel robust 
cluster was formed (cluster M25); the same cluster that appeared in analysis A. 
 
Analysis C 
One sequence from each of the initial robust clusters was deleted.  In total 27 
sequences were deleted, one from each cluster, leaving 473 sequences.     Of 
the remaining 473 sequences, no robust cluster was formed.       
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Table 4.3: Overall consistency of robust clusters between analyses A-F, London and Manchester 
London 
Number of robust 
clusters in each 
analysis 
Proportion consistent 
with initial tree x%(n/N)* 
Number of robust clusters that 
appeared as medium/weak in initial 
tree 
Number of 
novel 
clusters 
Initial tree  23  -  -  - 
Analysis A  15  87.5% (14/16)  0  1 
Analysis B  9  88.9%(8/9)  0  1 
Analysis C  4  100% (2/2)  1  1 
Analysis D  23  91% (21/23)  2  0 
Analysis E         
JC  23  95.7% (22/23)  0  1 
K2P  23  95.7% (22/23)  0  1 
F81  24  95.7% (22/23)  1  1 
HKY85  21  87.0% (20/23)  0  1 
Manchester         
Initial tree  12  -  -  - 
Analysis A  5  80% (4/5)  0  1 
Analysis B  3  100% (2/2)  0  1 
Analysis C  0  N/A  0  0 
Analysis D  13  100% (12/12)  1  0 
Analysis E         
JC  12  91.7% (11/12)  1  0 
K2P  11  83.3% (10/12)  1  0 
F81  12  100% (12/12)  0  0 
HKY85  13  91.7% (11/12)  2  0 
Analysis F**  21  45.7% (16/35)  2  3 
*Where n= number of robust clusters present in initial tree and in present analysis and N= total number of robust clusters in initial 
analysis. For analyses A-D, the denominator excludes the clusters that were disrupted by deletions. 
** Both Manchester and London datasets combined.  Total number of robust clusters in initial tree derived by adding London and 
Manchester robust clusters together. 
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Table 4.4: Stability of robust clusters under varying samples sizes, London 
  
Random 
deletions     Non random deletions 
Robust 
clusters 
Analysis A                                      
Fifth deleted 
Analysis B  
Half 
deleted 
Analysis C                                                   
One sequence form 
each initial cluster 
deleted 
Analysis D                                         
Half of non-clustering 
sequences deleted 
L1  No  No  N/A  No 
L2  Yes  N/A  N/A  Yes 
L3  Yes  Yes  N/A  Yes 
L4  Yes  Yes  N/A  Yes 
L5  Yes  N/A  N/A  Yes 
L6  Yes  N/A  N/A  Yes 
L7  Yes  Yes  N/A  Yes 
L8  Yes  N/A  N/A  Yes 
L9  Yes  Yes  N/A  Yes 
L10  Yes  Yes  N/A  Yes 
L11  N/A  N/A  N/A  No 
L12  N/A  N/A  Yes  Yes 
L13  N/A  N/A  N/A  Yes 
L14  Yes  Yes  N/A  Yes 
L15  N/A  N/A  N/A  Yes 
L16  N/A  N/A  N/A  Yes 
L17  Yes  Yes  N/A  Yes 
L18  No  Yes  Yes  Yes 
L19  Yes  N/A  N/A  Yes 
L20  N/A  N/A  N/A  Yes 
L21  N/A  N/A  N/A  Yes 
L22  Yes  N/A  N/A  Yes 
L23  Yes  N/A  N/A  Yes 
L27*  N/A  N/A  Yes  No 
L28*  N/A  N/A  N/A  Yes 
L29*  N/A  N/A  N/A  Yes 
L32*  Yes  Yes  No  No 
L33*  No  No  Yes  No 
N/A=sequences that constitute original clusters not available in present reconstruction 
*Clusters present as robust clusters in analyses A-D were not present as robust clusters in initial 
tree, cluster L27 was present as a medium cluster, L28 and L29 were weaker clusters and clusters 
L32-3  are novel clusters 
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Table 4.5: Stability of robust clusters under varying samples sizes, Manchester 
   Random deletions  Non random deletions 
Robust clusters 
Analysis A                                       
Fifth deleted 
Analysis B             
Half deleted 
Analysis C                                                   
One sequence from each initial cluster 
deleted 
Analysis D                                         
Half of non-clustering sequences 
deleted 
M1  Yes  N/A  N/A  Yes 
M2  N/A  N/A  N/A  Yes 
M3  N/A  N/A  N/A  Yes 
M4  Yes  N/A  N/A  Yes 
M5  N/A  N/A  N/A  Yes 
M6  N/A  N/A  N/A  Yes 
M7  N/A  N/A  N/A  Yes 
M8  N/A  N/A  N/A  Yes 
M9  No  Yes  N/A  Yes 
M10  Yes  N/A  N/A  Yes 
M11  Yes  Yes  N/A  Yes 
M12  N/A  N/A  N/A  Yes 
M17*  No  No  No  Yes 
M25*  Yes  Yes  No  No 
 
Notes:         
N/A=sequences that constitute original cluster not available in present reconstruction.   
*Clusters present as robust clusters in analyses A-D were not present as robust clusters in initial tree, cluster M17 was present as a medium 
cluster,  and M25 appeared as a novel cluster in this reconstruction. Alison Brown – Chapter Four 
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Analysis D 
Half of the sequences that did not form a cluster in the initial tree were deleted.  
In  total  223  sequences  were  deleted,  leaving  277  sequences.        With  this 
dataset,  13  robust  clusters were  formed  (clusters M1-12,  and  M17) from 27 
sequences.   No robust clusters in the initial tree were affected by the deletions 
of analysis D, with 100% (12/12) robust clusters in the initial tree also found in 
analysis D. The robust cluster M17, which was comprised of seven sequences, 
was identified as a medium cluster in the initial tree.  
 
In all instances, where a sequence had been deleted that had been part of a 
robust cluster in the initial analysis, the remaining sequence did not form any 
other cluster (robust, medium or weak) in subsequent analyses.   
4.3.3  Models of evolution  
London – analysis E 
Neighbour  joining  trees  were  constructed  under  four  different  models  of 
evolution: JC; K2P; F81; and HKY85, for the London datasets (Table 4.6). 
 
For the JC and K2P models gave similar results.  All of the robust clusters in the 
initial  tree  were  retained  with  the  exception  of  cluster  L1  –  95.7%  (22/23).      
Cluster L34 appeared as a new robust cluster in the present reconstruction; this 
cluster  was  not  apparent  as  a  robust,  medium  or  weak  cluster  in  the  initial 
analysis or analyses A-D.  
 
 Alison Brown – Chapter Four 
124 
 
Table 4.6: Stability of robust clusters under different models of evolution, London.  
Cluster  JC  K2P  F81  HKY85 
L1  No  No  No  No 
L2  Yes  Yes  Yes  Yes 
L3  Yes  Yes  Yes  Yes 
L4  Yes  Yes  Yes  Yes 
L5  Yes  Yes  Yes  Yes 
L6  Yes  Yes  Yes  Yes 
L7  Yes  Yes  Yes  Yes 
L8  Yes  Yes  Yes  Yes 
L9  Yes  Yes  Yes  Yes 
L10  Yes  Yes  Yes  Yes 
L11  Yes  Yes  Yes  Yes 
L12  Yes  Yes  Yes  Yes 
L13  Yes  Yes  Yes  Yes 
L14  Yes  Yes  Yes  Yes 
L15  Yes  Yes  Yes  Yes 
L16  Yes  Yes  Yes  No 
L17  Yes  Yes  Yes  Yes 
L18  Yes  Yes  Yes  Yes 
L19  Yes  Yes  Yes  Yes 
L20  Yes  Yes  Yes  Yes 
L21  Yes  Yes  Yes  Yes 
L22  Yes  Yes  Yes  No 
L23  Yes  Yes  Yes  Yes 
L34*  Yes  Yes  Yes  Yes 
L35*  No  No  Yes  No 
         
*Clusters present as robust clusters in analysis E were not present as 
robust clusters in initial tree,  M35 was a medium cluster in the initial 
analysis and  M34 appeared as a novel cluster in this reconstruction. 
 
Under the F81 model, the same observations were found as with the JC and 
K2P  model  giving  a  consistency  of  95.7%  (22/23)  –  Table  4.3.  However, 
cluster L35, a medium cluster found in the initial tree, was found as a robust 
cluster in the present reconstruction.  Under the HKY85 reconstruction, robust 
clusters L1, 16 and 22 found in the initial tree were not present in the current 
reconstruction giving a consistency of 87.0% (20/23).  As with the JC, KP2 and 
F81 models,   the novel, but robust cluster L34 appeared. Alison Brown – Chapter Four 
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Manchester – analysis E 
Neighbour  joining  trees  were  constructed  under  four  different  models  of 
evolution: JC; K2P; F81; and HKY85 for the Manchester dataset (Table 4.7). 
Table 4.7: Stability of robust clusters under different models of evolution, Manchester.  
Cluster  JC  K2P  F81  HKY85 
M1  Yes  Yes  Yes  Yes 
M2  Yes  Yes  Yes  Yes 
M3  Yes  Yes  Yes  Yes 
M4  Yes  No  Yes  No 
M5  No  No  Yes  Yes 
M6  Yes  Yes  Yes  Yes 
M7  Yes  Yes  Yes  No 
M8  Yes  Yes  Yes  Yes 
M9  Yes  Yes  Yes  Yes 
M10  Yes  Yes  Yes  Yes 
M11  Yes  Yes  Yes  Yes 
M12  Yes  Yes  Yes  Yes 
M18*  Yes  Yes  No  Yes 
M20*  No  No  No  Yes 
*Clusters present as robust clusters in analysis E were not present 
as robust clusters in initial tree, clusters 18 and 20 were present as 
medium clusters in the initial tree. 
 
Under the JC model, all of the robust clusters in the initial tree were present, 
with the exception of cluster M5 – this gave a consistency of 91.7% (11/12) – 
Table 4.3.   In addition, cluster M18, which appeared as a medium cluster in the 
initial tree, appeared as a robust cluster in present reconstruction.   
 
Under the K2P reconstruction, all of the robust clusters in the initial tree were 
present  with  the  exception  of  clusters  M5  and  M4  giving  a  consistency  .of 
83.3% (10/12).  Cluster M18 that was apparent in the initial tree as a medium 
cluster was apparent as a robust cluster in the present analysis.   
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For the F81 analysis, all of the robust clusters apparent in the initial analysis 
were present in the current analysis – (100% 12/12), and no additional clusters 
appeared.    For the HKY85 model, cluster M4 was not apparent in the current 
analysis, and clusters M18 and M20, which were medium clusters in the initial 
analysis, appeared as robust clusters in the present analysis.    
4.3.4   Combining datasets 
Analysis F 
The 500 sequences from Manchester, and 500 from London were combined 
and  a  phylogenetic  reconstruction  undertaken  using  a  neighbour  joining 
methodology.   
 
Of the 1000 sequences, 57 formed 23 robust clusters (Figure 4.4a - full tree not 
shown due to size).  Table 4.8a displays the robust clusters in the combined 
tree that were also robust clusters in the initial tree.  Overall 35 robust clusters 
were found in the initial London and Manchester trees.  Of these, less than half 
(20) were found as robust clusters in the combined tree (Table 4.3). 
 
For  London,  11  robust  clusters  were  identical  to  those  found  in  the  London 
initial  tree  (L1,  L2,  L5,  L7,  L11,  L12,  L13,  L14,  L18,  L21  and  L22).    The 
remaining 12 clusters that were robust in the initial London tree were apparent 
as medium or weak clusters in the combined tree.   Of the 23 robust clusters in 
the initial London tree 47.8% (11/23) were identical London robust clusters in 
analysis F. Cluster L18 had one additional Manchester sequence added to it – it 
did not alter cluster the topology of L18. Alison Brown – Chapter Four 
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Figure 4.4: Extracts from the phylogenetic reconstruction of HIV transmission events, 
combining sequences from London and Manchester  
 
For the Manchester sequences, seven of the 12 robust clusters in the initial 
robust tree were also robust clusters in the combined tree (58.3% - M3, M4, M6, 
M8, M9, M10, M11, and M12).  The remaining five clusters that were robust 
clusters in the initial Manchester tree (M1, M4, M5, M6, and M7) appeared as 
weaker or medium clusters in the combined tree.  Cluster M11 had an additional 
London sequence added to it, which did not disrupt the topology of the cluster. Alison Brown – Chapter Four 
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Table 7.8b shows robust clusters in analysis F that were not robust clusters in 
the initial tree. Two entirely new clusters appeared, clusters B1 and B2 (Figure 
4.4a  and  b):  these  were  each  comprised  of  a  London  and  Manchester 
sequence paired together.  These sequences did not form any cluster (including 
weak) with any other sequences in the initial tree or analyses A-E.  Clusters 
L24, L27 and L32 appeared as robust clusters in this analysis, but the former 
two were medium clusters in the initial analysis and L32 was novel. 
 
Table  4.8:  Number  of  robust  clusters  ascertained  through  phylogenetic  analysis 
combining sequences from London and Manchester 
a) Initial robust clusters maintained b) Novel robust clusters  
Initial 
clusters
Present in 
combined 
tree?
Novel 
clusters Notes
L1 yes L24  Present as medium cluster in initial tree
L2 yes L27  Present as medium cluster in initial tree
L3 yes L32  Not present in initial tree
L4 yes B1  Two sequences, one from Manchester one from London
L5 no B2  Two sequences, one from Manchester and one from London
L6 yes
L7 yes
L8 yes
L9 no
L10 no
L11 no
L12 no
L13 yes
L14 no
L15 no
L16 no
L17 no
L18 no
L19* yes
L20 no
L21 no
L22 no
L23 no
Total=23 Total=9
M1* yes
M2 no
M3 no
M4 no
M5 yes
M6 no
M7 yes
M8 yes
M9 yes
M10 yes
M11 yes
M12 no
Total=12 total=7
*Cluster L19 was maintained but incorporated a sequence from 
Manchester.  Cluster M1 was maintained but incorporated a sequence 
from London.
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4.4. Discussion  
One  thousand  HIV  pol  sequences  from  two  anonymous  population  samples 
were used: MSM diagnosed in London and in Manchester.  The consistency of 
the  phylogenetic  clusters  formed  within  each  dataset  was  assessed  under 
varied  sample  sizes  and  models of  evolution.    Overall,  the  consistency  was 
moderately  good  with  at  least  80%  of  phylogenetic  reconstructions  of 
transmission events identified in the initial analysis also found in subsequent 
analyses.  No more than three “novel” transmission events were found for each 
repeated analysis.  Importantly, none of the robust clusters found in the initial 
analyses were disrupted by the sequences within forming clusters with other 
sequences in subsequent analyses. 
4.4.1   Initial trees  
Both datasets were run through ModelTest, which gave different gamma rate 
heterogeneity values for Manchester (0.35) and London (0.76).  This suggests     
a higher proportion of the sites were identical among sequences in the London 
dataset, making this sample more homogeneous.    
 
A higher proportion of clusters formed robust clusters in the London dataset 
compared with the Manchester dataset (23 versus 12).  Overall, 10.4% (52/500) 
of  sequences  formed  a  cluster  in  London  compared  with  4.8%  (24/500)  in 
Manchester  (p<0.001).  This  was  expected,  given  the  higher  degree  of 
homogeneity observed among the sequences from London.     
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If  phylogenetic  reconstructions  are  accurate  representations  of  transmission 
events,  and  not  formed  by  chance,  it  would  be  expected  that  relatively  few 
“transmission  events”  would  be  added  as  parameters  were  weakened.    The 
presence  of  additional  weaker  clusters  would  suggest  that  the  creation  of 
clusters  was  relative  to  the  sample  diversity,  rather  than  reflecting  actual 
transmission events.   For London there were an additional five medium clusters 
and an additional four weak clusters.  This is an additional nine compared to 23 
robust clusters.  For Manchester, an additional eight medium clusters and four 
weak clusters were added.   This may indicate that the formation of clusters is 
affected by the relative genetic diversity of the sample. The greater occurrence 
of this phenomenon among the Manchester sample suggests weaker clusters 
are more likely to form when the population sample is more heterogeneous.  
4.4.2   Reducing the sample size     
The sample sizes were reduced in order to replicate what the effect of partial 
representation  of  an  HIV-infected  population  might  be  for  phylogenetic 
reconstructions of that population.    The initial tree was used as a proxy for the 
entirety of circulating sequences in the population, and the reductions in sample 
size undertaken to mimic the effect of sampling within this population.   
 
Overall,  for  both  Manchester  and  London,  there  was  moderately  good 
consistency between the robust clusters found in the initial trees and among 
analyses A-D.  Excluding the robust cluster affected by the deletions, in each 
analysis there was at least 80% consistency.   Alison Brown – Chapter Four 
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In each analysis, no more than two robust clusters appeared that had not been 
robust clusters in the initial tree.  Approximately half of these were clusters that 
appeared  as  medium  or  weak  clusters  in  the  initial  tree.    The  other  half 
represented "novel clusters”.  It was reassuring to note that in all subsequent 
analyses, the specific robust clusters not apparent in the initial reconstruction 
were broadly consistent between analyses A-D.    
 
Whilst the random reduction was used to mimic the effect of random sampling, 
the non-random reductions (i.e. deleting one sequence from each cluster) were 
used to assess the potential effect of not including sequences that were part of 
actual transmission chains. It is encouraging that in all instances, where one 
sequence had been deleted that had formed a robust cluster in the initial tree, 
the remaining sequence did not pair with any other sequences in subsequent 
analyses,  even  as  a  weak  cluster.      This  indicates  that  the  likelihood  of 
phylogenetic reconstructions providing contradictory results or “false” matches 
is  low.    It  also  suggests  that  there  are  unlikely  to  be  “false  matches”  as  a 
consequence  of  not  including  both  sequences  from  patients  included  in  an 
actual transmission chain. 
  
The non-clustering sequences were deleted to see if the formation of the “true 
clusters” were dependent on the presence of other sequences in the sample, or 
whether the transmission events were absolute. Analysis D indicated that the 
creation of robust clusters will occur if the sequences that comprise them are 
present; they are not substantially affected by the presence of other sequences 
(with which they do not form a cluster).    Alison Brown – Chapter Four 
132 
 
4.4.3   Models of evolution 
For  analysis  E  (changing  the  models  of  evolution)  the  results  for  both  the 
Manchester and  London  datasets  were  broadly  consistent  both  between  the 
models  of  evolution  and  through  comparing  the  subsequent  analyses  to  the 
initial  trees.    At  least  83%  of  the  initial  robust  clusters  were  found  in  each 
analysis.  However the slight discrepancies indicate that the models selected 
can affect results, and re-emphasizes that it is important to chose the model 
according to the parameters of the population sample rather than choosing one 
model for all reconstructions. 
4.4.4  Combining the datasets 
Analysis F (combining results) produced the least consistent results.   Overall, 
35 robust clusters were found in the initial London and Manchester trees.  Of 
these, less than half (20) were found as robust clusters in the combined tree.   
There was a higher degree of consistency between the initial Manchester tree 
and  the  combined  tree,  compared  with  London.      In  addition,  while  “novel” 
clusters appeared in the combined tree between sequences from London, no 
novel clusters appeared between the Manchester sequences.   
 
The reason why there was more consistency of clusters in the initial Manchester 
tree  and  analysis  F  may  be  due  to  differences  between  the  London  and 
Manchester  populations.    The  gamma  shape  –  a  measure  of  sample 
heterogeneity - of London was 0.76 and of Manchester was 0.35.  Therefore the 
Manchester  sample  contained  more  diverse  sequences  than  the  London 
sample.      It  may  be  more  difficult  to  resolve  robust  clusters  in  a  sample Alison Brown – Chapter Four 
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characterized by greater homogeneity, since there are fewer informative sites to 
inform clusters.   
 
For the novel clusters, once again, those that appeared were consistent with 
those found in analyses A-E, indicating that the formation of robust clusters is 
not a random process.  Clusters B1 and B2 are not of concern since they both 
were formed between a London and a Manchester sequence.  It is encouraging 
that the sequences involved in B1 and B2 did not form any sort of cluster with 
other sequences in analyses A-E.  
4.4.5  Limitations to the approach 
This  work  represents  an  exploratory  attempt  to  examine  the  consistency  of 
phylogenetic  reconstructions  of  HIV  transmission  events  for  public  health 
purposes.  However, there are several limitations with the approach.  Firstly, the 
analysis  uses  neighbour  joining  trees,  which  have  been  found  to  produce 
spurious results in previous analyses (Hillis D 1996).  However, in order to have 
a  population  sample  within  which  a  sufficient  number  of  clusters  could  be 
formed (even when a substantial proportion of sequences were deleted and for 
the  sample  size  to  be  varied),  a  bigger  sample  size  was  needed.    This 
precluded the construction of a maximum likelihood tree. 
 
Secondly, despite the use of 1000 sequences, only a handful of robust clusters 
were  available  for  comparisons  between  analyses  (in  some  cases  only  two 
clusters  per  analysis).    This  means  that  the  results  cannot  be  meaningfully 
extrapolated to provide a margin of error for phylogenetic reconstructions. Alison Brown – Chapter Four 
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Thirdly, the datasets from Manchester and London were anonymous.  Nothing 
was known about the population from which the sequences were taken except 
that  they  were  derived  from  MSM  diagnosed  in  Manchester  and  London.  
Importantly, both London and Manchester are large cities and sexual mixing is 
not likely to be retained exclusively within each city.     This means that there 
may be unusual aspects of the population samples that affected the results of 
this  chapter  that  remain  unknown.      The  specific  attributes  (e.g.  the 
geographic/temporal  sampling  and  sexual  behaviour)  associated  with  each 
population will have impacted upon the likelihood of finding transmission events 
within  each  dataset.    It  is  possible  that  the  results  of  analyses  A-F  may  be 
affected by the make up of the specific populations.  There was no attempt to 
compare  the  results  with  Lewis  et  al.  (Lewis,  Hughes  et  al.  2008)  for  two 
reasons.    Firstly  Lewis  et  al.  use  Bayesian  methods,  and  secondly,  the 
sequences  were  anonymised,  so  there  was  no  way  of  ascertaining  which 
sequences in the chapter were also used in the Lewis paper. 
  
Fourthly, whilst the robust clusters observed in the initial trees are used as the 
“comparison  point”  for  subsequent  analyses,  it  is  impossible  to  ascertain 
whether these represent actual transmission events.     They were used as a 
standard against which consistency could be measured and not interpreted as 
the gold standard. Finally, this analysis was unable to assess another aspect 
crucial to the use of phylogenetic reconstructions of HIV transmission events; 
the direction of transmission.  Alison Brown – Chapter Four 
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4.5. Conclusion 
This chapter represents an attempt to assess the consistency of phylogenetic 
reconstructions  of  HIV  transmission  events  for  public  health  purposes.    The 
consistency of robust clusters between analyses was broadly good with at least 
80% of robust clusters in each analysis sharing identical robust clusters when 
compared to the initial trees.  However, the small numbers of clusters identified 
in the population samples means that results can only be exploratory.   
 
Positively, the analysis indicates that the absence of one sequence from two 
patients involved in a transmission event is unlikely to lead to the remaining 
sequence erroneously forming a robust cluster with another sequence.  Also, 
the identification of robust clusters does not seem substantially dependent on 
the  presence  of  other  sequences  with  which  they  do  not  share  a  cluster.     
Negatively,  there  are  suggestions  that  phylogenetic  reconstructions  have 
insufficient “specificity” to identify robust transmission clusters.  This is indicated 
by the appearance and disappearance of a limited number of “robust clusters” 
as sample sizes were varied.   
 
Consistency analyses need to be repeated with other datasets using maximum 
likelihood  methods  to  test  whether  these  results  are  replicated.    Further 
investigation is needed into the relationship between sample heterogeneity and 
consistency of robust clusters.  Future analyses should work towards providing 
some sort of “margin of error” that phylogenetic reconstructions may reasonably 
be expected to produce.   In the meantime, the need for caution in interpreting 
such reconstructions, including those presented in this thesis, remains.   Alison Brown – Chapter Five 
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5  Chapter Five: Phylogenetic reconstructions of HIV 
transmission from patients with recent HIV infection 
 
 
 
 
 
This  chapter  describes  phylogenetic  reconstructions  of  HIV  transmission  events 
from patients with recent HIV infection at diagnosis to: 1) explore the transmission 
potential  from  this  population  and  compare  findings  to  those  published  in  the 
literature;  2)  critique  the  epidemiological  definitions  and  assumptions  used  in 
phylogenetic reconstructions. 
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5.1 Introduction 
This chapter explores the application of phylogenetic approaches to the analysis 
of  HIV  pol  sequences  from  patients  diagnosed  during  recent  HIV  infection.   
Phylogenetic analyses are conducted to explore the benefits of this approach, 
including examining the transmission potential from this group, and to compare 
the  findings  to  those  in  the  literature.    The  limitations  of  phylogenetic 
reconstructions  of  HIV  transmission  events  between  patients  diagnosed  with 
recent  infection  are  also  considered  (see  section  1.6.4),  and  tighter 
epidemiological definitions sought.   
 
The  first  three  datasets  described  in  chapter  three  were  used:    both  the 
Unlinked Anonymous STI survey (UA survey) and CASCADE are comprised of 
data drawn entirely from patients with recent HIV infection (at diagnosis or clinic 
attendance). For the Brighton dataset, only the 159 patients who were recently 
HIV-infected at diagnosis were included.  Two analyses are presented here: 
 
1.  A  phylogenetic  reconstruction  of  HIV  transmission  events  between 
patients with recent HIV infection at diagnosis was conducted using the 
UA survey.  This was to explore the transmission potential of the recently 
HIV-infected  population  and  compare  results  to  those  found  in  the 
literature;   
2.  Secondly, the CASCADE and Brighton datasets were used to critique the 
epidemiological definitions and assumptions used in such phylogenetic 
reconstructions. Alison Brown – Chapter Five 
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5.2 Methods 
5.2.1  Phylogenetic  reconstructions  of  HIV  transmissions  from 
populations with recently acquired infection 
Using  the  UA  survey  dataset  (Catchpole,  McGarrigle  et  al.  2000),  a 
phylogenetic  analysis  was  conducted  to  explore  the  occurrence  of  HIV 
transmission  from  recently  HIV-infected  individuals  before  diagnostic 
opportunity.    The population characteristics of this dataset were described in 
section  3.3.  HIV  pol  sequences  were  taken  from  patients  found  to  have  a 
previously undiagnosed HIV infection through UA testing and who were recently 
HIV-infected  through  the  Serological  Testing  Algorithm  for  Recent  HIV 
Seroconversion (STARHS) testing (Janssen, Satten et al. 1998).  Patients were 
categorized as “newly diagnosed” or “undiagnosed” according to whether they 
received  voluntary  confidential  HIV  testing  (VCT)  during  the  attendance 
(patients  HIV  diagnosed  before  the  clinic  attendance  were  excluded).    The 
newly diagnosed patients received VCT during the clinic attendance, but the 
undiagnosed did not receive VCT and remained undiagnosed when they left the 
clinic.   
 
The  phylogenetic  approach  used  was  described  in  section  2.2.11.  Before 
phylogenetic  analysis,  the  mutation  sites  associated  with  drug  resistance 
(Shafer,  Rhee  et  al.  2007)  were  deleted  from  all  sequences.  Protease  and 
reverse  transcriptase  sequences  were  aligned  across  998  nucleotides 
(Sequence Analyzer) and imported into the tree-building software PAUP. The 
sequence  alignment  was  run  through  ModelTest  and  a  heuristic  search Alison Brown – Chapter Five 
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conducted in PAUP for a maximum likelihood tree using the best fitting model 
(GTR+I+G) and its derived parameters (proportion of invariable sites=0.43 and 
gamma distribution=0.79) using the neighbour joining tree as the starting tree.  
A bootstrap analysis (500 replicates) was used to obtain statistical support for 
branching patterns.  Genetic distances were calculated from the consensus tree 
for  each  terminal  cluster.        The  transmission  events  were  interpreted  with 
regard  to  whether  the  observed  transmission  were  from  patients  with 
undiagnosed or diagnosed HIV infection. 
5.2.2  Moving  towards  more  rigorous  epidemiological  definitions 
(CASCADE)  
Two  phylogenetic  reconstructions  of  transmissions  from  patients  who  were 
recently HIV-infected at diagnosis are described in this section. The CASCADE 
data set comprises an HIV-infected cohort with precise definitions of recent HIV 
infection,  and  the  Brighton  cohort  contains  a  subset  of  patients  who  were 
recently HIV-infected at diagnosis.  Both datasets therefore not only enable the 
identification of transmission events, but also all of the transmission events to 
be dated crudely.  Differences between the infection dates within the observed 
clusters of patients who were recently HIV-infected at diagnosis were calculated 
to determine whether transmission could have occurred during recent infection.   
  
CASCADE 
The dataset is described in section 3.2.  For this analysis, a restricted definition 
of recent HIV infection was used.  Patients were included if they had either an 
HIV positive test within 90 days of an HIV negative test or an HIV antibody Alison Brown – Chapter Five 
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negative test with polymerase chain reaction positivity.  The estimated infection 
date was taken as midpoint between the diagnosis date and last negative test 
for the former and the date the sample was taken for the latter. 
 
The first plasma sample available after the estimated HIV infection date was 
obtained  for  genotypic  resistance  testing.    Samples  obtained  more  than  18 
months  after  the  estimated  infection  date  or  from  drug  experienced  patients 
were excluded.  Nucleotide sequence data spanned the protease gene and at 
least  codons  41-236  of  reverse  transcriptase  (RT).    The  sequencing 
methodology  has  been  described  previously  (Masquelier,  Bhaskaran  et  al. 
2005).  Drug resistance mutations were defined on the basis of the standardised 
list of mutations for use in epidemiological studies (Shafer, Rhee et al. 2007).  
 
Before  phylogenetic  analysis,  the  sites  associated  with  drug  resistance 
mutations  (Shafer,  Rhee  et  al.  2007)  were  deleted  from  all  sequences.  
Protease and RT sequences were aligned across 998 nucleotides and imported 
into the tree-building software PAUP. A neighbour joining (NJ tree) was created 
under  the  General  Time  Reversible  (GTR)  model  with  gamma  rate 
heterogeneity set at 0.5.  The resultant clusters were selected, together with 10 
other sequences taken at random.  This second sequence alignment was run 
through ModelTest and a heuristic search  conducted in PAUP for a maximum 
likelihood  tree  using  the  best  fitting  model  (GTR+I+G)  and  its  derived 
parameters (proportion of invariable sites=0.43  and gamma distribution=0.79) 
using the NJ tree as the starting tree.  A bootstrap analysis (500 replicates) was 
used  to  obtain  statistical  support  for  branching  patterns.    Genetic  distances Alison Brown – Chapter Five 
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were  calculated  from  the  consensus  tree  for  each  terminal  cluster.  A   
transmission  “during  recent  infection”  was  defined  as  clusters  containing 
sequences  from  patients  with  a  difference  of  fewer  than  180  days  between 
estimated infection dates. 
 
Brighton 
The dataset was described in section 3.4.  For this analysis, only patients who 
were recently HIV-infected at diagnosis were included.  Methods to ascertain 
recent infection included: p24 antigen; western blot; STARHS; and an interval of 
six months between last HIV negative test date and date of HIV diagnosis.  The 
calendar quarter of diagnosis was taken as the estimated infection date. 
 
The  phylogenetic  approach  used  was  described  in  section  2.2.11.  The 
sequence  alignment  was  run  through  ModelTest  and  a  heuristic  search 
conducted in PAUP for a maximum likelihood tree using the best fitting model 
(GTR+I+G)  and  its  derived  parameters (proportion of  invariable  sites=0.2070 
and gamma distribution=0.64) using the neighbour joining tree as the starting 
tree.  A bootstrap analysis (500 replicates) was used to obtain statistical support 
for branching patterns.  Genetic distances were calculated from the consensus 
tree for each terminal cluster.  The definition of a transmission generated by an 
individual  during  recent  HIV  infection  was  taken  as  a  cluster  containing 
sequences  that  had  a  difference  of  up  to  three  calendar  quarters  between 
estimated  infection  dates  of  the  sequences  involved.    This  chapter  is 
descriptive,  but  statistical  tests  of  association  were  employed  where 
appropriate. Alison Brown – Chapter Five 
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5.3 Results 
5.3.1  Phylogenetic  reconstructions  of  HIV  transmissions  from 
populations with recently acquired infection (UA STI survey) 
Between  1999  and  2002,  28530  UA  tests were  conducted  on  samples from 
MSM attending 15 STI clinics in England, Wales and Northern Ireland (Figure 
5.1).  Of these, 3592 samples were found to be HIV positive of which 1072 were 
derived from patients with a previously undiagnosed infection (newly diagnosed 
or undiagnosed HIV infection).  Among this group, 21% (229) samples were 
derived from recently-infected MSM.  Complete PR and RT sequences were 
obtained from 127 samples from recently HIV-infected MSM (the remaining 102 
could not be amplified due to problems associated with using residual samples).   
 
Overall,  of  the  229  samples  from  recently  HIV-infected  MSM,  86%  (196) 
attended clinics in London, 56% (127) were UK-born and 15% (35) were born 
elsewhere in Europe.  Of the 127 linkable to sequences, equivalent figures were 
86% (109), 58% (74) and 15% (19) respectively. 
  
Of the 127 sequences from recently HIV-infected MSM, 16 (12.6%) fell into a 
cluster with at least one other sequence with a bootstrap support of at least 99% 
and  a  genetic distance  under 0.015  nucleotide  substitutions  per site  (Figure 
5.2).  These formed seven clusters (A-G): cluster A contained four sequences, 
and  clusters  B-G  each  comprised  sequence  pairs.  Cluster  E  comprised 
sequences from Wales;  the  remaining  six  were  from  London.    Clusters C-G 
were from samples obtained within the same, or successive, calendar quarters.  Alison Brown – Chapter Five 
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Figure 5.1: Flow diagram of MSM attending sentinel STI clinics, UA survey: 1999-2002 
  
 
Clusters B, C and F were comprised entirely from sequences from recently HIV-
infected individuals who received voluntary confidential HIV tests (VCT), and 
consequently had their  HIV infection  diagnosed at that STI clinic attendance 
(Figure 5.2).  Clusters D and E comprised sequences from individuals who left 
the clinic remaining unaware of their HIV infection.  Of the 16 sequences from 
MSM  that  clustered,  56.3%  (9)  were  also  diagnosed  with  an  STI.    This 
compares to 34.2% (38/111) from sequences from MSM that did not cluster 
(p=0.9). Alison Brown – Chapter Five 
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Figure  5.2:  Phylogenetic  reconstruction  transmission  events  among  HIV-infected  patients  attending  sentinel  STI  clinics  during  recent 
infection, UA survey: 1999-2002 
 Alison Brown – Chapter Five 
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5.3.2  Moving towards more rigorous epidemiological definitions 
CASCADE 
Of the 8993 dated HIV seroconverters from data pooled in December 2004, HIV 
sequences were submitted from 10 European cohorts. Using this definition, 165 
sequences  were  full  length  and  from  drug  naïve  patients.  Specifically,  131 
(79%)  had  had  a  documented  seronegative  test  within  90  days  before  their 
diagnosis (mean number of days between tests was 38 days) (Figure 5.3), and 
34 (21%) were HIV antibody negative with PCR positivity. 
  
The  majority  of  sequences  were  from  MSM  (73%,  120/135).    The  sample 
proportion from each country varied annually: 23% (38) of the samples were 
from Italy, 23% (38) were from France, 20% (33) from Germany, and 17% (28) 
from the UK, with the remainder from Denmark, Spain and the Netherlands.  
 
Of the 165 sequences, 18 (11%) formed a phylogenetic cluster with at least one 
other  sequence  (clusters  A-I  Figure  5.3).    These  formed  nine  phylogenetic 
clusters with two sequences in each cluster.  All nine phylogenetic clusters were 
comprised of sequences derived from patients who had their samples obtained 
within the same country.  Two of the nine clusters contained sequences that 
had a difference between infection dates of 104 and 29 days (clusters E and G 
respectively).    For  the  remaining  seven  clusters,  the  average  difference  of 
infection dates within clusters was 675 days (187-1571 days).  
 Alison Brown – Chapter Five 
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Figure  5.3:  Phylogenetic  reconstruction  of  transmission  events  among  European  HIV-
infected patients with recent HIV infection at diagnosis, CASCADE: 1989-2004 
 
Nucleotide substitutions per site. 
 
Brighton 
Of the 859 HIV-infected patients with sequences available, 159 were derived 
from  MSM  who  were  recently  HIV-infected  at  diagnosis.    Of  these  21  were Alison Brown – Chapter Five 
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identified through p24 antigen; three were recognised through Western blot; 119 
were identified  through STARHS; and 16  had an interval of less than  183 days 
between last HIV negative test date and date of HIV diagnosis. 
 
Where demographic data were available, patients with recent HIV infection at 
diagnosis  were  disproportionately  white  (98.1%,  152/155),  born  in  the  UK 
(83.0%, 127/153) or elsewhere in Europe (9.8%, 15/153).    There was a fairly 
even distribution by age-group with approximately half under 35 years of age at 
diagnosis (48.4% 77/159).  Around one fifth had an STI diagnosed at the same 
time as their HIV infection was diagnosed (21.0%, 34/159). 
 
Of the 159 sequences from MSM, 31 (19.5%) sequences formed a phylogenetic 
cluster with  at  least  one other sequence  (Clusters A-N,  Figure  5.4).   These 
formed 14 clusters, with an average of 2.4 sequences per cluster (range 2-4).  
Of the 14 clusters, only five (A, C, E, I and N) contained at least two sequences 
that had a difference of under three calendar quarters of diagnosis.  For the 
remaining  nine  clusters,  the  average  number  of  calendar  quarters  between 
sequences was 7.8 (range 4-8 calendar quarters). 
 
 
 
 
 
 
 Alison Brown – Chapter Five 
148 
 
Figure 5.4: Phylogenetic reconstruction of transmission events among HIV-infected MSM 
with recent infection at diagnosis, Brighton: 2000-2006  
 Alison Brown – Chapter Five 
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5.4 Discussion 
5.4.1  Phylogenetic  reconstructions  of  HIV  transmissions  from 
populations with recently acquired infection  
Phylogenetic analyses of HIV pol sequences from recently HIV-infected MSM 
attending sentinel STI clinics identified at least seven possible instances of HIV 
transmission before the first routine opportunity for diagnosis.  Five clusters had 
closeness in the likely infection dates between the sequences involved.  This 
demonstrates  the  potential  for  HIV  transmission  to  occur  rapidly  from  the 
recently  HIV-infected,  even  among  those  who  attend  the  clinic  soon  after 
infection (Brown, Murphy et al. 2009b).  
 
The rate of clustering observed (12.6%) is lower than that observed in other 
studies of patients diagnosed during recent HIV  infection: 34% (Pao, Fisher et 
al. 2005) and 50% (Brenner, Roger et al. 2007).  This may be because Pao‟s 
and Brenner‟s populations were local whereas data from the UA survey was 
taken from 15  sites across  England, Wales  and  Northern Ireland.    Pao  also 
found an association between clustering and STI diagnosis at HIV diagnosis.  
While data from Brighton presented in this chapter may have also indicated a 
similar association, this was not statistically significant at the 5% level (p=0.08). 
 
The UA survey methodology allows patients to be sampled (within the same 
clinic)  up  to  four  times  annually,  but  not  within  the  same  calendar  quarter.  
Therefore,  theoretically,  the  transmission  clusters  identified  could  have  been Alison Brown – Chapter Five 
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formed between the same individual, sampled multiple times.  Furthermore, the 
UA survey is necessarily designed to prevent the identification of individuals.  
However, five of the possible transmissions (C-G) involved patient pairs who 
had a different birth regions or age-group (Figure 5.2) making it unlikely that the 
sequences came from the same person.  Similarly, there must have been at 
least  two  individuals  included  in  cluster  A  –  but  not  necessarily  four.    The 
patients in cluster B both attended the same clinic within the same calendar 
quarter,  meaning  they  should  be  different  patients  according  to  the  UA 
algorithm.     
  
Whilst the differences in calendar quarter of diagnosis between recently HIV-
infected  patients  were  relatively  tight,  the  factors  potentially  associated  with 
transmission  (e.g.  STIs)  cannot  be  definitively  associated  with  transmission 
events at around the time of transmission.  For the UA survey, the definition 
used to identify recent infection (STARHS) and the time interval used to date 
diagnosis (calendar quarter) are too broad to allow an accurate comparison of 
infection dates.  Therefore it can not be ascertained whether the transmissions 
identified  between  patients  diagnosed  with  recent  HIV  infection  actually 
occurred during recent infection.   
 
The phylogenetic analysis illustrates the potential for HIV-infected patients who 
were  recently  HIV-infected  at  diagnosis  to  rapidly  generate  new  infections.   
Even  within  a  small  dataset  taken  from  15  regions  of  England,  Wales  and 
Northern Ireland, three transmissions (B, C and F) were observed among those Alison Brown – Chapter Five 
    151 
 
 
that received VCT soon after their infection. This suggests that VCT alone may 
not  have  a  sufficient  impact  on  the  transmission  potential  of  recently  HIV-
infected MSM.  Alternative strategies include: more rigorous partner notification; 
post exposure prophylaxis among recently–exposed MSM; the encouragement 
of more frequent regular testing; and the education of MSM and health care 
providers about the transmission risk and symptoms of seroconversion illness.  
 
5.4.2  Moving towards more rigorous epidemiological definitions  
Two  phylogenetic  reconstructions  were  described  using  populations  of  MSM 
diagnosed  during  recent  infection.    Both  datasets  contained  MSM  with  well 
estimated infection dates.  For each cluster observed, the difference between 
the estimated infection dates was calculated in order to ascertain whether the 
possible transmission event could have been generated during recent infection.  
For CASCADE, nine transmissions may have occurred between individuals in 
this sample.  Of the possible transmission events observed, only two could have 
been generated during recent HIV infection (Brown 2009a).  For Brighton, 14 
possible transmissions may have occurred.  Of these, only five could have been 
generated during recent infection. 
 
This analysis demonstrates the need for caution in the design and interpretation 
of  phylogenetic  analyses  that  link  HIV  pol  sequences  to  data  relating  to  the 
patient‟s infection stage.  In addition to the identification of transmission events 
between patients recently HIV-infected at diagnosis, the time intervals between Alison Brown – Chapter Five 
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infection  dates  between  patients  involved  in  a  possible  transmissions  event 
have  been  explored.    This  comparison  revealed  only  a  small  proportion  of 
possible  transmissions  could  have  been  generated  during  recent  infection. 
Given the time intervals between the infection dates, the remainder are more 
likely  to  have  been  transmitted  from  individuals  during  chronic  infection.  
Previous analyses that use more liberal definitions of recent HIV infection and 
do  not  take  the  transient  nature  of  this  infection  stage  into  account  may  be 
overestimating the extent that the recently HIV-infected population is generating 
new transmission events.   
 
A  criticism  of  phylogenetic  reconstructions  between  patients  with  recent 
infection is that the datasets do not represent patients with chronic infection. 
However,  this  work  demonstrates  that  sequences  involved  in  phylogenetic 
reconstructions  should  not  be  permanently  categorized  as  coming  from  the 
recently and chronically HIV-infected according to the patients‟ infection stage at 
diagnosis.    This  is  because  just  as  phylogenetic  reconstructions  of  possible 
transmission  events  between  patients  diagnosed  as  recently  HIV-infected  do 
not necessarily equate to recent to recent transmissions, transmission events 
identified between patients diagnosed with chronic infection do not necessarily 
equate to transmissions during chronic infection.  Without information on the 
approximate date of the infection for the majority of sequences included in the 
analysis, and without dating the transmission events in some way, the infection 
stage  of  the  transmitter,  at  the  time  of  transmission,  cannot  be  ascertained.  
Instead, provided that the study population has been well selected in terms of Alison Brown – Chapter Five 
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coverage of a local HIV-infected population, and contains a substantial sample 
of  sequences  with  well  estimated  infection  dates,  both  the  recently  and 
chronically infected will be in represented in the dataset.   
 
It  is  recommended  that  future  analyses  should  comprise  sequences  from 
patients from a reasonably complete and closed HIV-infected population and 
contain  a  large  proportion  of  patients  with  well-estimated  infection  dates.  
Methods should then allow each patient‟s infection stage to change from recent 
to chronic infection to reflect the natural progression of HIV infection.  Secondly, 
it is suggested that transmission events involving patients with recent infection 
could  be  used  to  approximate  the  “transmission  date”  i.e.  transmissions 
involving a recently HIV-infected individual are likely to have occurred around 
that  patient‟s  diagnosis.    This  “dating”  will  allow  researchers  to  ascertain 
whether  the  patient  most  likely  to  have  generated  the  recent  infection  was 
themselves recently or chronically infected at the transmission date (provided 
they also have an estimated infection date, or a diagnosis date of at least six 
months earlier). 
 
This analysis is not an attempt to measure the extent that the recently HIV-
infected are generating new transmissions.  The data were selected because 
they  contained  well  estimated  infection  dates.    This  allowed  the  temporal 
relationship between sequences involved in a possible transmission event to be 
explored.  However,  the  size  and  inconsistent  geographic  and  demographic 
population make up of the CASCADE prevents the wider extrapolation of the Alison Brown – Chapter Five 
    154 
 
 
results and the calculation of the rate of transmission from the recently HIV-
infected population.  While the Brighton dataset is more representative of a local 
HIV population, the limitations of using exclusive recently HIV-infected cohorts 
limits the interpretation of this analysis. 
 
There  are  further  problems  associated  with  datasets  that  are  exclusively 
comprised from patients who were recently HIV-infected at diagnosis.  While it 
may be possible to account for the transient nature of recent infection through 
calculating infection dates for each patient and allowing them to progress from 
recent to chronic infection, there may be an intrinsic difference between patients 
who were diagnosed during recent infection and those diagnosed during chronic 
infection in terms of the HIV testing and sexual behaviours.   Those who present 
for HIV testing shortly after a recent risk exposure may have different levels of 
risk behaviour. Patients who are diagnosed during recent infection may be more 
likely to have symptoms of seroconversion illness.   
 
Patients only remain recently HIV-infected for a brief period of time compared to 
the  overall  length  of  their  infection.    Consequently,  studies  that  focus  upon 
transmission from the recently HIV-infected population ignore individuals living 
with chronic HIV infection; the majority of the HIV-infected population.  Within 
the  chronically  HIV-infected  population,  transmission  risk  will  vary  with  viral 
load/treatment status, and STI acquisition.  Indeed, plasma viral load has been 
demonstrated to be the most important risk factor in increasing the likelihood of 
transmission.      It  is  essential  that  future  phylogenetic  reconstructions Alison Brown – Chapter Five 
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incorporate other variables of importance, and also essential that variables that 
constitute  transient  values  (e.g.  viral  load,  STI  presence,  CD4  counts)  are 
treated as such.  For instance, they will only be informative for phylogenetic 
reconstructions provided that transmission, and the presence of the values, can 
be dated in some way. 
 
5.6 Conclusion  
This chapter has demonstrated the utilities of phylogenetic reconstructions of 
HIV transmission events between patients who were diagnosed with recent HIV 
infection.  It  has  identified  that  this  population may  have  an  important  role in 
generating  new  transmissions.    It  also  suggested  that  such  approaches  are 
likely  to  overestimate  the  extent  this  population  generates  new  infections, 
unless precise definitions of recent infection are used, and some technique of 
“dating” transmission events is employed.   
 
Work undertaken in this chapter did not attempt to determine the extent that 
those  with  recent  HIV  infection  are  driving  transmission,  but  suggested  that 
such attempts require three conditions.  Firstly, the sample population needs to 
include patients who were recently, and chronically HIV-infected at diagnosis 
(and  be broadly  representative  of  an  HIV-infected  population  with  respect  to 
geography  and  time).  Secondly,  the  sample  population  must  include  a 
substantial  proportion  of  patients  with  well  estimated  infection  dates  and 
recognize that such patients are only recently HIV-infected for a short duration.  Alison Brown – Chapter Five 
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Thirdly, it requires a mechanism that allows transmission events to be dated, so 
that the infection stage of the transmitter can be ascertained, at around the time 
of  transmission.        Only  then  can  transmissions  from  recently  HIV-infected 
patients be measured with any precision.  The chapter also suggests analyses 
need  not  and  should  not  be  restricted  investigating  transmissions  from  the 
recently HIV-infected; the approach can be extended to include other relevant 
risk factors for HIV transmission.      
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6  Chapter Six: The source of new HIV infections in a local 
HIV-infected population 
 
 
 
 
 
In this chapter, a local UK population of diagnosed HIV-infected UK MSM is 
described, with particular emphasis on its transmission potential. A phylogenetic 
reconstruction of HIV transmission events is conducted.  An approach that links 
transmission events with the specific factors associated with the transmitters, at 
around the time of transmission, is used to identify the factors that are important 
in generating new transmissions.  
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6.1 Introduction  
To date, the majority of phylogenetic reconstructions of HIV transmission have 
focussed  on  the  recently  HIV-infected  population  (Pao,  Fisher  et  al.  2005), 
(Yerly, Kaiser et al. 1999; Brenner, Roger et al. 2007).  The chronically HIV-
infected population is usually either absent or the infection stage poorly defined 
(Brenner, Roger et al. 2007) (see section 1.5.1).    Generally, patients have 
been categorised as being either recently or chronically HIV-infected according 
to their infection stage at diagnosis, with a failure to recognise the transient 
nature  of  infection  stage  (see  section  1.6.4).    This  failure  may  have 
overestimated the transmissions events generated by the recently HIV-infected 
population (chapter five), (Brown 2009a).  
 
This  chapter  aims  to  describe  the  HIV-infected  population  in  Brighton  with 
particular  emphasis  on  its  transmission  potential  (e.g.  plasma  viral  load, 
treatment  and  STI  diagnoses).    A  phylogenetic  reconstruction  of  HIV 
transmission events was undertaken among this population.  An approach was 
used that can link “dated” transmission events to specific risk factors associated 
with the transmitters at the time of transmission.  Finally, the groups that are 
important in generating HIV transmission events were ascertained.    Alison Brown – Chapter Six 
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6.2 Methods 
6.2.1  The categorization of patients by risk factor 
This section describes the diagnosed HIV-infected population of Brighton with 
reference to its transmission potential. The demographic and clinical details of 
the  Brighton  dataset  are  described  in  section  3.4.  In  brief,  during  the  study 
period (2000-2006, comprising 28 calendar quarters), HIV pol sequences were 
obtained  from  HIV-infected  men  who  have  sex  with  men  (MSM)  attending 
Brighton HIV clinic.  Sequences were linked to the following data (Figure 3.2):    
  recent/chronic infection;  
  treatment (untreated/treated/treatment interruption);  
  plasma viral load;   
  CD4 count; 
  STI diagnosis; 
  age-group; 
  ethnicity;  
  world region of birth.   
The study period was stratified into a series of three month calendar quarters 
and the characteristics of patients under follow-up were summarised at the start 
of each quarter.  For each patient, data were collected for the first calendar 
quarter of attendance during the study period (this was the quarter of diagnosis 
if  diagnosis  occurred  during  the  study  period),  and  updated  for  each 
consecutive  calendar  quarter  throughout  the  study  period.    This  enabled 
patients‟ variables (where relevant) to change over time.   It was not possible to Alison Brown – Chapter Six 
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know whether patients attended during every calendar quarter during the study 
period.  Where patients did not attend during a calendar quarter, the data from 
the previous quarter were carried forward.  Patients who did not attend for 12 
consecutive months were considered lost to follow-up and excluded from the 
study period from their last quarter of attendance. 
 
For each patient ascertained as recently HIV-infected at diagnosis, an earliest 
and latest infection date was calculated according to which marker was used to 
identify the recent infection (Table 6.1).      An estimated infection date was 
taken as the mid point between the earliest and the latest infection date for each 
patient.   
 
Table  6.1:  Estimated  infection  dates  for  patients  identified  as  recently  HIV-infected  at 
diagnosis: Brighton    
Algorithm  Earliest infection date  Latest infection date 
Evolving antibody response/p24 antigen  Diagnosis date -30 days  Date diagnosis -1 day 
Western blot  Diagnosis date -60 days  Date diagnosis -30 days 
STARHS  Diagnosis date -183 days  Date diagnosis -60 days 
HIV negative <6 months before diagnosis  Date last negative +1 day  Date diagnosis -30 day 
 
To ensure consistency, each patient was categorized as recently HIV-infected 
for exactly six months following their estimated infection date.  However in order 
to mask the identity of patients, it was necessary to present data by calendar 
quarters.  While  each  patient  remained  recently  HIV-infected  for  exactly  six 
months, the number of calendar quarters during which they remained recently Alison Brown – Chapter Six 
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HIV-infected depended on where their  estimated infection date fell in relation to 
the calendar quarter.  For instance, a patient whose infection date was at the 
end of March, would be categorised as recently HIV-infected for three calendar 
quarters,  whereas  a  patient  infected  at  the  beginning  of  April  would  remain 
recently HIV-infected for only two quarters (Figure 6.1).      
 
Figure 6.1: Flow diagram showing how infection category was ascertained and updated 
over time for each patient: Brighton    
Combining  the  estimated  infection  date  information  with  the  clinical  data, 
patients were subdivided into infection category as follows:   
  recently HIV-infected 
  chronically HIV-infected and untreated with ARV 
  chronically HIV-infected and treated with ARV 
  chronically HIV-infected currently interrupting ARV treatment 
Each patient had their infection category updated for each subsequent calendar 
quarter following diagnosis (or their first attendance in the study period if they 
Estimated 
infection 
date
Diagnosis date
Latest 
infection date
Earliest 
infection date
Recent infection Chronic infection untreated Chronic infection  treated
Time
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were  diagnosed  before  the  study  period),  according  to  the  data  available 
(Figure 6.1).  
6.2.2  Describing  the  HIV-infected  population  and  its  transmission 
potential 
Due  to  the  difficulties  of  describing  a  diagnosed  HIV-infected  population  in 
relation  to  its  distribution  by  infection  category  (see  section  2.3.5)  and  risk 
factors for transmission (see section 2.4.7), three approaches were developed. 
All  three  approaches  included  every  patient  who  attended  during  the  study 
period, but the calendar quarter of the study period selected varied between the 
different groups.  These are outlined in Table 6.2. 
6.2.3  Phylogenetic reconstruction of HIV transmission events in Brighton   
A  phylogenetic  reconstruction  of  transmission  events  among  all  MSM  in 
Brighton is described in this section.  It compares the risk factors from patients 
whose  sequences  formed  a  cluster  against  those  whose  sequences  did  not 
form a cluster.         
Phylogenetic methods  
Amino acid positions associated with ARV resistance mutations (Shafer, Rhee 
et al. 2007) were deleted prior to phylogenetic analysis.  The sequences were 
aligned across 998 nucleotides using Sequence Analyzer.  A neighbour joining 
tree  was  constructed  with  gamma  rate  heterogeneity  set  at  0.5  and  500 
bootstrap replicates. Alison Brown – Chapter Six 
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Table 6.2: Description and attributes of the three approaches used to analyse the Brighton HIV-infected population   
 
 
Approach  Description  Method  Attributes  Representing? 
1  Only  included  the 
patients‟  first 
attendance  within  the 
study period.   
The  patients‟  calendar  quarter  of  diagnosis  was  selected  for  those 
diagnosed during the study period.  For those diagnosed before the study 
period, the first quarter of the study period was selected.  
859  patients  with 
one  calendar 
quarter included. 
Previous 
phylogenetic 
analyses  that 
categorise 
according  to  data 
obtained  at 
diagnosis 
2  Only  included  data 
from  one  calendar 
quarter  for  each 
patient  for  the  entire 
study  period,  but  the 
calendar  quarter  was 
selected at random. 
Patients  were  allocated  an  anonymous  number  which  was  sorted  in 
ascending order.  Every calendar quarter of the study period was presented 
chronologically (i.e. quarter 1, 2, 3) for each patient.  For the first patient, 
the  first  quarter  was  selected,  for  the  second  quarter  was  selected  etc.   
Once the first 28 patients had a calendar quarter selected (there were 28 
calendar quarters during the study period) the process started again with 
patient 29 having the first calendar quarter selected. Where patients did not 
have  the  relevant  calendar  quarter  (for  instance  if  information  was  only 
available  for  quarters  1-4  for  a  patient,  but  quarter  16  was  due  to  be 
selected), the patient was skipped.  The process was repeated until all 859 
patients had a calendar quarter selected. 
859  patients  with 
one  calendar 
quarter included. 
 
A “snap-shot” of the 
HIV-infected 
population 
attending  Brighton 
clinic  between 
2000-6.  
3  Included every patient, 
for  every  calendar 
quarter (including and) 
following diagnoses 
Each patient could be included up to 28 times within this dataset. Patients 
were  not  included  if  they  were  lost  to  follow-up  (no  attendance  for  12 
months).   It is not know whether patients attended every quarter. Where 
data were unavailable, data from the previous quarter were carried forward.  
Number  of 
calendar  quarters 
of  each  patient 
following 
diagnosis  or  the 
first  study  period, 
until  end  of  study 
period,  or  lost  to 
follow-up.  
A  representation  of 
the cumulative HIV-
infected  population 
of Brighton between 
2000-6. Alison Brown – Chapter Six 
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The  large  sample  size  precluded  maximum  likelihood  methods  (see  section 
2.2.11).  Consequently, sequences that fell into a robust cluster were selected, 
along with a random selection of 50 sequences that did not form any sort of 
cluster. Together, these sequences underwent a second neighbour joining tree 
reconstruction with gamma rate heterogeneity set at 0.5.  The alignment was 
then run through ModelTest.  A maximum likelihood tree was constructed using 
the selected model (K81uf+I+G) and its estimated parameters (the proportion of 
invariable sites set as 0.4477 and the heterogeneity set at 0.6946). The same 
cluster definitions were used; only those clusters that were identical between 
the neighbour joining and maximum likelihood trees were retained.  
Factors associated with HIV transmission 
The number  of  possible  transmission events  were  calculated  and  described.   
The  attributes  associated  with  patients  involved  in  a  possible  transmission 
event were  ascertained: infection category; plasma viral load; STI diagnosis; 
WRB; and age-group.   For each patient, the variables selected were those 
allocated at the patient‟s first attendance.  
6.2.4    A revised method: where do new infections come from? 
Unlike  previous  reconstructions  (see  section  1.5.1),  this  method  adopted  a 
strategy that: a) identified the most likely sources of transmission of patients 
diagnosed with a recent HIV infection; b) used the date of the recent infection to 
approximate  the  date  of  transmission;  c)  ascertained  the  attributes  (e.g. 
infection  category,  plasma  viral  load,  treatment  status)  of  the  most  likely 
transmission source, at around the time of transmission. Alison Brown – Chapter Six 
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Identifying the transmitters with estimated transmission dates 
The phylogenetic reconstruction described in section 6.2.3 was used for this 
analysis.  However, in this instance, only the transmission sources of patients 
diagnosed during recent HIV infection were sought.  This was in order to date 
the  transmission  events  approximately;  transmissions  to  patients  with  recent 
infections, by definition, must have occurred shortly before the diagnosis.  Such 
transmitters  are  referred  to  as  “transmission  sources  with  estimated 
transmission  dates”  throughout  the  remainder of  this thesis.   The  method  is 
graphically summarized in Figure 6.2.  
 
All patients within the dataset, regardless of infection category were considered 
potential transmission sources and a window of transmission was considered 
from their earliest appearance in the study period to the end of the study period 
(or  when  they  were  lost  to  follow-up).    In  order  to  be  considered  as  a 
transmission source with an estimated transmission date, candidate sequences 
had to form a robust cluster with a patient who was diagnosed during recent 
infection.  Where there was more than one candidate, the candidate with the 
shortest genetic distance was selected.  Where genetic distances between two 
candidates were identical, the candidate with the lowest number of nucleotide 
differences  to  the  sequence  from  the  recently  HIV-infected  patient  was 
selected.  Where this was equal, transitions were preferred over transversions.  
A distinction was made between where the clusters formed between the recent 
HIV-infection and its transmission source was unambiguous (the only sequence 
to form a cluster with the sequence from the recently HIV-infected patient) and Alison Brown – Chapter Six 
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transmitters  that  formed  a  cluster  with  the  sequence  from  the  recently  HIV-
infected sequence, along with other sequences. 
 
Candidate  transmission  sources  with  estimated  transmission  dates  were 
identified for as many patients who were recently HIV-infected at diagnosis as 
possible.  Candidate transmitters were excluded if they  had been diagnosed 
during chronic infection and their quarter of diagnosis occurred after diagnosis 
quarter of the recently HIV-infection patient, with which it was linked.  This is 
because,  in  these  instances,  the  direction  of  transmission  could  not  be 
ascertained  (e.g.  it  could  not  be  established  whether  the  recent  infection 
generated the chronic infection or vice versa).    
 
Where  a  transmission  event  was  identified  between  two  patients  both 
diagnosed  as  recently  HIV-infected  during  the  same  calendar  quarter,  the 
patient  identified  as  recently  HIV-infected  using  the  marker  with  the  longest 
window period was selected as the transmission source.  The recent infection 
with  the  shortest  window  period  was  excluded  as  a  transmission  source.  
Where the same marker of recent infection had been used for both patients, the 
pair  was  excluded  from  analysis  since  it  was  impossible  to  determine  the 
direction  of  transmission  between  the  two.  Candidate  transmitters  were  only 
included in the analysis provided they were also present in the dataset during 
the calendar quarter in which the recently HIV-infected patient of interest was 
diagnosed  (i.e.  the  period  of  transmission).    Transmission  sources  that 
“transmitted” after they were lost to follow up were excluded. Alison Brown – Chapter Six 
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Once  the  subset  of  transmission  sources  with  estimated  transmission  dates 
were  identified,  the  calendar  quarter  of  transmission  was  taken  to  be  the 
calendar quarter of diagnosis of the recent HIV-infection (which the candidate 
transmission source had generated).     Clinical data (infection category, plasma 
viral load, CD4 count and STI diagnosis) was then collated for the transmission 
source, during the calendar quarter of transmission.  In this way, the risk factor 
data were obtained at the approximate time of the transmission event. 
Descriptive analysis 
Once the subset of sources with estimated transmission dates were ascertained 
and collated, the distribution of this groups‟ infection categories,  plasma viral 
load, treatment status and STI diagnoses were described. This was compared 
to the distribution of the same variables of the concurrent Brighton population.  
Statistical tests of association were employed where appropriate. 
Statistical analyses 
The rate of transmission was calculated for each risk factor, per 100 person 
years of follow-up (PYFU).  The PYFU were calculated through summing every 
calendar quarter of the study period for each patient from their first attendance 
to  the  end  of  the  study  period  (or  the  patient‟s  last  attendance,  where  the 
patients were lost to follow-up).     
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Figure  6.2:  Flow  diagram  of  method  used  to  identify  transmission  source  of  patients 
diagnosed during recent HIV infection: Brighton 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
Note B's infection stage at the time of 
A's diagnosis
Yes
ID2 recent Q4 01
ID 1 recent Q2 04
For each A: are there any sequences 
that form a robust cluster
2 with A?
Categorise every sequence into infection 
category
1 according to the information 
available on the patient from which it was 
derived, and update for each subsequent 
calendar quarter.  E.g. recent HIV 
infection, chronic untreated, chronic 
treated, chronic treatment interruption
Example 1 Example 2
ID 1 recent Q2 04 ID 3 recent Q3 04
Label all sequences that were taken 
during recent HIV-infection as "A"
A recent Q2 04 A recent Q3 04
Phylogenetic reconstruction of HIV 
transmission events using all 
sequences
ID2 recent Q4 01
A recent Q2 04
ID 3 recent Q3 04 A recent Q3 04
ID2 recent Q4 01
ID 1 recent Q2 04
Yes No
Yes Yes
Remove sequences 
that form robust 
cluster, but whose 
date of infection is 
AFTER A's.
The most likely 
transmission source 
cannot be identified
ID2 recent Q4 01
A recent Q2 04
ID 3 recent Q3 04
For each A: are there any sequences 
that form a robust cluster
2 with A?
Yes No Yes
The most likely 
transmission source 
cannot be identified
Is there more than 
one sequence 
forming a cluster ? 
with A?
No Yes
Yes
Chose the sequence 
with the shortest 
genetic distance
This is the most likely 
transmission source -
labelled "B"
3
Count the infection stage distribution 
of all the Bs during the period when A 
was probably infected
A recent Q3 04
B recent Q4 01 B recent Q2 04
In Q2 04, B is a chronic 
untreated infection
In Q3 04, B is  a recent 
infection
chronic untreated - 1
recent infection - 1
Compare the distribution of infection stages of the Bs to the distribution of infection stages of the HIV-infected population
1 Infection stage is updated for each calendar quarter.  E.g. an individuals with recent HIV infection in quarter one 2003 will be 
a chronic  infection in quarter three 2003.
2 Robust cluster: >99% bootstrap and genetic distance <0.015 nucleotide substitutions per site.
3 A's may form robust clusters with other As.  Each A is considered individually, for instance, one A may have another A 
considered its most likely transmission source.  This second A, in turn, is  examined separately to find its most likely transmission 
source.
4 E.g. B may have been a recent infection at the time B's sample was sequenced - however, B may have "transmitted", 
generating A after recent HIV infection.  There the infection stage of B, at the time of As infection, is taken.   Alison Brown – Chapter Six 
    169 
 
 
Factors  independently  associated  with  transmission  were  identified  using 
univariable  and  multivariable  Poisson  regression  models  (SAS  version  9.1).  
Every calendar quarter of the study period was included separately in analyses 
with a covariate to indicate whether or not transmission occurred during that 
period.      Sensitivity  analyses  were  conducted  to  assess  the  impact  of  the 
assumptions used to allocate infection categories, and the impact of missing 
data.      This  involved  repeating  the  multivariable  analyses,  whilst  adjusting 
relevant variables (e.g. altering the estimated infection date to the earliest, and 
then the latest infection date).  
Case studies of transmitters 
For  each  of  the  transmission  sources  with  estimated  transmission  dates,  a 
graphical representation is provided for the time period they were present within 
the dataset.  The possible transmission event was illustrated within the wider 
context of their evolving viral loads, STI diagnoses and infection categories.     
6.3 Results 
6.3.1  Transmission potential of the HIV-infected population 
Population size and characteristics 
Of 1144 HIV-infected patients attending  the Brighton HIV clinic during 2000-
2006,  75.1%  (859)  patients  were  linkable  to  complete  protease  (PR)  and 
reverse transcriptase (RT) sequences.  Only these patients are considered in 
this  analysis.    The  description  of  the  demographic  data  and  the  difference 
between the patients with and without sequences is provided in section 3.6.5.   Alison Brown – Chapter Six 
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Data completeness 
Of the 859 patients included in the phylogenetic analysis, 428 were diagnosed 
before the year 2000 and 431 were diagnosed during the study period (2000-6).  
The total number of patients, with sequences available, represented in each 
calendar quarter of the study period is presented in Figure 6.3.  The number of 
patients within the dataset rose annually until  the first quarter of 2006 when 
numbers began to decline. Overall, there were 6176 patient years of follow-up.  
Between 2000-2006, the average number of patients represented was 606.7 
(range  451-724)  for  each  calendar  quarter.    On  average,  patients  had  data 
available  for  21.2  consecutive  calendar  quarters  (range:  3-28,  standard 
deviation 8.8 calendar quarters) and eight patients were lost to follow-up every 
calendar quarter.   
 
The proportion of patients with missing demographic data  was calculated for 
each field for each patient (world region of birth, ethnicity, and age-group) and 
also for each calendar quarter the study period for clinical data (plasma viral 
load, CD4 count and STI diagnosis).  The proportion of patients with missing 
demographic data was 10.1% (87/859) for world region of birth, 2.6% (22/859) 
for ethnicity and 0% (0/859) for age-group.  The proportion of fields with missing 
data was 9.9% (1685/16988) for plasma viral load and 9.7% (1641/16988) for 
CD4 counts.  The records that had missing values for viral load were more likely 
to have missing CD4 values. 
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Figure  6.3:  Number  of  diagnosed  HIV-infected  patients  with  complete  pol  sequences 
represented, and number lost to follow up, by calendar quarter, Brighton: 2000-2006 
Infection category distribution 
Of  the  859  patients,  159  (18.5%)  were  found  to  be  recently  HIV-infected  at 
diagnosis.  Of these, 104 were ascertained through STARHS, 20 through the 
p24 antigen, two from western blot and 21 through the dates algorithm (Table 
6.1).    Three  approaches  were  devised  to  understand  the  attributes  of  the 
Brighton  population  –  these  are  outlined  in  Table  6.2.    The  distribution  of 
infection category, using all three approaches, is given in Figure 6.4.    
 
Approach one 
Approach one described the population through taking the first calendar quarter 
of attendance.     Patients were further subdivided into those diagnosed before, 
and during, the study period. Of the patients diagnosed before the study period, 
2.2%  ((11/498)    95%  confidence  intervals  (CI)  0-14.95)  were  recently  HIV-
infected  at  their  first  attendance  during  the  study  period  (none  were  HIV-
diagnosed during this calendar quarter).  In contrast, 34.3% (148/431, 95%CI Alison Brown – Chapter Six 
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30.1-38.9) of  patients  diagnosed  during  the  study  period  were  recently  HIV-
infected  at  their  first  clinic  attendance  (which  was  their  calendar  quarter  of 
diagnosis)   Overall, during the first calendar quarter of attendance during the 
study  period,  18.5%  (159/859,  95%CI  16.1-21.3)  were  recently  HIV-infected, 
41.0% (352/859, 95%CI 37.7-44.3) were chronically HIV-infected and not ARV 
treated, 32.0% (275/859, 95%CI 29.0-35.2) were chronically HIV-infected and 
ARV treated, and 8.5% (73/859, 95%CI 6.8-10.6) were chronically HIV-infected 
and currently interrupting ART. 
 
Approach two 
Approach two included every patient who attended during the study period but 
for each, a random calendar quarter of the study period was selected (Table 
6.2).  Arguably, this approach shows a “snap-shot” of the population between 
2000-6.  Using this approach, 4.7% (40/859, 95%CI 3.4-6.3) of patients were 
recently  HIV-infected,  34.3%  (295/859,  95%CI  31.2-37.6)  were  chronically 
infected  and  untreated,  46.1%  (396/859,  95%CI  42.9-49.4)  were  chronically 
HIV-infected and treated and a further 14.9% (128/859, 95%CI 12.7-17.4) were 
currently interrupting treatment.     
 
Approach three 
This approach included every calendar quarter of the study period for every 
patient (from their first quarter of attendance to the end of the study period (or 
last quarter of attendance if lost to follow-up)).  Alison Brown – Chapter Six 
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Figure 6.4: Infection category distribution among diagnosed HIV-infected MSM, Brighton: 
2000-2006 
 
 
Overall, 2.1% (355/16988, 95%CI 1.9-2.3) of calendar quarters during the study 
periods  were  linked  to  patients  experiencing  recent  HIV  infection.  A  further   
27.6% (4695/16988, 95%CI 27.0-28.3) of quarters were linked those who were 
chronically infected and untreated, and 55.4% (9411/16988, 95%CI 55.4-56.2) 
of  quarters  were  linked  to  the  chronically  HIV-infected  and  treated.    Finally, 
14.9%  (2531/16988,  95%CI  14.4-15.4)  of  quarters  were  linked  to  those 
currently interrupting treatment.  
 
The distribution of infection category over time is presented, using data from 
approach three in Figure 6.5.  The proportion of calendar quarters linked to the 
patients  who  were  recently  HIV-infected  increased  from  1.49%  (28/1875)  in 
2000 to 2.8% (80/2834) in 2005 (p=0.001) but then dropped to 0.64% (18/2774) 
in  2006.  The  proportion  of  calendar  quarter  linked  to  patients  who  were 
currently  ARV  treated  increased  from  50.1%  (956/1875)  in  2000  to  63.4% 
(1760/2774) in 2006 (p<0.0001).      Alison Brown – Chapter Six 
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Plasma viral load by infection category 
This section uses approach three to describe the data.  Plasma viral load by 
infection category, using every patient and every quarter they were represented 
in the study period, is presented in Figure 6.6. There was a strong association 
between  viral  load  and  infection  category  (Yates‟  chi  square,  corrected  for 
continuity  p<0.0001).    Those  not  currently  on  treatment  (the  recently  and 
chronically infected, and those interrupting treatment) had significantly higher 
viral  loads  than  those  currently  on  treatment.    Specifically,  the  proportion  of 
calendar quarters linked to patients with  viral loads over 10,000 copies/mL was 
69.3% (95%CI 64.0-74.09, 221/319) among the recently HIV-infected, 78.1% 
(95%CI 76.8-79.4, 2957/3784)   among the chronically-infected and untreated 
patients, and 47.7% (95%CI, 45.7-49.8, 1077/2257) among patients interrupting 
treatment.  In contrast the proportion of calendar quarters linked to patients with 
viral load over 10,000 copies/mL was 3.5% (95% CI 3.2-3.9, 316/8943) among 
the treated population, Chi square, (p<0.0001).     
 
The proportion of calendar quarters linked to patients with viral loads under 50 
copies/mL  was  5.64%  (95%CI  3.6-8.74,  18/319)  among  the  recently  HIV-
infected,  0.71%  (95%CI  0.49-1.03,  27/3784),  among  the  chronically  HIV-
infected who were untreated and 31.10% (95%CI 29.2-33.0, 702/2257) among 
calendar quarters linked to those currently interrupting treatment.  In contrast, 
the proportion of calendar quarters linked to patients with viral loads of under 50 
copies/mL  was  83.1%  (95%CI  82.3-83.8) among  the  treated  population  (Chi 
squared, p<0.001).      
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Figure  6.5:  Distribution  of  patient  infection  category  for  each  calendar  quarter  of  the 
study period  (using approach three), Brighton: 2000-2006    
 
 
 
Figure 6.6: Distribution of patient viral load, by infection category, using data from every 
calendar quarter of the study period (using approach three) Brighton: 2000-2006 
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STI diagnosis by infection category 
Overall, 39.5% (339/859) patients had an STI diagnosis at some point during 
the  study  period.    Excluding  patients  who  had  STIs  diagnosed  at  the  same 
quarter as their HIV diagnosis, this proportion reduced to 35.5% (305/859).  Of 
those who were diagnosed with an STI 64.6% (219/339) had one diagnosis, 
23.0%  (78/339)  were  diagnosed  twice,  8.8%  (30/339)  were  diagnosed  three 
times, 3.2% (11/339) four times and 0.29% (1/339) five times.  Data were only 
available on whether patients had an STI diagnosis, and not on the frequency of 
STI screening.     
 
Using approach three, the proportion of calendar quarters linked to patients who 
had STI diagnoses was 12.7% (45/355, 95%CI 9.6-16.6) among attendances 
from recently HIV-infected population (Figure 6.7), 3.9% (185/4695) from the 
untreated, 2.1% (193/9407) from the treated, and 2.3% (58/2531) from those 
currently interrupting treatment.    
 
Figure 6.7: Proportion of calendar quarters linked to diagnosed HIV-infected MSM with an 
STI diagnosis, by infection category, (using approach three) Brighton: 2000-2006   
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CD4 by infection category 
The distribution of patient CD4 count by infection category is provided in Figure 
6.8.  Using approach three, no calendar quarters (0/355) were linked to patients 
with CD4 counts less than 50 cells/mm
3 among the recently infected.  However, 
the proportion with CD4 counts under 50 cells/mm
3 was 0.37% (14/3835) from 
calendar  quarters  linked  to  the  chronically  HIV-infected  and  untreated 
population, 0.61% (55/8947) from the currently treated population and 2.14% 
(48/2248) among the population currently interrupting treatment.   
 
 
Figure  6.8:  Distribution  of  patient  CD4  count,  by  infection  category,  using  data  from 
every calendar quarter of the study period (using approach three) Brighton: 2000-2006 
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6.3.2   Phylogenetic reconstruction of HIV transmissions in Brighton  
Phylogenetic analysis 
Using  all  sequences  obtained  from  Brighton,  the  first  neighbour  joining  tree 
found  24.3%  (209/859)  sequences  fell  into  a  robust  cluster  with  another 
sequence (Figure 6.9).  These formed 78 clusters (mean size=2.67 sequences 
per cluster, range 2-10).  The 209 clustering sequences were selected, along 
with 50 sequences that did not cluster, chosen at random, to create a maximum 
likelihood tree.   
 
The maximum likelihood reconstruction retained 61.7% (129/209) of the original 
clustering sequences from the neighbour joining tree.   Of the original clusters, 
19.2% (15/78) were not retained in the maximum likelihood tree. These clusters 
were  disproportionately  those  containing  larger  numbers  of  sequences  per 
cluster.  The mean number of sequences per cluster was 2.08 (range 2-3) for 
the retained clusters, and 3.43 (range 2-9) for the clusters lost.  Eight novel 
clusters, involving 19 sequences, were formed in the maximum likelihood tree 
that had not clustered in the neighbour joining tree.  Overall 62 clusters were 
consistent between the neighbour joining tree and the maximum likelihood tree: 
only  these  were  considered  to  be  robust  clusters  for  the  remainder  of  this 
chapter.      Within  clusters,  the  genetic  distances  altered  slightly  for  some 
sequences within clusters, between the two trees, but still met the definition of 
robust cluster. 
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Figure 6.9: Phylogenetic reconstruction of transmission events among diagnosed HIV-
infected MSM, Brighton: 2000-2006 
 
Attributes of clustering sequences 
Overall,  15%  (129/859)  of  sequences  fell  into  a  robust  cluster  with  another 
sequence.  Of  the  159  patients  who  were  recently  HIV-infected  at  the  first 
attendance during the study period, 29.6%  (47/159) fell into a cluster with any 
other  sequence  and  11.3%  (18/159)  fell  into  a  cluster  with  one  or  more 
sequences  from  a  patient  diagnosed  with  recent  infection  in  the  same  or 
consecutive  calendar quarter.    In  comparison,  11.7%  (82/700) of  sequences 
from chronically HIV-infected patients clustered with any other sequence.    Alison Brown – Chapter Six 
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Characteristics associated with sequences that did cluster, and sequences that 
did not cluster, are provided in Table 6.3.    Sequences that clustered were 
more  likely  to  be  from  patients  who  were  recently  HIV-infected  at  their  first 
attendance during the study period compared to those who were not recently 
HIV-infected  at  their  first  attendance:    36.4%,  (47/129)  vs.  15.3%  (112/730) 
p<0.001).  Similarly, sequences that formed a robust cluster were less likely to 
have been from a patient treated at some point compared to those that did not 
cluster: 22.5% (29/129) vs. 43.7% (319/730), p=0.028.  An STI diagnosis at the 
first attendance was associated with an increased risk of clustering: of those 
that  clustered,  16.3%  (21/129)  had  an  STI  at  first  attendance,  compared  to 
6.2%  (45/730)  of  those  who  did  not  have  an  STI  at  their  first  attendance 
(p<0.001).  Equivalent figures for those who ever had an STI diagnosis during 
the study period were 56.6% (73/129) and 36.9% (270/730) (p=0.0002).  
Table 6.3: Characteristics of the pol sequences that did, and did not, cluster, Brighton:  
2000-2006  
 
Risk factor  Sequences that 
clustered (N=129) 
Sequences that did not 
cluster (N=730) 
Chi 
square 
%  n  %  n 
Recent HIV infection  36.4  47  15.3  112  p=0.028 
Ever treated  22.5  29  43.7  319  p<0.0001 
Age-group*           
<35  58.1  75  37.0  270  p<0.0001 
>35  41.9  54  63.0  460  p<0.0001 
World region of birth           
UK  71.3  92  72.5  529  p=0.8 
Sub-Saharan Africa  4.7  6  3.3  24  p=0.4 
Rest of Europe  12.4  16  7.7  56  p=0.07 
STI at diagnosis  16.3  21  6.2  45  p<0.001 
STI during study period  56.6  73  36.9  270  p<0.0002 
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6.3.3  Revised method: where do new infections come from? 
Transmitters with estimated transmission dates  
Of the 159 sequences that were derived from patients who were recently HIV-
infected at first attendance during the study period, 47 fell into a robust cluster 
and could thereby be allocated a candidate most likely transmitter. Of the 47 
candidate transmitters identified, 42 were confirmed the most likely transmission 
source of the patients recently HIV-infected at diagnosis.  This is because the 
transmission  sources  were  diagnosed  before  the  recent  HIV-infected  patient 
with whom they were associated (or same calendar quarter if they had a chronic 
infection), indicating the direction of transmission (see section 6.2.4).  Of the 42 
transmission  sources,  41  had  data  available  during  the  calendar  quarter  in 
which the transmission took place (i.e. the calendar quarter of diagnosis of the 
recent infection generated) (Figures 6.10 and 6.11).   
 
Two potential transmission sources were excluded since it was impossible to 
select  the  most  likely  transmitter  in  these  instances.    This  is  because  the 
sequences  from  the  two  candidate  transmitters  were  identical  (although  one 
sequence was shorter than the other, indicating that this was not a cutting and 
pasting  error).  This  left  39  most  likely  transmission  sources.    Of  the  39 
transmitters, 27 were unambiguously paired with the recent infection and 12 
formed a cluster with the recent infection alongside additional sequences.   
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Figure 6.10: Phylogenetic reconstruction of HIV transmission events among diagnosed 
HIV-infected  MSM  attending  Brighton  clinic,  with  most  likely  transmission  sources 
highlighted, Brighton: 2000-2006 
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Figure  6.11:  Flow  diagram  showing  ascertainment  of  transmission  sources  with 
estimated transmission dates, Brighton: 2000-2006   
 
The 39 most likely transmission sources were predominantly white (37/39), and 
born in the UK (29/39) with the remainder born elsewhere in Europe and in sub-
Saharan Africa.   The majority of transmitters were aged under 35 years (27/39) 
with the transmissions disproportionately occurring during or after 2005 (16/39).   Alison Brown – Chapter Six 
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Descriptive analysis 
Overall, of the 39 transmitters with estimated transmission date, 24.4% (9/39) 
were  recently  infected  at  the  time  of  transmission  and  46.3%  (19/39)  were 
chronically HIV-infected but untreated.  The remainder comprised 4.8% (2/39) 
who  were  currently  on  treatment,  and  22.0%  (9/39)  who  were  undergoing 
treatment  interruption.  The  distribution  of  the  infection  categories  of  the 
transmissions  was  compared  the  distribution  of  the  infection  categories  of 
concurrent  diagnosed  HIV-infection  population  (described  through  approach 
three) (Figure 6.12).  
 
At  the  estimated  time  of  transmission,  39  of  the  most  likely  transmission 
sources,  2.7%  (1/39)  had  plasma  viral  loads  under  50  copies/mL,  with  an 
additional 2.7% (1/39) with viral loads between 50-1000 copies/mL.  A further 
7.7% (3/ 39) had viral loads from 1001-10,000 copies/mL, and 38.5% (15/39) 
had viral loads from 10,001-100,000 copies/mL.  An additional 38.5% (15/39) 
had viral loads over 100,000 copies/mL.   Figure 6.13 shows the distribution of 
viral  load  for  the  transmitters  compared  to  concurrent  Brighton  population, 
described through approach three.   
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Figure  6.12:    Comparison  of  the  distribution  of  infection  category  between  the 
transmission  sources  with  estimated  transmission  dates  and  the  concurrent  Brighton 
population (using data from every calendar quarter of the study period - approach three) 
Brighton: 2000-2006 
 
   
Figure 6.13: Comparison of the viral load distribution between the transmission sources 
with estimated transmission dates and the concurrent Brighton population (using data 
from every calendar quarter of the study period - approach three) Brighton: 2000-2006 
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At the estimated time of transmission, 0% (0/39) of transmission sources had a 
CD4 count less than 50 cells/mm
3, 5.1% (2/39) had CD4 counts from 50-200 
cells/mm
3, 23.1% (9/39) had CD4 counts from 200-350 cells/mm
3 and 28.2% 
(11/39) had CD4 cell counts from 350-500 cells/mm
3 and 41.0% (16/39) over 
500  cells/mm
3.  Figure  6.14  shows  the  distribution of the  CD4  counts  of  the 
transmitters compared to the concurrent Brighton population  
 
Overall 25.6% (10/39) of the transmission sources had an STI diagnosis around 
the estimated time of transmission.    Figure 6.15 shows the distribution of STI 
diagnoses  among  the  transmitters  compared  to  the  concurrent  Brighton 
population. Overall, 69.2% (27/39) of patients had an STI diagnosis at some 
point during the study period, excluding two who only had STI diagnoses during 
the same calendar quarter in which they were diagnosed. 
 
Figure 6.14: Comparison of the CD4 count distribution between the transmission sources 
with estimated transmission dates and the concurrent Brighton population (using data 
from every calendar quarter of the study period - approach three) Brighton: 2000-2006 
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Figure 6.15: Comparison of the distribution of STI diagnoses between the transmission 
sources  with  estimated  transmission  dates  and  the  concurrent  Brighton  population 
(using data from every calendar quarter of the study period - approach three) Brighton: 
2000-2006 
 
Among the transmission sources, nine had their estimated transmission dates 
within the same calendar quarter in which they themselves were diagnosed with 
HIV.    This  suggests  they  were  likely  to  be  undiagnosed  at  the  time  of 
transmission.  
Statistical analysis 
In order to account for the biases inherent within the descriptive analyses (e.g. 
the  shorter  length  of  time  that  the  recently  HIV-infected  population  have  to 
generate  infections  compared  to  chronically  infected  population)  the  rate  of 
observable HIV transmission per person years of follow-up was ascertained for 
each risk factor (Table 6.4).   Overall, 39 transmissions occurred from the most 
likely  transmission  sources  during  6176  years  of  patient  follow-up.    This 
generated  a  transmission  rate  of  0.63  per  100  person  years  of  follow-up Alison Brown – Chapter Six 
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(PYFU). Transmission rates of over one per 100 years of follow up were found 
among the under 35s, those with viral loads over 10,000 copies/mL, the recently 
HIV-infected and the chronic untreated population.   
Univariable and multivariable analyses 
Rate ratios of transmission were calculated using Poisson regression models. 
The  results  from  the  univariable  analysis  are  shown  in  Table  6.5,  and  the 
results from the multi-variate analysis are shown in Table 6.6.  
 
The univariable analysis indicated that the rate ratio of transmission increased 
2.38 per log10 of viral load increase.  STI diagnosis during the same period as 
transmission had a rate ratio of 12.53.  The rate ratio of transmission was higher 
among  younger  ages  (p<0.0001).    AIDS  was  associated  with  lower  
transmission rates; there was no association between CD4 cell count and HIV 
transmission rate.   
 
Within  the  multivariable  analysis,  overall,  the  factors  associated  with 
transmission were: younger age; high viral load; recent HIV infection; and STI 
diagnosis  at  around  the  same  period  of  transmission.    Treatment  was 
associated with lower transmission risk in a univariable model, rate ratio 0.04 
(0.01-0.19; p=0.0), but the effect was less profound in the multivariable model 
rate ratio 0.24 (0.05-1.24; p=0.11). 
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Table  6.4:  Number  of  transmissions,  person-years  of  follow-up  (PYFU),  transmission 
rates and 95% confidence intervals generated by transmission sources with estimated 
transmission dates, Brighton: 2000-2006  
 
Factor  Transmissions  PYFU  Rate 
(/100PYFU) 
95%CI 
Overall    39  6167  0.63  0.46-0.86 
Age-group   <35      27  1502  1.80  1.24-2.61 
  35-44  9  2592  0.35  0.18-0.66 
  >45  3  2082  0.14  0.05-0.42 
CD4  <200  2  582  0.34  0.09-1.24 
  201-350  9  1269  0.71  0.37-1.34 
  351-500  11  1564  0.70  0.39-1.25 
  >500  16  2242  0.71  0.44-1.15 
  Not known  1  521  0.19  0.03-1.08 
Viral load  <50  1  3176  0.03  0.01-0.18 
  50-1000  1  482  0.21  0.04-1.17 
  1001-10,000  3  427  0.70  0.24-2.04 
  10,001-100,000  15  941  1.59  0.97-2.61 
  >100,000  15  611  2.45  1.49-4.0 
  Not known  4  541  0.74  0.29-1.89 
Infection 
category 
Recently HIV-
infected 
9  194  4.64  2.46-8.58 
  Chronic infection, 
untreated 
19  1485  1.28  0.8-2.0 
  Chronic infection, 
treated 
2  3556  0.06  0.02-0.21 
  Chronic infection, 
treatment 
interruption 
9  941  0.96  0.51-1.81 
AIDS    38  6016  0.63  0.46-0.86 
    1  160  0.63  0.11-3.46 
STI diagnosis  No  29  4972  0.58  0.4-0.83 
  Yes  10  1204  0.83  0.45-1.52 
Year  2000-1  5  1403  0.36  0.015-0.84 
  2002-3  12  1663  0.72  0.41-1.26 
  >2004  22  3050  0.72  0.48-1.11   
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Table  6.5:  Univariable  analysis  of  transmission  rate  ratio  using  poisson  regression 
model, generated by transmission sources with estimated transmission dates, Brighton: 
2000-2006 
 
Factor  Rate 
ratio 
95% CI  p-value 
Age-group  <35  5.37  2.53-11.37  0.0001 
  35-44  1     
  >45  0.41  0.11-1.53  0.19 
   Per five years older  0.51  0.41-0.65  0.0001 
CD4  <200  0.49  0.10-2.25  0.36 
  201-350  1     
  351-500  0.99  0.41-2.39  0.99 
  >500  1.01  0.44-2.28  0.99 
  Not known  0.81  0.22-3.00  0.75 
    Per 50 cells per mm
3 higher  1  0.94-1.07  0.93 
Viral load  <50  0.07  0.01-0.37   
  50-1000  0.44  0.08-2.42  0.002 
  1001-10,000  1    0.35 
  10,001-100,000  1.7  0.24-2.04   
  >100,000  2.44  0.56-5.13  0.34 
  Not known  0.79  0.8-7.42  0.12 
  Per log 10 higher  2.38  1.82-3.11  0.74 
Infection category  Recently HIV-infected  4.03  1.88-8.68  0.0001 
  Chronic infection, untreated  1    0.0004 
  Chronic infection, treated  0.04  0.01-0.19  0.0001 
  Chronic infection, treatment interruption  0.75  0.34-1.65  0.47 
AIDS  No  1     
  Yes  0.11  0.01-0.77  0.03 
STI diagnosis  No  1     
  Yes  12.53  6.13-25.64  0.0001   
Table  6.6:  Multivariable  analysis  of  transmission  rate  ratio  using  poisson  regression 
model generated by transmission sources with estimated transmission dates, Brighton  
 
Factor  Rate ratio  95% CI  p-value 
Age (per five years older)    0.68  0.54-0.86  0.001 
Viral load (per log higher)    1.64  1.16-2.31  0.005 
Infection category  Recent  3.06  1.32-7.08  0.009 
  Recent, untreated  1     
  Chronic  treated  0.26  0.05-1.38  0.11 
  Chronic, treatment 
interruption 
1.66  0.71-3.86  0.24 
STI diagnosis  No   1     
  Yes  6.07  2.83-12.99  0.0001 
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Sensitivity analyses 
Sensitivity  analyses  were  conducted  to  assess  the  impact  of  the  algorithms 
used to estimate infection date, and the impact of missing data on the results.   
This  involved  repeating  the  multivariable  analyses  four  times,  each  time 
adjusting a specific variable under investigation.  
 
a) Excluding patients who had missing CD4/viral load data at the start of each 
calendar quarter. 
Under this variation, records that had missing CD4/viral load data at the start of 
each  calendar  quarter  were  excluded.    The  number  of  transmitters  with 
estimated infection dates dropped from 39 transmitters over 6167 PYFU to 27 
transmitters over 5463 PYFU. The association between increased transmission 
rate ratio with viral load and infection category did not remain significant (Table 
6.7).   
 
Table 6.7: Multivariable  analysis of transmission rate ratio from transmission sources 
with estimated transmission dates, using poisson regression model, excluding patients 
who had missing CD4/viral load data at the beginning of each calendar period, Brighton: 
2000-2006 
Factor  Rate ratio  95% CI  p-value 
Age (per five years older)    0.70  0.53-0.91  0.007 
Viral load (per log higher)    1.4  0.97-2.04  0.08 
Infection category  Recent  2.13  0.48-9.40  0.32 
  Recent, untreated  1     
  Chronic untreated  0.18  0.03-0.99  0.05 
  Chronic, treatment 
interruption 
1.37  0.55-3.37  0.50 
STI  No   1     
  Yes  3.88  1.32-11.36  0.01 
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b) Taking data from the quarter end, rather than the quarter start, and excluding 
patients with missing data 
Under this variation, data related to the patients was taken from the end of each 
calendar  quarter  (rather  than  the  beginning),  and  patients  with  missing  data 
were  excluded.    Three  transmission  sources  were  lost.    The  relationship 
between  increased  rate  ratio  of  transmission  risk,  and  viral  load  remained 
(Table  6.8).    However,  the  association  with  infection  category  became  non-
significant. 
 
Table 6.8: Multivariable  analysis of transmission rate ratio from transmission sources 
with  estimated  transmission  dates,  using  poisson  regression  model,  taking  treatment 
data from the end of the quarter and excluding patients who had missing data, Brighton: 
2000-2006  
Factor  Rate ratio  95% CI  p-value 
Age (per five years older)    0.68  0.54-0.86  0.001 
Viral load (per log higher)    2.26  1.56-3.26  0.0001 
Infection category  Recent  1.31  0.38-4.51  0.67 
  Recent, untreated  1     
  Chronic untreated  0.54  0.14-2.06  0.36 
  Chronic, treatment 
interruption 
1.14  0.49-2.63  0.76 
STI  No   1     
  Yes  6.58  3.08-14.07  0.0001 
 
 
 
 
 
 
 
 
 Alison Brown – Chapter Six 
193 
c) Reclassifying recent HIV infection based on earliest infection date  
Each patient had an estimated infection date calculated as the mid-point of their 
earliest and latest infection date, based on the markers used to ascertain recent 
HIV infection (see section 6.2.1).   For this variation, the estimated infection 
date was taken as the earliest date.   
 
When patients were categorized as being recently HIV-infected based on the 
earliest possible date of infection then only two of the transmissions occurred 
from  the  “recently  HIV-infected”  (Table  6.9).    The  association  between 
increased rate ratio of transmission and recent HIV infection stage did not retain 
its significance.  The relationship with viral load was retained. 
 
Table 6.9: Multivariable  analysis of transmission rate ratio from transmission sources 
with estimated transmission dates, using poisson regression model, using the earliest 
possible infection date, Brighton: 2000-2006 
Factor  Rate ratio  95% CI  p-value 
Age (per five years older)    0.68  0.54-0.86  0.001 
Viral load (per log higher)    2.26  1.56-3.26  0.0001 
Infection category  Recent  1.31  0.38-4.51  0.67 
  Recent, untreated  1     
  Chronic untreated  0.54  0.14-2.06  0.36 
  Chronic, treatment 
interruption 
1.14  0.49-2.63  0.76 
STI  No   1     
  Yes  6.58  3.08-14.07  0.0001 
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d) Reclassifying recent infection based on the latest infection date  
When patients were categorized as being recently HIV-infected based on the 
latest possible date of infection, a further nine transmissions were classified as 
occurring  during  “recent  infection”.    The  association  between  increased 
transmission  rate  ratio  and  infection  category  and  viral  load,  was  retained 
(Table 6.10). 
 
Table 6.10: Multivariable analysis of transmission rate ratio from transmission sources 
with  estimated  transmission  dates,  using  poisson  regression  model,  using  the  latest 
possible infection date,  Brighton: 2000-2006 
Factor  Rate 
ratio 
95% CI  p-value 
Age (per five years older)    0.67  0.53-0.85  0.0008 
Viral load (per log higher)    1.69  1.20-2.39  0.003 
Infection category  Recent  3.39  1.48-7.73  0.004 
  Recent, untreated  1     
  Chronic untreated  0.28  0.05-1.44  0.13 
  Chronic, treatment interruption  1.64  0.71-3.78  0.25 
STI  No   1     
  Yes  5.86  2.77-12.40  0.0001 
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Case studies of transmitters 
The life histories of most likely transmission sources are presented graphically 
in Figure 6.16. Selected graphs are presented to illustrate relevant points: all of 
the  graphs  are  presented  in  appendix  C.  For  each  graph,  the  transmission 
event is marked as a black arrow; the viral load is shown on the y axis.  The 
background indicates the infection category.  STI diagnoses are marked with a 
black diamond. 
 
The  life  history  graphs  demonstrate  the  potential  of  plasma  viral  load  to 
fluctuate  within  an  individual  (transmitter  37  and  38)  and  its  relationship  to 
treatment (transmitter 12, 23, 30).   Frequently, possible transmission events 
coincided with a surge of viral load (transmitter 9, 29, and 33) and/or treatment 
interruption (transmitter 12, 15 and 29).     Overall, 55% (15/27) of transmitters 
had an STI diagnosis, which coincided with the calendar period of estimated 
transmission (or an adjacent calendar quarter).       
 
One of the two transmitters, who were estimated to have generated infection 
whilst being on treatment, was interrupting treatment on the calendar quarter 
before the transmission  (transmitter 15).  There was one instance out of 39 
where there was no “explaining factor” as to why HIV transmission may have 
occurred  (patient  was  treated,  with  viral  load  <50  copies/mL,  no  STI  – 
transmitter 4).  
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Figure  6.16:  Life  histories  of  a  selection  of  transmission  sources  with  estimated 
transmission dates, Brighton: 2000-2006 
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6.4 Discussion 
6.4.1  The HIV-infected population and its transmission potential   
The  Brighton  dataset  provides  a  rare  opportunity  to  study  localized  HIV 
transmission that can be linked to demographic and clinical data.  Over a six 
year  period,  patients  attending  the  clinic  were  subdivided  into  infection 
categories,  and  their  clinical  data  updated  for  each  subsequent  calendar 
quarter.  The distribution of infection category was estimated for the Brighton 
population  and  analysed  with  specific  regard  to  its  transmission  potential.   
Using  a  method  that  improved  upon  methods  of  previous  analyses,  the 
transmission sources of new HIV infections were sought. 
Data completeness  
Data were analysed to examine the length of time patients were represented 
during  the  study  period,  and  the  drop  out  rate.      The  size  of  the  dataset 
increased  over  time  since  new  patients  were  diagnosed  each  year,  and  the 
proportion of patients lost to follow-up was relatively low.  Consequently, the 
majority of patients were represented through the entire study period.   
 
Overall, the demographic data had high levels of completeness.  Over 90% of 
viral  load  and  CD4  count  data  were  complete for each  patient  per calendar 
quarter.   Since the rate of STI screening was unavailable, the STI diagnosis 
data presented is likely to be an underestimate of the STI prevalence in this 
population. 
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Infection category 
It  is  important  to  ascertain  the  relative  size  of  the  HIV-infected  Brighton 
population by infection category in order to determine whether any particular 
patient category is disproportionately driving new infections.  This is because if 
all  else  is  equal,  the  chance  that  a  new  infection  will  be  generated  by  a 
particular infection category will be directly proportional to the relative size of 
that  infection  category.  For  instance,  if  the  proportion  of  the  HIV-infected 
population who were recently HIV-infected was 5%, it would be expected that 
5% of infections generated to be driven by patients who were  recently HIV-
infected themselves. If the proportion of new infections generated by those with 
recent HIV infection was significantly higher than 5% this would suggest that the 
transmissions generated from this group were disproportionate.    
 
The method for ascertaining the most accurate representation of the Brighton 
HIV-infected  population  is  therefore  crucial.    The  Brighton  dataset  was 
characterized  using  three  approaches  to  assess  which  provided  the  best 
representation of the size and transmission potential of the local HIV-infected 
population.    Approach one included data collected at the patients‟ first clinical 
attendance  only;  approach  two  included  only  one  calendar  quarter  for  each 
patient for the entire study period, with the calendar quarter selected at random; 
and approach three included every patient, for every calendar quarter during the 
study period.  Each patient could be included up to 28 times within this dataset.     
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Approach  one  resulted  in  one  in  five  patients  categorized  as  recently  HIV-
infected.  This is substantially higher than estimated using approach two (5%) 
and three (2%).  This is because the first calendar quarter of attendance in the 
study  period  was  synonymous  with  HIV  diagnosis for approximately  half the 
study population.  Using diagnosis data to ascertain the proportion of recent HIV 
infections will lead to an overestimate:  patients may have been prompted to 
attend  for  VCT  (voluntary  confidential  HIV  testing)  following  a  recent  risk 
exposure (Calzavara, Burchell et al. 2002).  Approach one demonstrates that 
using data collected during a patient‟s diagnosis is likely to overestimate the 
size of the recently HIV-infected population.  
 
Approach two provided a snap-shot of the Brighton population between 2000-
2006 and goes some way to reduce the bias arising from the over inclusion of 
patients  with  recent  HIV  infection  –  the  proportion  was  measured  at  5%.  
However,  bias  still  remains;  this  approach  draws  from  a  population,  half  of 
whom are more likely to be included at earlier stages of their HIV infection.  This 
population,  on  average,  will  also  have  fewer  calendar  quarters  available  for 
selection, increasing the chance that the quarter selected is one in which the 
patient was recently HIV-infected.   
 
In  contrast  to  approaches  one  and  two,  approach  three  allowed  the  natural 
course of HIV infection to progress for each patient over the course of the study 
period.      Approach  three  showed  that  the  proportion  of  the  HIV-infected 
population  who  were  recently  HIV-infected  at  any  one  time  is  likely  to  be 
relatively low, at around 2%.  For this reason, approach three was used as the Alison Brown – Chapter Six 
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best representation of the size and transmission potential of the Brighton HIV-
infected  population,  and  was  consequently  used  as  the  comparator  for  the 
descriptive analysis.   
 
However, for approach three, it was not known if patients attended for every 
calendar  quarter.    Infection  category  data  was  updated  for  each  calendar 
quarter  according  to  section  6.2.1.  Where  other  data  were  missing  for  a 
calendar  quarter,  the  data  from  the  previous  quarter  was  carried  forward.  
Where  patients  had  not  attended  for  12  consecutive  months,  they  were 
considered  lost  to  follow-up,  and  excluded  from  subsequent  quarters  of  the 
study period.  This method was preferable to only including calendar quarters 
for each patient, where patients were known to have attended.  This is because 
attendances  during  the  study  period  are  unlikely  to  be  distributed  equally 
between infection category (e.g. patients who are ARV treated may be more 
likely to attend more frequently than the untreated population).  However the 
potential  for  each  patient  to  transmit  their  infection  onwards  needed  to  be 
constant throughout the study period, regardless of clinic attendance.  
 
Approach three is not with out its limitations; like approach one and two, it will 
exclude certain groups of patients.  All approaches exclude patients resident in 
Brighton who attend other providers for HIV care.   Approximately 10% of HIV-
infected MSM patients resident in Brighton and Hove city PCT attended sites 
other  than  the  Brighton  clinic  for  their  treatment  and  care  (Personal 
communication - SOPHID).  All approaches exclude patients with undiagnosed 
HIV infection who are disproportionately likely to be recently HIV-infected and Alison Brown – Chapter Six 
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have higher risk behaviour due to being unaware of their infection.  Additionally, 
approaches two and three exclude those who did not attend the clinic following 
diagnosis (who  may  constitute  a more  vulnerable  group  that  may  also  have 
higher infectivity and risk behaviour).    
 
Approach three also contains a major bias within the dataset.  Patients who 
were diagnosed with HIV infection towards the end of the study period will be 
represented in fewer calendar quarters compared to those diagnosed before the 
study period.  This will have affected those recently HIV-infected at diagnosis 
disproportionately.   It is for this reason that transmission rates per PYFU were 
calculated for the statistical analysis.   
 
Plasma viral load by infection category 
Patients  who  were  not  being  treated  (including  the  recently  HIV-infected 
population) had higher plasma viral loads compared to the treated population.  
This  is  expected  since  treatment  is  designed  to  suppress  viral  replication 
(Ledergerber,  Egger  et  al.  1999).    The  viral  load  levels  of  the  patients 
undergoing treatment interruption was slightly lower than that of the untreated 
patients, perhaps because they have recently been on treatment and/or they 
are doing well clinically.   The high proportion of patients currently being treated 
who have undetectable viral loads (83% less than <50 copies/mL) is striking.  
This work supports the evidence that treatment is associated with a reduced 
patient infectivity.   Alison Brown – Chapter Six 
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STI by infection category 
Nearly 40% of HIV-infected patients were also diagnosed with an STI at some 
point during the study period.  This reduced only slightly to 35% when the STI 
diagnoses  made  during  the  same  calendar  quarter  as  HIV  diagnoses  were 
removed.  This demonstrates continuing sexual risk among a population aware 
of their HIV infection.   
CD4 count by infection category 
CD4  counts  were  highest  among  those  interrupting  treatment  and  those  on 
treatment.   
6.4.2   Phylogenetic reconstruction of HIV transmissions in Brighton 
A phylogenetic reconstruction was undertaken among the Brighton population, 
and the factors associated with clustering were ascertained.   Overall, 15.3% of 
sequences fell into a robust cluster.  The rate of clustering between patients 
who were diagnosed during recent HIV infection was 11.3%.  Sequences that 
clustered were significantly more likely to be from MSM who were recently HIV-
infected  at  diagnosis,  have  an  STI  diagnosis,  and  not  ARV  treated  at  first 
attendance, compared to those that did not form a cluster.  
 
The  observed  rate  of  clustering  is  somewhat  lower  than  that  found  in  the 
literature.      In a similar population, (containing only Brighton patients who 
were  recently  HIV-infected  at  diagnosis,  and  taken  from  earlier  years),  Pao 
calculated  the  rate  of  clustering  between  patients  recently  HIV-infected  at 
diagnosis, to be almost double, at 29.6% (Pao, Fisher et al. 2005).   Similarly Alison Brown – Chapter Six 
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Brenner  found  that  50%  of  sequences  clustered  from  patients  who  were 
recently HIV-infected at diagnosis  (Brenner, Roger et al. 2007).    
 
The rate of clustering may be lower in the current analysis because the majority 
of  sequences  contained  within  the  dataset  were  not  recently  HIV-infected  at 
diagnosis.      Pao  and  Brenner  both  (albeit  initially  for  the  latter)  restricted 
phylogenetic reconstructions to include only patients diagnosed during recent 
infection.        Partner  notification  exercises,  and  an  increased  likelihood  that 
patients diagnosed during recent HIV infection within the same calendar period 
will be drawn from the same transmission network, raises the chance that these 
populations contain a higher proportion of patients who infected each other.  In 
contrast,  sequences  from  patients  who  were  chronically  HIV-infected  at 
diagnosis will have a broader range of infection dates, and will be more likely to 
be drawn from separate transmission networks.   
 
The present analysis is an improvement  upon on the analyses conducted in 
chapter five, because they are not restricted to populations who were recently 
HIV-infected at diagnosis.   As discussed in section 4.4.2, such populations may 
be different from populations who were not diagnosed during recent infection, 
which  may  be  related  to  infectivity.    However,  two  major  limitations  remain. 
Firstly, the risk factors apparently associated with clustering may not have been 
present at the time of transmission. Secondly, the current population is likely to 
disproportionately contain patients diagnosed with recent HIV infection. These 
limitations are discussed in turn. 
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As  with  recent  infection,  the  observation  of  transmission  events  between 
sequences  from  MSM  who  had  a  specific  risk  factor  at  diagnosis,  does  not 
necessarily mean that that risk factor was present at the time of transmission 
(this  is  applicable  to  infection  category,  viral  load,  CD4  count,  and  STI 
diagnosis). For instance, the comparison of infection dates in the clusters that 
formed between patients diagnosed with recent HIV infection in this analysis, as 
with chapter four, found that only about half could have been generated during 
recent  infection.  However,  an  association  between  clustering  with  infection 
category and STI does seem to exist, perhaps indicative that patients with risk 
factors at diagnosis may be at high risk of transmission throughout the course of 
their infection.  This requires further examination. 
  
This  analysis  also  revealed  inconsistencies  between  phylogenetic 
reconstructions.    There  were  inconsistencies  between  the  original  neighbour 
joining  tree  and  the  maximum  likelihood  tree.  Nearly  one  in  five  clusters 
originally ascertained in the neighbour tree were lost in the maximum likelihood 
reconstruction.    The  neighbour  joining  clusters  that  did  not  appear  in  the 
maximum  likelihood  tree  contained  a  higher  proportion  of  sequences  per 
cluster; clusters that constituted sequence pairs were more likely to be retained.  
The occurrence of novel clusters in the maximum likelihood tree requires further 
investigation.  
 
Though the datasets contain the same patients, there was a difference between 
the clustering rate found between patients who were recently HIV-infected at 
diagnosis  in  this  analysis  (11.3%  -  when  the  recently  and  chronically  HIV-Alison Brown – Chapter Six 
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infected  at  diagnosis were  included)  compared  to  that  found  in  chapter four 
(20.8% - when only the 159 patients diagnosed during recent infection were 
included).  This may indicate that reconstructions may have been affected by 
the presence of other sequences (section 4.4.2).   
6.4.3  A revised methodology: where do new infections come from? 
A  phylogenetic  reconstruction  was  conducted  using  a  dataset  from  a  well 
defined population to ascertain the origin of new infections.  The reconstruction 
included developments from previous analyses.  The richness of the  dataset 
allowed a wide range of risk factors potentially associated with transmission to 
be explored for patients throughout the study period (compared to studies that 
only  categorise  patients  as  “recently”  and  “chronically”  HIV-infected  at 
diagnosis).  Additionally, a method was employed that allowed the attributes of 
candidate transmitters to be ascertained at around the time of transmission.  
 
A quarter of transmission sources had an STI diagnosis during the calendar 
quarter,  or  the  previous  calendar  quarter.  Interestingly,  the  transmitters  with 
estimated transmission dates were more likely to ever have an STI diagnosis 
during the study period, compared to the rest of the HIV-infected population.  
This suggests that the transmitters with estimated transmission dates may have 
riskier sexual behaviours compared with the rest of the population. 
 
Through multi-variate analysis, the factors associated with an increased rate 
ratio  of  transmission  risk  were:  recent  infection;  high  viral  load;  and  STI 
diagnosis.  Almost one in four observed transmissions were likely to have been 
generated  by  patients  with  recent  HIV  infection:  in  contrast,  this  group Alison Brown – Chapter Six 
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constituted 2% of the concurrent Brighton population (using approach three).  
Those  with  viral  loads  over  10,000  copies/mL  contributed  70%  of  observed 
transmissions.    Importantly  69.2%  of  transmission  sources  originated  from 
patients  with  CD4  counts  over  350  mm
3.    This  is  above  the  level  at  which 
discussions  about  ARV  should  commence  between  patient  and  clinician.  
Finally,  despite  comprising  more  than  half  of  the  HIV-infected  Brighton 
population, only two instances were recorded of transmission occurring from the 
treated population.     
 
The analysis suggests that the transmission rate from the recently HIV-infected 
is  elevated,  but  not  as  high  as  previous  calculations  (Brenner,  Roger  et  al. 
2007).  Unlike other studies, it has also highlighted that the transmission rates 
from  the  chronically  HIV-infected  is  also  important,  and  varies  considerably 
within  this  population.  Specifically,  the  untreated  population  (containing  an 
uncertain, but elevated proportion of the recently HIV-infected individuals) was 
responsible  for  generating  approximately  half  of  the  transmissions  identified.   
Furthermore, the use of treatment was significantly associated with a reduced 
risk  of  transmission.  Around  20%  of  transmissions  originated  from  those 
currently  interrupting  treatment.    Those  with  the  low  CD4  counts  (<200 
copies/mm
3) were least likely to generate transmission.  This could be because 
such  individuals  are  more  likely  to  be  treated  (and/or  more  likely  to  have 
symptomatic illness), which may impact on their sexual activity.     
 
The sensitivity analysis examined the consistency of the statistical significance 
of the findings as the assumptions and definitions of treatment and estimated Alison Brown – Chapter Six 
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infection dates were varied.  Throughout each repetition, the presence of an STI 
was consistently associated with an increased transmission risk.  When patients 
with  missing  viral  load/CD4  data  at  the  start  of  a  calendar  quarter  were 
excluded, the association with infection stage and viral load did not retain its 
significance.    This  is  likely  to  be  because  the  exclusion  disproportionately 
affected patients  with  recent  HIV  infection;  such patients may  not  have  viral 
load/CD4  count  recorded  until  a  few  weeks  after  diagnosis.    Varying  the 
definition of recent infection from the mid-point to earliest and latest possible 
date  of  infection  substantially  impacted  on the  association  between  infection 
category  and  transmission  risk.    This  indicates  the  importance  of  allowing 
infection category to follow the natural course of infection in the analysis.   
Case studies of transmitters 
The case studies provide some validation of the methods of section 6.4.3.  The 
fluctuating  viral  loads  observed  within  individuals  confirm  the  importance  of 
finding a method to date the transmission event in relation to viral load: viral 
load at diagnosis will not reflect viral load at later stages of infection.   The 
congruence of transmission events with surges of viral load, lack of treatment 
and STI diagnoses provide some reassurance of the accuracy of this analysis in 
identifying the right individual as the transmitter and the approximate time of 
transmission.    The  instances  where  transmission  occurred  shortly  after  viral 
load surges/STIs/treatment changes may be indicative of the relative inaccuracy 
of the technique in approximating the transmission date.  The case studies put 
the findings into context, but should not be over-interpreted. 
In one of the two instances where transmission occurred despite the patient 
being  on  treatment,  the  case  studies  suggest  that  the  patient  had  been Alison Brown – Chapter Six 
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interrupting  treatment  very  recently.    For  the  second  patient,  it  may  be  that 
transmission occurred despite the patient having an undetectable plasma viral 
load.  Alternative explanations include: the data may not have captured surges 
of viral load at the relevant transmission time; the phylogenetic reconstruction 
was incorrect, and did not identify actual transmission source.   
 Limitations 
The analysis has several limitations related to:  the representativeness of the 
population  of  transmitter  sources  with  estimated  transmission  dates;  and 
assumptions about sexual mixing.   
 
As  with  all  phylogenetic  reconstructions,  the  results  may  not  necessarily 
represent actual transmission events (section 1.6.1 and 1.6.2 and chapter four).    
Even in cases where the clusters remained consistent between the neighbour 
joining  tree  and  the  maximum  likelihood  tree,  small  differences  in  genetic 
distances were observed within clusters. This is relevant because it was at this 
level that decisions were made on which candidate sequence was the most 
likely transmitter. The overall method relies exclusively upon data from specific 
transmission pairings.  If the specific pairings are incorrect, then the results will 
be incorrect.   While the life histories demonstrate a congruence of transmission 
dates with events that are likely to increase the chance of transmission, the 
accuracy  of  phylogenetic  approaches  in  reconstructing  specific  transmission 
events requires further assessment.   Finally, the analysis does not consider 
chains of transmissions; just transmission pairs.   
The  markers  used  to  ascertain  the  estimated  infection  dates  varied.  
Consequently using the diagnosis date of the recently HIV-infected patients in Alison Brown – Chapter Six 
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combination  with  the  marker  used  to  identify  recent  infection  to  “date”  the 
transmission  events may  not  be  entirely  accurate.   The  “calendar quarter  of 
transmission” may have been up to six months after the actual  transmission 
event,  particularly  where  the  serological  testing  algorithm  for  recent  HIV 
seroconversion (STARHS) was used.  Additionally, extent that STARHS can 
reasonably  reconstruct  infection  dates  is  uncertain  due  to  variation  between 
individuals  (Reed  2004).    However,  no  adjustments  were  made  in  these 
instances.  Future work needs to include intervals of uncertainty or calculate 
what scale of adjustments need to be made in such analyses.   
  
The data were summarized into three monthly intervals to anonymise the data; 
attendance dates were not available.  For viral load, and treatment data, the 
data were carried forward from the previous calendar quarter unless that data 
had  changed.    Consequently  the  accuracy  of  data  around  the  time  of  the 
estimated transmission event is dependent on the patient attending the clinic 
regularly and having the relevant fields updated.    The exclusion of patients lost 
to  follow-up  (no  attendance  within  12  months)  from  candidate  transmission 
sources will limit any error.   However, in order to assess the timeliness of  data  
linkable to the 39 transmitters at the time of transmission, the occurrence of 
“movement”  in  viral  load  during  the  period  of  transmission,  or  the  quarter 
directly preceding or following it, was taken as evidence that such measures 
were timely.   
In all but seven of 39 transmission sources, there was movement in viral load in 
the period of transmission or the calendar quarters consecutive with it.  For the 
remaining seven transmission sources: transmitters 4, 18 and 24 all had a gap Alison Brown – Chapter Six 
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of under six months between the quarter a new viral load were recorded, each 
side of the transmission quarter.  For transmitters 16, 23 and 30, there was a 
gap of 12 months in total spanning the interval in which the transmission event 
occurred.  For each of these, there was no recorded change in treatment during 
the  period,  suggesting  that  viral  load  was  unlikely  to  change  substantially.  
Transmitter 2 did not have a viral load recorded until treatment was started, but 
was untreated at the time of transmission, suggesting viral load was detectable 
at this time. 
  
The multivariable analysis assumed each person was at risk for the whole three 
month  period  of  the  calendar  quarter  when  calculating  person  years.    This 
assumption is probably reasonable since even if a patient was not diagnosed 
until half way through the period, they could still have transmitted in the weeks 
leading up to the diagnosis. 
     
The methods do not consider the undiagnosed HIV-infected population.  This 
group is likely to have an important role in transmission since they are: unaware 
of  their  infection;  more  likely  to  be  recently  HIV-infected;  and  have  riskier 
behaviour, compared to the rest of the HIV-infected population.   It is noted that 
for  39  transmitters,  nine  transmitted  during  the  period  close  to  their  own 
diagnosis,  suggesting  they  were  undiagnosed  at  the  time  of  transmission.  
Additionally, the fact that only 39 transmission sources of 159 recent infections 
were  identified  suggests  that  the  undiagnosed  population  is  likely  to  have  a 
substantial role in generating transmission events.   
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The transmission sources had higher rates of STI diagnoses compared to the 
concurrent Brighton population.  This suggests that they may be a group with 
higher  risk  sexual  behaviour.    This  indicates  that  behavioural,  in  addition  to 
biological  factors  drive  transmission.    However,  behaviour  markers  were  not 
measured or considered in the analysis.    
 
Further limitations relate to assumptions made about the Brighton population.   
The methodology assumes that the Brighton population is closed, with random  
sexual mixing patterns.  However patients attending care in Brighton may meet 
sexual partners elsewhere in the UK, and abroad.  It is also known that sexual 
risk behaviours are affected by diagnosis status (Dodds, Mercey et al. 2004) 
and perceived infectivity is related to treatment (Stephenson, Imrie et al. 2003).  
6.5 Conclusion  
The Brighton dataset has provided a rare opportunity to understand the sources 
of new infections in a localised population.  It allowed the development of a 
method  capable  of  creating  phylogenetic  reconstructions  of  transmission 
events,  but  also  of  dating  these  events.    Consequently,  this  enabled  the 
identification of risk factors for transmitters, at around the time of transmission.  
 
The  factors  associated  with  transmission  are:  recent  HIV  infection;  elevated 
viral load, and presence of an STI.  Additionally, this chapter provided estimates 
of  the  size  of  the  population  in  relation  to  transmission  risk;  the  association 
between infection category and transmission; that despite making up 2% of the 
HIV-infected  population,  the  recently  HIV-infected  generate  a  quarter  of  new 
infections; that 70% new infections originate from the untreated population; 70% Alison Brown – Chapter Six 
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of  new  infection  originate  from  those  with  CD4  counts  >350  mm
3;  and  that 
despite  making  up  more  than  half  of  the  HIV-infected  population,  few 
transmissions occur from the treated population. 
 
This work has important public health implications.  Current BHIVA guidelines 
(BHIVA 2008) (that suggest discussions to start ARV should commence when 
CD4  counts  reach  200-350  cells/mm
3)  are  unlikely  to  impact  upon 
transmissions between MSM.  The analysis suggests that treating HIV-infected 
patients on a large scale, and reducing phases of treatment interruption, could 
potentially reduce transmission.   
 
Additionally,  with  a  quarter  of  observed  transmissions  originating  from  the 
recently HIV-infected, the continued drive to increase VCT may be limited in its 
ability to prevent HIV transmission.  Alternative strategies include promoting: 
frequent HIV testing among the at-risk population; awareness of seroconversion 
illness and its association with higher infectivity; and universal access to fourth 
generation HIV tests. The need to prevent and treat STIs continues.  
 
The analysis is not without its limitations.  Future work needs to: better account 
for the undiagnosed HIV-infected population; ensure algorithms that ascertain 
recent  infection  are  consistently  applied;  and  consider  the  implications  and 
importance of rapid transmission chains.  Alison Brown – Chapter Seven 
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7  Chapter Seven: The prevalence, source and onward 
transmission of HIV drug resistance 
  
 
 
 
 
This  chapter  describes  the  prevalence  of  transmitted  HIV  drug  resistance 
among patients who were recently HIV-infected at diagnosis. The distribution of 
drug  resistance  mutations  are  compared  between  datasets  and  infection 
categories.    The  transmission  potential  of  the  drug  resistant  population  is 
compared  between  the  drug  naïve  and  those  who  have  been  treated.   
Phylogenetic  reconstructions  of  possible  transmission of  resistant  strains  are 
undertaken.  Finally, the sources of transmitted drug resistance are explored 
using a phylogenetic approach. 
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7.1 Introduction  
It is the higher prevalence of TDR among the recently HIV-infected  (Devereux, 
Youle et al. 1999) coupled with their elevated viral load (Wawer, Gray et al. 
2005)  that  suggests  that  this population has  an  important  role  in  generating 
TDR (section 1.5.3). However, this may not be the only factor in determining 
TDR.  Patients with diagnosed HIV infection continue to have unprotected sex 
(Elford and Hart 2005) and a proportion of them will have drug resistant viruses.  
Chapter six indicated that the recently HIV-infected, the chronically HIV-infected 
untreated population and those interrupting therapy had potentially important 
roles  in  generating  onward  transmission.    Additionally,  the  relative  fitness  of 
mutations may affect which mutations are transmitted onwards (both from men 
who have sex with men (MSM) with transmitted and acquired drug resistant 
mutations) (section 1.5.3 and 2.5.2).   
 
This chapter aims to measure the level of TDR within the available datasets, 
and describe the distribution and transmission of specific mutations between 
patients recently HIV-infected at diagnosis.  Using the whole Brighton dataset, it 
also aims to ascertain the transmission sources of patients with TDR who were 
recently HIV-infected at diagnosis, and consequently ascertain their attributes at 
around the time of transmission. 
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7.2 Methods 
7.2.1  Prevalence of HIV drug resistance 
Transmitted drug resistance 
The prevalence of TDR was ascertained for patients recently HIV-infected at 
diagnosis  using  the  CASCADE,  UA  survey  and  Brighton  datasets.   The 
definition  of  drug  resistance  mutations  was  taken  from  the  list  of  mutations 
judged suitable for surveillance purposes (Shafer, Rhee et al. 2007). 
Differences between transmitted and acquired drug resistance 
For  Brighton,  the  prevalence  of  drug  resistance,  and  the  specific  mutations 
involved were compared between the recently HIV-infected, the chronically HIV-
infected  and  the  treated  population.  Statistical  tests  of  association  were 
employed where appropriate. 
Distribution of specific mutations 
Specific  mutations  were  identified  from  sequences  obtained  from  patients 
recently HIV-infected at diagnosis and compared between datasets.  Using the 
Brighton dataset, all patients (regardless of infection stage at diagnosis) with 
drug  resistant  mutations  were  categorized  as:  TDR  (recently  infected),  TDR 
(chronically infected) or acquired on the basis of infection stage, and clinical and 
treatment history. 
7.2.2  Phylogenetic reconstructions of HIV transmissions of TDR from the 
recently HIV-infected   
The phylogenetic reconstructions described in this chapter are identical to those 
in previous chapters, but this analysis maps the drug resistance mutations on to Alison Brown – Chapter Seven 
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sequences  included  in  the  reconstructions.  Two  phylogenetic  reconstructions 
were undertaken from the Brighton dataset: first only including those sequences 
from patients who were recently HIV-infected at diagnosis (section 5.3.2) and 
second including the whole dataset (section 6.3.2).    
 
For each dataset, robust clusters (section 2.2.11) that contained drug resistance 
mutations were identified, and compared to clusters formed between wild-type 
sequences.   Comparisons were made between the mutations occurring among 
sequences that were involved in a possible transmission event and mutations 
found  among  non-clustering  sequences.  The  differences  between  estimated 
infection dates were compared within clusters in order to ascertain whether the 
transmission could have taken place during recent infection.   
7.2.3  Attributes and transmission potential of patients with transmitted 
and acquired drug resistance 
Using  the  Brighton  dataset,  patients  with  viruses  containing  drug  resistance 
mutations were placed in to three categories on the basis of infection stage and 
ARV history.  The categories include: those with TDR and recently HIV-infected 
at  diagnosis;  those  with  TDR  and  chronically  HIV-infected  at  diagnosis;  and 
those  with  acquired  drug  resistance.    The  plasma  viral  load  was  compared 
between  the  three  groups  and  also  to  the  population  with  wild-type  viruses.  
This was to gauge whether the transmission potential of the patients with drug 
resistance  mutations  was  different  to  that  among  those  with  wild-type 
sequences. 
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7.2.4  Where does TDR come from?  
Using all of the Brighton dataset, a phylogenetic reconstruction was undertaken 
of  all  possible  transmission  events.  The  most  likely  transmission  source  for 
each  recently-infected  patient  with  TDR  was  identified  using  the  same 
methodology described in section 6.2.4.  The transmitter was categorised as 
having acquired resistance or TDR (recently or non-recently acquired) at the 
time of the likely transmission.  
7.3  Results  
7.3.1  Prevalence of HIV drug resistance 
Transmitted drug resistance 
Prevalence  of  TDR  was  ascertained  using  populations  that  were  recently 
infected at HIV diagnosis only.  Overall, 10.9% (18/165) of recently HIV-infected 
CASCADE  patients  sampled  were  infected  with  a  drug  resistant  HIV  variant 
(Figure 7.1).  Fourteen patients had a virus considered to be resistant to one or 
more  of  NRTIs,  three  carried  resistance  mutations  to  NNRTIs  and  one  had 
resistance to PIs.   One patient was infected with viruses resistant to both NRTI 
and NNRTI mutations with the remainder being resistant to one class of drug 
resistance only (14 to NRTIs, two to NNRTIs and one to PIs). 
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Figure 7.1: Prevalence of TDR among MSM diagnosed during recent infection, CASCADE, 
UA survey and Brighton: multiple years 
 
Overall,  within  the  Unlinked  Anonymous  (UA)  Sexually  Transmitted  Infection 
(STI) survey, 14.2% (18/127, 95% CI 9.3-21.6%) of recently HIV-infected MSM 
sampled were infected with a drug resistant strain.  Eight patients had a virus 
considered resistant to NRTIs, nine to NNRTIs, and four to PIs. Sixteen patients 
were infected with a virus considered resistant to one class of drug only, one to 
two classes and one to three classes of drug.             
 
Among  the  patients  who  were  recently  HIV-infected  at  diagnosis  among  the 
Brighton dataset,   12.6% (20/159, 95%CI 8-18%) of patients sampled were 
infected with a drug resistant HIV variant.  Nine patients had a virus considered 
to be resistant to one or more of NRTIs, 14 to NNRTIs and four had resistance 
to PIs.   Fifteen patients were infected with a virus considered to be resistant to 
one class of drug only (five to NRTIs, nine to NNRTIs and one to PIs), with 
three to two classes and two to all three main classes of drugs.  Alison Brown – Chapter Seven 
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Differences between transmitted and acquired drug resistance 
Among the Brighton dataset, overall, 22.2% (191/859) of patients sampled were 
infected with a drug resistant HIV variant.  Of these, 148 patients had a virus 
considered  to  be  resistant  to  one  or  more  of  NRTIs,  102  carried  resistance 
mutations to NNRTIs and 58 had resistance to PIs.   Of these, 106 patients 
were infected with a virus considered to be resistant to one class of drug only 
(67 to NRTIs, 34 to NNRTIs and five to PIs), 53 to two classes and 32 to all 
three main classes. 
 
Brighton patients with drug resistant viruses were further subdivided into three 
categories:  those  recently  HIV-infected  at  diagnosis;  the  drug  naïve,  but 
chronically HIV-infected at diagnosis; and the drug experienced at the time the 
sequence was taken. The differences in prevalence was 12.6% (20/159), 9.7% 
(34/352) and 39% (74/396) respectively.  For 63 patients with drug resistance 
mutations, the category of drug resistance could not be ascertained from their 
clinical data. 
 
There were differences in class of drug resistance between drug naïve patients 
who  were  recently  and  chronically  HIV-infected  at  diagnosis.    While  the 
prevalence  of  resistance  to  PIs  was  similar  between  both  groups,  the 
prevalence of resistance to NNRTIs may have been higher than the prevalence 
of  resistance  to  NRTIs  among  the  recently  HIV-infected  (8.8%  vs.  5.7% 
respectively) (p =0.14). The converse was true of the chronically HIV-infected at 
diagnosis (3.4% vs. 7.6% respectively) (p=0.007) (Figure 7.2). 
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Figure 7.2: The prevalence of drug resistance mutations among the recently HIV-infected, 
the  untreated  chronically  HIV-infected  and  the  treated  chronically  HIV-infected 
population, Brighton: 2000-2006  
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Distribution of specific mutations 
The  distribution  of  specific  mutations  among  those  recently  HIV-infected  at 
diagnosis is described in Figure 7.3.  The most frequent mutation overall was 
the T215 variant followed by the K103N.  Among the CASCADE dataset, five 
patients  had  M41L,  but  this  mutation  was  not  identified  in  the  other  two 
datasets.  
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Figure 7.3: Distribution of specific mutations found among recently HIV-infected MSM, 
CASCADE, UA survey, and Brighton: multiple years 
 
 
  
The differences between the specific mutations for each infection category are 
described in Figure 7.4.     Where specific mutations were observed in all three 
categories,  the  frequency  of  mutations  was  substantially  higher  among  the 
treated  population.      There  were  mutations  from  all  three  classes  that  were 
observed  in  the  treated  population  that  were  not  apparent  in  the  naïve 
populations  including:  V106A  (NNRTI),  K219E  (NRTI),  and  V82A  (PI).   
Conversely, mutations were observed among the drug naïve populations that 
were  not  apparent  in  the  treated  population,  for  instance:  M41L  and  F77L 
(NRTIs) and G73T (PI). 
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Figure 7.4: Distribution of specific drug resistance mutations between the recently HIV-
infected, the untreated chronically HIV-infected and the treated chronically HIV-infected 
population, Brighton:  2000-2006 
 
7.3.2  Phylogenetic reconstructions of HIV transmissions of TDR from the 
recently HIV-infected 
Of  the  165  sequences  from  the  CASCADE  dataset,  18  (10.9%)  formed  a 
phylogenetic relationship with at least one other sequence (Figure 7.5).  These 
formed nine robust clusters, with two sequences within each cluster.  Of the 18 
sequences  with  drug  resistance  mutations,  only  two  formed  one  cluster  (C).  
Both sequences shared the F77L mutation, and were derived from patients with 
a difference of  226 days between their infection dates (Brown 2009a).  
 
Of the 127 sequences from the UA STI dataset, 16 (12.6%) formed a robust 
cluster with at least one other sequence (Figure 7.6).     Of the 18 sequences 
with drug resistance mutations, six formed two clusters (cluster A and cluster Alison Brown – Chapter Seven 
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E).   All four sequences that formed cluster A contained the K103N mutation, 
and  both  sequences  that  formed  cluster  E  contained  T215V/D  with  one 
sequence also contained F77L.  Cluster A contained two sequences that had 
the same calendar quarter, and two with a difference of two calendar quarters.  
Cluster  E comprised sequences obtained from patients who had a difference in 
calendar quarter of nine.    
   
Considering only the recently HIV-infected at diagnosis (n=159) from Brighton, 
31 sequences fell into a cluster with at least one other sequence (Figure 7.7).   
Of the 20 sequences with drug resistance mutations, four fell into a cluster with 
at least one other sequence.  One cluster contained sequences that shared the 
K103N mutation.  Two other sequences (with G190A/E) each formed a cluster 
with a wild-type sequence.        
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Figure 7.5: Phylogenetic reconstruction of HIV transmission events and distribution of 
drug resistance mutations between MSM recently HIV-infected at diagnosis, CASCADE: 
1989-2004  
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Using the whole Brighton dataset, overall, 15% (129/859) sequences fell into a 
robust  cluster  with  another  sequence  (figure  not  shown).  These  formed  62 
phylogenetic relationships, five clusters had three sequences per cluster; the 
remaining 57 consisted of sequence pairs.  Of the 191 sequences with drug 
resistance mutations, 23 fell into a cluster with another sequence. These formed 
eleven clusters and, of these, four sequences formed a cluster with a wild-type 
sequence.    The  remaining  nine  sequences  clustered  with  another  sequence 
sharing an identical mutation.  Three clusters each comprised K103N, and three 
comprised T215 variants.   Other mutations included 154L, G73T, I84V, I54L, 
and Y188L. 
 
For the CASCADE and Brighton dataset, there was no significant difference 
between the proportion of clusters that formed between sequences with drug 
resistance  mutations  compared  to  the  proportion  formed  between  wild-type 
sequences (Figure 7.8). For CASCADE, overall,   11.1% (2/18)   of sequences 
with mutations clustered compared with 10.1% (16/147) of wild-type sequences 
(p=0.7).  Among  the  recently  HIV-infected Brighton  population,  20%  (2/20) of 
sequences  with  drug  resistance  mutations  clustered  compared  with  19% 
(27/139) of wild type sequences (p=0.3).  For the UA STI survey, 33.3% (6/18) 
of sequences with drug resistance mutations clustered, compared with 9.2% 
(10/109)  of  wild-type  sequences  (p=0.03).      For  all  datasets,  mutations  that 
were found in clusters tended to be those that occurred most frequently in terms 
of prevalence.  Alison Brown – Chapter Seven 
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Figure 7.6: Phylogenetic reconstruction of HIV transmission events and distribution of drug resistance mutations between MSM recently HIV-
infected at diagnosis, UA survey: 1999-2002 
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Figure 7.7: Phylogenetic reconstruction of HIV transmission events and distribution of 
drug resistance mutations between  MSM recently HIV-infected at diagnosis, Brighton: 
2000-2006 
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Figure  7.8:  Distribution  of  specific  mutations  between  clustering  and  non  clustering 
sequences from patients recently HIV-infected at diagnosis, CASCADE, UA survey and 
Brighton; multiple years 
 
7.3.3  Attributes and transmission potential of patients with transmitted 
and acquired drug resistance  
Using  all  calendar  quarters  of  the  study  period,  the  viral  load  and  STI 
distribution  were  compared  between  the  patients  with  drug  resistance 
mutations, and those with wild-type sequences, by infection category.  
 
With  the  exception  of  those  currently  untreated,  there  was  no  statistical 
difference in the mean viral load between patients whose sequences had drug 
resistance  mutations  and  those  with  wild-type  sequences  (Table  7.1).    The 
distribution of viral load by infection category is summarized in Figure 7.9.  
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Table 7.1: Mean viral load (copies per mL) by infection category, between drug resistant 
and wild-type sequences from diagnosed HIV-infected MSM, Brighton: 2000-2006 
Infection category  Drug resistant  Wild-type  p-value (t-test) 
Recent  235883  209928  p=0.8 
Chronic, untreated  62961  78642  p=0.02 
Chronic, treated  14643  22624  p=0.1 
Chronic, treatment interruption  58408  50643  p=0.2 
 
 
Figure 7.9: Viral load distribution by infection category between drug resistant and wild-
type sequences from diagnosed HIV-infected MSM, Brighton: 2000-2006 
 
Including every calendar quarter of the study period, (approach three, table 6.2) 
overall, 34% (1521/4428) calendar quarters were linked to patients with drug 
resistance  mutations  who  also  had  an  STI  diagnosis  compared  to  43% 
(5847/13750)  (p<0.0001)  of  quarters  linked  to  patients  with  wild-type 
sequences.    Among  the  recently  HIV-infected  the  proportions  were  65.9% 
(29/44) and 58.2% (181/311) respectively (p=0.17), and among the chronically 
infected, 56% (235/413) and 45.8% (2067/4510) (p<0.0001) respectively.  The 
inverse  was  true  for  the  treated  population;  those  with  wild-type  were  more Alison Brown – Chapter Seven 
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likely to have STIs.  Of patient calendar quarters with wild-type viruses, 38.7% 
(2500/6457) had an STI diagnosis compared with 31.3% (943/3012) (p<0.0001) 
of those with drug resistance mutations (Figure 7.10).   
 
Figure 7.10: STI distribution by infection and drug resistance category among diagnosed 
HIV-infected MSM: Brighton, 2000-2006  
 
7.3.4  Where does TDR come from?  
Of the 20 patients who were recently HIV-infected at diagnosis, and who had 
drug resistance mutations, the most likely transmission source was identified in 
four cases (20%) (Figure 7.11).  The source of transmission could not be found 
for nine. For the remaining seven, the direction of transmission could not be 
ascertained,  or  data  was  not  available  during  the  calendar  quarter  of 
transmission.  Two of the most likely transmitters had chronic TDR (A and B) 
and two had acquired resistance (C and D).  The mutation sites were identical Alison Brown – Chapter Seven 
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between the transmission sources and the patients with recently acquired TDR 
(Figure 7.12). 
 
Figure 7.13
 describes the attributes of the four transmission sources at the time 
of transmission. The untreated transmission sources had viral loads of >20,000 
copies/mL (transmitters A and B) and the transmitters with acquired resistance 
had interrupted therapy with viral loads of >550,000 copies/mL (transmitters C 
and D).  The most likely transmitter could not be identified for nine (69%). 
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Figure 7.11: Flow diagram of ascertainment of transmission sources of patients recently 
HIV-infected with TDR HIV strain 
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Figure  7.12:  Phylogenetic  reconstruction  of  possible  HIV  transmission  events  that 
generated patients recently HIV-infected with TDR HIV strain, Brighton: 2000-2006 
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Figure  7.13:  Attributes  of  transmission  sources  of  TDR  at  around  the  time  of 
transmission  
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 Alison Brown – Chapter Seven 
237 
7.4 Discussion 
This  chapter  examined  the  level  of  TDR  within  the  available  datasets,  and 
described  the  distribution  and  transmission  of  specific  mutations  between 
patients  recently  HIV-infected  at  diagnosis.    It  described  the  distribution  of 
specific  drug  resistance  mutations  between  datasets,  and  for  the  Brighton 
dataset, between infection categories.  The distribution of viral load and STI 
diagnoses  was  compared  between  infection  categories.    It  also  aimed  to 
ascertain  the  sources  of  TDR  and  their  attributes  at  around  the  time  of 
transmission.     
7.4.1  Prevalence of HIV drug resistance 
Transmitted drug resistance 
The prevalence of TDR mutations among the recently HIV-infected at diagnosis 
was  measured  at:  10.9%  for  CASCADE,  14.2%  for  the  UA  STI  survey  and 
12.6% among the (recently HIV-infected) Brighton dataset.  These are broadly 
consistent  with  the  literature  for  the  UK  (UKCollaborativeGroup  2007)  and 
Western Europe (Wensing, van de Vijver et al. 2005).     
 
The variation in the prevalence of TDR between the three datasets is likely to 
be due to three factors.  Firstly the definitions used to gauge recent infections.  
While the UA STI survey used the serological testing algorithm for recent HIV 
seroconversion (STARHS) only, Brighton and CASCADE used more than one 
algorithm  to  identify  recent  infection,  some  of  which  have  shorter  window 
periods (section 3.6.4).  Consequently Brighton and CASCADE may be more 
likely to identify drug resistant mutations.  Alison Brown – Chapter Seven 
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Secondly, the period of time from which the sequences were taken may explain 
the variation between the three datasets.  The UK data suggest that prevalence 
of  TDR  peaked  at  14%  in  2001/2  and  decreased  to  8%  in  2004 
(UKCollaborativeGroup 2007).  This reduction was largely due to a decline in 
NRTI mutations, while NNRTI mutations increased in prevalence.  Data from 
the UA survey and CASCADE date from earlier years.  Brighton data extends 
from  2000-2006  and  also  showed  a  higher  prevalence  of  NNRTI  mutations.  
The small samples sizes precluded the presentation of prevalence over time for 
each dataset.    
 
Finally, the geographic range from which the sequences were taken is likely to 
affect  the  prevalence.    Specifically,  CASCADE  constitutes  a  broad  range  of 
countries and the sequences were taken during a time period spanning over a 
decade:  each  country  represented  is  likely  to  have  different  underlying 
transmission networks.  While the UA STI survey is taken from a narrower time 
period,  it  is  less  likely  to  include  transmission  events  since  it  is  taken  from 
several national sites. 
Differences between transmitted and acquired drug resistance 
Using  the  entire  Brighton  dataset,  the  overall  prevalence  of  drug  resistance 
mutations  (transmitted  or  acquired)  was  22.2%.    This  is  substantially  higher 
than that found among sequences from MSM who were recently HIV-infected at 
diagnosis.  This is expected since the overall Brighton population will contain 
patients with acquired resistance.  Among the treated Brighton population, 36% 
had  drug  resistance  mutations.    Among  the  drug  naïve  population,  the 
prevalence of drug resistance mutations was higher among those recently HIV-Alison Brown – Chapter Seven 
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infected at diagnosis compared with those with a chronic infection at diagnosis.  
While this difference may be explained by the relative weaker fitness of drug 
resistance mutations (Devereux, Youle et al. 1999) other considerations related 
to the timing of HIV testing require exploration.     Those who were diagnosed 
during  recent  infection  may  have  been  prompted  to  come  forward  for  HIV 
testing either through recent risk exposure or seroconversion illness.   Higher 
risk  sexual  mixing  (some  HIV  diagnosed  MSM  with  sub-optimal  treatment 
adherence may also be more likely to have risky sex)  and any clinical effects of 
the  specific  drug  resistant  viruses  respectively  could  both  be  independently 
associated with being infected with drug resistant strains.   
 
While sexual factors and symptoms possibly associated with resistant viruses 
may be a factor, the uneven distribution of specific classes of drug resistance 
mutations  between  the  recently  and  chronically  HIV-infected  population 
suggests the relative fitness of specific mutations may have a major role. This 
work  demonstrates  that,  within  one  population,  there  is  a  difference  in  the 
specific  mutations  found  depending  on  the  time  the  sequence  was  taken 
relative  to  infection.    This  adds  further  evidence  of  the  potential  for  under-
detection  of  specific  drug  resistance  mutations  in  the  chronic  population.  
Consequently the use of deep sequencing or other methods to detect minority 
species should be considered for MSM who are not recently HIV-infected at 
diagnosis (Johnson, Li et al. 2008).  
Distribution of specific mutations 
The  distribution  of  specific  mutations  varied  between  infection  categories.  
Mutations  V106A,  K219E  and  V82A  were  not  observed  in  the  drug  naïve Alison Brown – Chapter Seven 
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populations,  only  in  the  treated.    Conversely,  M41L,  G73T  and  F77L  were 
observed among the drug naïve but not among the treated populations.   
 
This  analysis  demonstrates  that  the  likelihood  of  identifying  drug  resistant 
mutations is affected by the specific mutations under investigation.  It indicates 
that there is a difference in the TDR prevalence between infection categories 
but also that this may be directional to specific mutations.   The results remain 
exploratory and need to be interpreted with caution due to small sample sizes. 
7.4.2  Phylogenetic reconstructions  
Using phylogenetic reconstructions comprised of sequences from patients who 
were  diagnosed  during  recent  infection,  the  extent  of  clustering  between 
sequences from patients  with  drug  resistance  mutations  was fairly  low.    For 
CASCADE, 11% formed a cluster, for UA STI 33.3% formed a cluster and from 
Brighton (recent) 20% formed a cluster.   The sequences with drug resistance 
mutations  that  clustered  were  limited  to  K103N,  F77L,  and  G190  and  T215 
variants.  All of them shared identical mutations within clusters.   
 
Including all three datasets, the formation of a robust cluster that consisted of a 
sequence with a drug resistance mutation, and a wild-type sequence, occurred 
only three times.  Two cases occurred within the Brighton dataset and involved 
the G190 site and one occurred within the UA STI survey involving the F77L 
mutation.  The  G190  mutation  has  been  known  to  revert  after  infection 
(Bezemer, de Ronde et al. 2006).  If the phylogenetic reconstruction did not 
reflect  reality,  by  chance,  it  would  be  expected  that  a  higher  proportion  of Alison Brown – Chapter Seven 
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clusters  would  be  formed  between  wild-type  and  drug  resistant  mutations.    
Consequently this adds some support to the reconstruction.  
 
Comparing the estimated infection dates within clusters demonstrates whether 
transmission could have occurred during recent infection (section 5.2.3).  The 
one instance of a cluster containing sequences with an identical drug resistance 
mutation, identified in CASCADE could not have been generated during recent 
infection  because  there  was  a  difference  of  226  days  between  the  infection 
dates).  Cluster A could have been generated during recent infection for the UA 
survey (difference of one calendar quarter), but cluster E could not (difference 
of three calendar quarters).   For the Brighton dataset (the recently HIV-infected 
only) no transmission could have been generated during recent infection. 
 
With  the  exception  of  the  UA  survey,  there  was  no  significant  difference 
between  the  proportion  of  phylogenetic  clusters  formed  between  sequences 
with mutations compared with clusters formed between wild-type sequences.  
This suggests that patients with drug resistant viruses may not be any more 
likely  to  pass  on  their  infection  compared  to  those  infected  with  wild-type 
sequences.  This is despite those with TDR mutations being more likely to have 
been undiagnosed and more likely to be experiencing recent HIV infection.  
7.4.3  Attributes and transmission potential of patients with transmitted 
and acquired drug resistance  
With the exception of the untreated, chronic population, there was no significant 
difference  in  mean  viral  load  between  Brighton  patients  with  drug  resistant 
viruses and those with wild-type viruses, by each category.  Untreated patients Alison Brown – Chapter Seven 
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with  drug  resistant  mutations  may  be  less  likely  to  transmit  their  infection 
onwards compared to the untreated wild-type population. 
 
Patients  with  drug  resistance  mutations  were  less  likely  to  have  an  STI 
diagnosis during the study period compared to those with wild-type sequences 
(p<0.0001).   This may be because those with mutations are disproportionately 
the treated population who may have been attending treatment and care for 
long period of time and may have therefore modified their sexual behaviour.   
However,  among  the  recently  HIV-infected,  those  with  drug  resistance 
mutations may have been more likely to have STIs compared to those with wild-
type  sequences.    This  occurrence  may  be  associated  with  risk  behaviours: 
those with TDR may have acquired their infection through sex between men 
with acquired resistance.  This may suggest that HIV-infected MSM with sub-
optimal ARV adherence may be more “risky” in relation to treatment and sex. 
7.4.4  Where does TDR come from?  
Identifying  the  transmission  source  of  patients  with  recently  acquired  TDR 
allows the direction and approximate date of transmission to be ascertained.  
This in turn allows the infection stage and attributes of the likely transmission 
source to be ascertained at around the time of infection (section 5.2.3). 
 
The identified transmission sources of patients with recently acquired TDR were   
untreated  individuals,  and  those  going  through  a  period  of  treatment 
interruption.   The transmission source could not be identified for the majority of 
patients with recently acquired TDR, indicating that a substantial proportion may 
have  been  derived  from  MSM  with  undiagnosed  infection.  However,  the Alison Brown – Chapter Seven 
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unidentified transmission sources of the patients with TDR may also have come 
from diagnosed MSM with no sequence available, or MSM attending clinical 
care elsewhere.  Further limitations include the small sample size (making it 
difficult to extrapolate to the wider population) and the inability of the methods 
employed to detect minority species.   
7.5 Conclusion 
The prevalence estimates of TDR mutations found in this chapter are broadly 
consistent with other studies.  The chapter also lends further evidence that the 
relative  fitness  of  drug  resistance  mutations,  and  their  likelihood  to  be 
transmitted, is differential to specific mutations.  The refined definition of the 
recently  HIV-infected  population  and  drug  resistant  mutations  has  allowed 
improvements on the methods used in previous analyses.   
 
This chapter suggests that patients with viruses with drug resistance mutations 
do not seem any more likely to transmit their infection onwards compared with 
those with wild-type viruses.   However, those with TDR may represent riskier 
populations in terms of acquiring STIs.  The exploratory analysis suggests high 
viral  load  as  a  risk  factor for the  transmission,  including  the  transmission of 
resistant strains. It also implicates individuals with undiagnosed infection as an 
important source of TDR.  Our data therefore support earlier HIV testing and 
initiation of ARV as public health measures. Alison Brown – Chapter Eight 
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8  Chapter Eight: Discussion and conclusions 
 
 
 
 
 
This chapter describes how the thesis contributes to research and links with the 
current literature.  It also outlines the thesis limitations and describes the future 
research needed in this field.  Finally, the implications for policy and practice are 
discussed. 
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8.1 Contributions to research 
The objective of the thesis was to enhance understanding of HIV transmission 
between MSM through combining HIV pol sequences with laboratory, clinical 
and demographic information.    The specific contributions that the thesis has 
made to research are divided into two categories:  increased understanding of 
factors associated with HIV transmission and methodological developments.    
 
The thesis has contributed several findings related to HIV transmission that are 
of  public  health  importance.        Chapter  four  suggested  that  while  the 
consistency  of  phylogenetic  reconstructions  of  HIV  transmission  events  was 
broadly good, the need to interpret results with caution remains, as results are 
at  least  partially  dependent  on  the  sample  size  and  heterogeneity.  The 
phylogenetic  reconstructions  of  transmission  events  from  MSM  diagnosed 
during recent infection, as described in chapter five confirmed the recently HIV-
infected  as  an  important  group  in  generating  HIV  transmission.    Improved 
methods  in  chapter  six  demonstrated  that  the  recently  HIV-infected  are 
disproportionately  generating  onward  transmission,  with  a  rate  ratio  of  3.04 
(compared with 1 from the untreated, chronically HIV-infected). However, the 
majority of transmissions are generated by the currently untreated population – 
regardless of infection category – with the risk of transmission from the treated 
population  being  extremely  low.    Importantly,  70%  of  transmissions  were 
generated from patients with CD4 counts over 350 cells/mm
3.  Chapter seven 
provided further evidence that specific drug resistance mutations are different 
with respect to transmission risk and patients with drug resistant mutations may 
represent riskier populations in terms of acquiring STIs.  The chapter also found Alison Brown – Chapter Eight 
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that transmitted drug resistance (TDR) may be disproportionately generated by 
the undiagnosed population.    
  
The  methodological  improvements  can  be  subdivided  into  three.      Firstly,  a 
method  was  developed  to  assess  the  consistency  of  phylogenetic 
reconstructions of transmission events for public health purposes (chapter four).     
Secondly,  chapter five  demonstrated  that  previous  phylogenetic  studies  may 
have overestimated the transmission risk from the recently HIV-infected through 
failing to recognize that “recent” infection is a transient attribute: a phylogenetic 
relationship  between  sequences  from  two  patients  recently  HIV-infected  at 
diagnosis does not mean both patients were recently HIV-infected at the time of 
transmission  (Brown  2009a).  Thirdly,  on  this  basis,  an  improved  method  for 
ascertaining  risk  factors  associated  with  transmission  events  through 
phylogenetic  reconstructions  (including  recent  infection)  was  developed  in 
chapter  six.    This  method  can  be  applied  to  factors  that  may  vary  over  the 
course  of  an  individual‟s  infection  (e.g.  STI,  viral  load,  and  ARV  treatment).   
This method was applied to study the transmission of drug resistant viruses in 
chapter seven.   
8.2 How the research fits into the current literature 
The phylogenetic reconstructions presented in this thesis are compared to other 
phylogenetic reconstructions of HIV transmission events.  The specific findings 
from the reconstructions will then be discussed in the context of other relevant 
literature. 
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The  thesis  has  been  written  at  a  time  when  an  increasing  number  of 
phylogenetic  reconstructions  of  HIV transmission  events  are being  published 
(Brenner, Roger et al. 2007; Lewis, Hughes et al. 2008; Paraskevis, Pybus et al. 
2009;  Yerly,  Junier  et  al.  2009).    All  use  anonymous  datasets  so  that  it  is 
impossible  to  identify  any  individual  involved  in  a  transmission  event.  Such 
reconstructions  can  be  subdivided  according  to  their  methods.   Firstly  those 
(like  that  presented  in  this  thesis)  that  use  maximum  likelihood  methods  to 
reconstruct transmission events (Pao, Fisher et al. 2005; Brenner, Roger et al. 
2007), link such events to the patients‟ clinical and demographic information 
(usually data on recent infection at diagnosis) and explore associations between 
transmission events and the specific risk factors. As previously discussed, our 
methods are an improvement on previous methods since they take account of 
the fact that infection stages (and other risk factors) are transient and change 
over the course of an HIV infection.    
 
The  second  type  of  phylogenetic  reconstructions  use  Bayesian  methods 
(Drummond and Rambaut 2007) that permit possible transmission events to be 
“dated”  through  calibrating  nucleotide  substitution  rates  against  known  HIV 
transmission  events  (Drummond,  Ho  et  al.  2006)  using  software  such  as 
BEAST  (Bayesian  evolutionary  analysis  by  sampling  trees)  (Drummond  and 
Rambaut  2007).    Using  these  methods,  the  dates  that  certain  lineages 
appeared, or the time intervals between transmission events can be estimated 
(Lewis, Hughes et al. 2008).  
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Through  such  methods,  Lewis  et  al.  estimated  that  25%  of  transmissions 
occurred at intervals of under six months of each other, and interpreted this as 
evidence of the recently HIV-infected  driving transmission (Lewis, Hughes et al. 
2008).  While the methods are not the same as those used in this thesis, it is 
encouraging that the results are broadly consistent. 
 
Following on from the Lewis et al paper, Hughes et al. presented a paper in 
CROI 2009 of a phylogenetic reconstruction of HIV transmission events among 
heterosexuals  within  the  UK.    Using  BEAST  they  calculated  the 
intertransmission intervals and found them to be substantially longer than those 
identified among MSM (Lewis, Hughes et al. 2008).  From this they concluded 
that recent infection was not as an important driver of transmission among the 
heterosexual  population  as  it  is  among  the  MSM  population,  and  that  less 
transmission occurred within this population.  However, rather than representing 
transmission  from  the  chronically  infected,  it  may  be  that  the  longer  time 
intervals are due to the reduced probability of identifying transmission events 
among heterosexual populations; sampled MSM are more likely to be drawn 
from the same transmission networks, since more transmission occurs within 
UK for this risk group.  However, this finding is consistent with the lower rates of 
sexual partner change found among heterosexual populations (Fenton, Mercer 
et al. 2005) compared with the homosexual male population (Dodds, Mercey et 
al.  2004).    The  inclusion  of  epidemiological  and  clinical  data  through  this 
approach could have assisted with interpretation.   
 Alison Brown – Chapter Eight 
249 
A  disadvantage  of  the  Bayesian/BEAST  approach  is  its  inability  to  link 
transmission  events  to  the  attributes  of  the  patient  at  around  the  time  of 
transmission.  This is because it can ascertain ancestral transmission events 
(with no representation in the dataset) or reconstruct events that occurred while 
patients were undiagnosed (and consequently no information is known at the 
time  of  transmission).    The  only  factors  that  can  be  used  to  assist  with 
interpretation  are  the  time  intervals  between  transmissions  and  the  sources 
from which the sequences were derived.   
 
The thesis confirmed recent HIV infection as a risk factor associated with an 
increased transmission risk; the reasons for this have been well documented 
(Gray, Wawer et al. 2001; Wawer, Gray et al. 2005).  Through phylogenetic 
methods,  it  is  estimated  that  approximately  a  quarter  of  transmissions  were 
generated by MSM with recent infection; this is lower than the half estimated by 
Brenner et al. (Brenner, Roger et al. 2007).  This is partially explained through 
Brenner  et  al.  interpreting  transmission  events  between  patients  recently 
infected  at  diagnosis  as  “recent  to  recent  transmissions”,  even  though  the 
transmission events may have occurred during chronic infection (Brown 2009a).   
 
Secondly,  the  work  presented  found  that  a  substantial  proportion  of 
transmission is coming from the currently untreated, diagnosed population.   It is 
known  that  the  diagnosed  HIV-infected  population  continues  to  have 
unprotected anal intercourse (Dodds, Mercey et al. 2004; Elford and Hart 2005). 
This is to  a  greater extent  with  regular  partners and  to  a  lesser extent  with 
casual partners (Elford 2009 ISTTDR).  Additionally, those on treatment may Alison Brown – Chapter Eight 
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have unprotected sex due to a perceived reduced infectiousness (Crepaz, Hart 
et al. 2004; Elford and Hart 2005).     
 
The third main finding is that treatment reduces the risk of transmission.  It is 
well  established  that  HIV-infected  patients  who  have  been  treated  with,  and 
adhere to combinations of treatment typically achieve a suppressed viral load 
(Cu-Uvin, Caliendo et al. 2000; Vernazza, Troiani et al. 2000).  In studies of 
serodiscordant  couples  (where  researchers  study  transmission  within 
monogamous couples with different HIV serostatuses) treatment has also been 
shown  to  substantially  reduce  transmission  (section  1.1.10).    The  current 
literature  recognizes  that  treatment  greatly  reduces  transmission,  but  cannot 
state definitively that it eliminates the risk of transmission.  There have been 
instances  where  vertical  transmission  has  occurred  where  patients  have 
undergone treatment – however all mothers that transmitted had advanced HIV 
disease (EuropeanCollaborativeStudy 2005).  It has also been noted that blood 
viral load is not synonymous with genital fluid viral load. Specifically it has been 
found that among individuals who achieve undetectable blood viral load through 
ARV, viral shedding has been observed in genital fluids (Zhang, Dornadula et 
al. 1998; Neely, Benning et al. 2007). Plasma viral load only reflects the level of 
cell-free virus in the blood.  Latently infected cells might transmit infection in the 
absence  of  virus.    Consequently,  using  viral  load  as  a  definitive  marker  for 
infectivity may be inaccurate (Adelisa L. Panlilio 2005).  Finally, patients fully 
adherent  to  ARVs  may  experience  transient  low-level  viral  rebound  (blips) 
(Garcia-Gasco, Maida et al. 2008). The transmission risk from such blips is not 
clear. Alison Brown – Chapter Eight 
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8.3 Limitations 
There are several limitations to the thesis.  These relate to: the datasets used; 
the phylogenetic methods employed; the techniques used to link infection stage 
and clinical data; and the lack of behavioural data. These will be taken in turn. 
 
The selection of the specific dataset for use in phylogenetic reconstructions will 
influence the number of transmission events that potentially can be identified.  
There are additional biases to consider. For instance, every sequence included 
will  have  been  derived  from  a  patient  with  a  diagnosed  HIV  infection.  
Consequently the undiagnosed population is difficult to include (unless samples 
are obtained from Unlinked Anonymous testing).  Furthermore, the sequences 
that are selected may not be representative of the HIV-infected population: they 
may over-represent the recently HIV-infected.  This population may have been 
prompted to come forward due to a recent risk exposure, or have symptoms of 
seroconversion illness (Burchell, Calzavara et al. 2003).   They may differ in 
important  ways  to  the  HIV-infected  population  as  a  whole.    Chapter  four 
suggests  that  sample  heterogeneity  might  affect  the  accuracy  of 
reconstructions, suggesting the extent of sexual mixing within one geographic 
locality is likely to be an important factor. 
 
The limitations and concerns with phylogenetic reconstructions were examined 
in  detail  in  chapter  four.    However,  there  are  additional  problems.    The 
technique  used  only  considers  pair-wise  relationships;  there  have  been  no 
attempts to look at alternative methods of interpreting larger clusters. The size 
of the sample available is also a limitation to phylogenetic reconstructions.  It is Alison Brown – Chapter Eight 
252 
difficult to predict a sample size that would generate an interpretable number of 
phylogenetic  reconstructions.    Additionally,  phylogenetic  reconstructions  that 
use a larger number of sequences are limited by the extensive computational 
power that would be needed to undertake such analyses.  
 
The  thesis  exclusively  studies  pol  sequences  from  MSM.    Firstly,  this  is 
because,  historically,  this  population  has  tended  to  have  subtype  B  virus.  
Arguably this increases the likelihood of finding transmission events within a 
population  sample  of  sequences,  since  circulating  viruses  are  less  likely  to 
contain  viruses  acquired  abroad.    Secondly,  the  analyses  frequently  include 
infection  stage,  derived  from  laboratory  algorithms.    These  have  been 
developed and validated with subtype B (Janssen, Satten et al. 1998), however   
use of the avidity assay means the serological testing algorithm for recent HIV 
seroconversion  (STARHS)  can  now  be  applied  to  heterosexual  populations 
(Suligoi,  Butto  et  al.  2008).    With  approximately  half  of  the  HIV-infected 
population comprising heterosexuals, many of whom are infected with non-B 
virus, there is a need to see if the results are also applicable to this population.  
    
The greatest limitation of the thesis is the lack of behavioural data.  Sexual risk 
behaviour is likely to have a vital role in mitigating the effect of patient infectivity; 
transmission cannot occur without an exposure event.   Behaviour is known to 
vary  between  diagnosed  HIV  positive,  undiagnosed  HIV  positive  and  HIV 
negative men, and also with respect to whether partners are casual or regular 
(Dodds, Mercey et al. 2004).     Elford et al. (ISSTDR 2009) found that UAI was 
more likely to occur between MSM in stable relationships. This has important Alison Brown – Chapter Eight 
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implications  both  in  terms  of  interpretation  of  phylogenetic  reconstruction 
events,  and  also  for  prevention  messages.  Markers  of  sexual  behaviour 
linkable  to  HIV  sequences  are  needed  to  assist  with  the  interpretation  of 
transmission rates by infection category. Patterns of sexual mixing would also 
facilitate interpretation (e.g. gauging the extent that sexual mixing is random).   
8.4 Future research 
Two main areas of further research are needed.  Chapter six indicated that the 
recently HIV-infected are disproportionately likely to generate infection, and that 
transmission is unlikely to occur from the treated population with suppressed 
viral load.  It is important to determine whether these results can be replicated in 
other  settings,  or  whether  the  results  are  applicable  to  Brighton  MSM  only.  
Investigation is required among heterosexual populations in particular; this is 
now possible since avidity assays used in conjunction with STARHS, enables 
recent infection to be consistently identified regardless of subtype (Suligoi, Butto 
et al. 2008).  The Health Protection Agency is rolling out incidence tests for 
every new HIV diagnosis made in the UK.  This will increase the availability of 
infection  category  data  linkable  to  HIV  pol  sequences  nationally.    Further 
analyses should also attempt to integrate behavioural data to the sequences 
from patients to assist with interpretation.  The integration of sexual behaviour 
could help in three ways: patterns of sexual behaviour by infection category 
would help adjust the transmission risks from each category; linking markers of 
risky sexual behaviour to patients from whom the sample was obtained would 
help to ascertain the extent to which infectivity, and the frequency of exposure 
events,  are  drivers  of  transmission;    and  the  inclusion  of  sequences  from 
patients with known transmission histories to inform the phylogenetic accuracy.  Alison Brown – Chapter Eight 
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It  is  also  important  that  further  work  is  undertaken  to  develop  phylogenetic 
methods that can be applied appropriately for public health purposes. Further 
work is needed to improve definitions of what constitutes a definite transmission 
event (particularly with regard to heterogeneity).  Work is needed to generate 
some measure of the degree of error that can be expected from population level 
phylogenetic reconstructions. 
8.5 Implications for policy and practice 
There  are  two  main  implications  for  policy  and  practice:  the  need  for  the 
recently HIV-infected to be targeted for testing; and the possibility that wide-
spread treatment for HIV could be used to prevent transmission from the HIV 
diagnosed population.  
 
The obvious solution to the disproportionate level of transmission arising from 
the recently HIV-infected is to encourage testing in this population.  However, 
this is not necessarily easy to achieve.   Work undertaken using data from the 
Unlinked Anonymous (UA) sexually transmitted infection (STI) survey, but not 
presented in the main part of the thesis, looked at the rate of HIV testing by HIV 
status, by STI presence and, for the HIV-infected,  and whether the infection 
was recently or non recently acquired.  Between 1999-2002 more than half of 
recently  HIV-infected  MSM  and  nearly  80%  of  all  undiagnosed  HIV-infected 
MSM  with  an  STI  did  not  receive  HIV  tests  (Brown,  Murphy  et  al.  2009b) 
(Figure 8.1).  The rate of HIV test uptake has since increased from 45% in 1996 
to 86% in 2007.    However, in the same year it was measured at 42% among 
the  HIV-infected  with  an  STI  and  63%  among  the  recently  HIV-infected.  
Therefore despite an increased voluntary confidential HIV testing (VCT) uptake Alison Brown – Chapter Eight 
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generally,  a  substantial  proportion  of  those  at  highest  risk  of  onward 
transmission left the clinic remaining undiagnosed.    
Figure 8.1: Proportion of MSM attending sentinel STI clinics survey receiving voluntary 
confidential HIV testing, by diagnosis status,   UA survey:1999-2002. 
 
 
 
 
 
 
 
 
 
 
Source: (Brown, Murphy et al. 2009b) 
The reason for poor VCT uptake among the recently HIV-infected may have 
been due to a practice exemplified in older BASHH guidelines (BHIVA 2006) 
that suggested that recently HIV-exposed patients receive two HIV tests: one 
immediately and one 3 months after exposure (the “three month rule”).  This is 
because  of  concerns  that  HIV  testing  shortly  after  exposure  may  not  yield 
accurate results.  However, recent improvements in HIV test sensitivity mean 
that the latest (so-called „fourth generation” tests) can detect both anti-HIV and 
HIV  p24  antigen  within  four  weeks  of  infection  (Busch,  Glynn  et  al.  2005). 
However, delaying the second test for three months may be detrimental; it will 
include  a  subset  of  MSM  with  recent  infection  remaining  unaware  of  their 
infection at a time when they are highly infectious.  A BASHH audit found that 
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the most commonly cited reason for not receiving VCT was deferral because of 
concerns relating to the accuracy of HIV testing shortly after exposure (Munro 
2007).  The rate of reattendance for the second test was low.   The BASHH 
guidelines have since been updated to include every patient attending, including 
the targeting of those with recent risk exposure (Gazzard 2008). 
  
This suggests that VCT may be limited in its ability to prevent HIV transmission.  
An  alternative  solution  may  be  to  target  those  with  seroconversion  illness 
presenting  at  settings  outside  of  STI  clinics.    This  has  been  found  to  be  a 
feasible  practice  in  Brighton,  achieved  through  raising  awareness  of 
seroconversion illness symptoms (and its association with elevated infectivity) 
among  health  care  workers  and  among  MSM  at  risk  in  areas  of  high  HIV 
prevalence (Sudarshi, Pao et al. 2008) (Fox, White et al. 2009).   
 
Secondly,  the  finding  that  treatment  is  protective  of  transmission  risk  adds 
further weight to the argument that treating the entire diagnosed HIV-infected 
population  could  substantially  impact  on  reducing  transmission.      In  recent 
times,  the  possibility  has  been  considered  that  wide-spread  treatment  could 
prevent HIV transmission from the diagnosed population.  In 2008, the Swiss 
federation on HIV and AIDS published a controversial paper stating that HIV 
serodiscordant heterosexual partners may have unprotected sex, provided the 
infected partner is ARV treated with viral load <40 copies/mL (Vernazza 2008).   
 
Table 8.1 presents viral load by treatment for MSM attending care services in 
the  UK  during  2005-7  (SOPHID,  personal  communication).    The  table Alison Brown – Chapter Eight 
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demonstrates the elevated viral load among the untreated population. It can be 
seen  that  in  2007,  almost  one  third  of  the  diagnosed  HIV-infected  MSM 
population  were  untreated,  with  a  viral  load  over  10,000/mL;  this  level  was 
found  to  be  associated  with  an  increased  transmission  risk  in  chapter  six.  
Treatment  of  this  population  could  therefore  substantially  impact  upon 
transmission at the population level. 
 
However, the Swiss report has been criticized as inconclusive and dangerous, 
jointly by the World Health Organization and UNAIDS (UNAIDS 2008), and the 
American Centers for Disease Control (CDC 2008). The mass treatment of the 
diagnosed population is controversial for several reasons.  Firstly, it cannot be 
ascertained definitively that patients fully adherent to treatment will have their 
risk  of  transmission eliminated.    Even  if patients achieved undetectable  viral 
load in their blood, it does not mean that their genital fluid will also  have an 
undetectable viral load.   For instance, a recent paper (Sheth, Kovacs et al. 
2009) demonstrated that among 25 HAART treated HIV positive MSM, blood 
viral  load  was  undetectable  in  all  subjects  by  week  16;  however,  HIV  RNA 
shedding was detected in semen among 12/25 subjects, and at a high level 
(>5000 copies/mL) in 4 of the 25.      Secondly, even if treatment was 100% 
efficacious in preventing transmission, it cannot be guaranteed that patients will 
fully adhere to treatment.   Thirdly, there are concerns about the mass treatment 
of patients, regardless of clinical need.  This is because of the side effects for 
the  patients,  but  also  it  increases  the  risk  of  acquiring  drug  resistance.   
Fourthly,  mass  treatment  among  the  diagnosed  population  will  ignore  the 
transmission risk from the undiagnosed population, an elevated proportion of Alison Brown – Chapter Eight 
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whom  will  be  experiencing  recent  HIV  infection.      However,  if  large-scale 
treatment  is  successful  in  reducing  transmission,  the  proportion  of  the  HIV-
infected population who are recently HIV infected should diminish.  
 
In  late  2008,  Wilson  et  al.  (Wilson,  Law  et  al.  2008)  published  an  exercise 
based on modelling transmission risks at certain viral loads to ascertain the risk 
of transmission from HIV-infected patients over a prolonged period.  Assuming 
monogamous serodiscordant relationship with 100 sexual encounters per year, 
for MSM they calculated a transmission risk of 0.043 per sex act.  While this 
seems low, they point out that this translates as of 10,000 HIV negative MSM 
exposed to HIV each year, 3524 would become infected per year.   In 2009, 
Granich et al. published a mathematical model that demonstrated that universal 
VCT in combination with immediate ARV could reduce HIV incidence within 10 
years, and drive global prevalence to less than 1% within 50 years (Granich, 
Gilks  et  al.  2009).  A  recent  meta-analysis  of  HIV  transmission  risk  through 
unprotected sexual intercourse by ARV and/or viral load found that there are 
few studies that examine the effect of ARV and viral load (Attia, Egger et al. 
2009)  on  transmission.    However,  on  the  limited  data,  it  concluded  that  the 
overall HIV transmission rate in the presence of ARV was around 0.5 per 100 
person years – substantially higher than that presented in this thesis  (Table 
6.4).    While data are lacking, preliminary results show the risk of transmission 
from  the  treated  population  cannot  be  eliminated.  A  randomized  control  trial 
(START) has been launched by the US National institutes of Health to ascertain 
the magnitude and durability of the benefits of early treatment to prevent HIV Alison Brown – Chapter Eight 
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transmission between  serodiscordant couples in practice (Cohen, Mastro et al. 
2009; De Cock, Gilks et al. 2009). 
Table 8.1: Viral load by treatment status among diagnosed HIV-infected MSM attending 
treatment  services,  UK:  2005-2007Table  8.2:  Viral  load  by  treatment  status  among 
diagnosed HIV-infected MSM attending treatment services, UK: 2005-2007 
viral load/mL   ARV level  2005  2006  2007  Grand total 
<50  None  163  229  343  1069 
   Mono  25  64  78  333 
   Dual  74  112  170  596 
   Triple  430  678  886  3172 
   Quadruple +  207  310  453  1589 
   Not known  15  130  70  218 
50-999  None  1115  1757  1881  6051 
   Mono  61  107  95  361 
   Dual  125  223  199  688 
   Triple  1615  2430  2772  9093 
   Quadruple +  774  1285  1271  4271 
   Not known  27  252  60  339 
1000-9999  None  2696  4507  4506  14666 
   Mono  26  50  34  135 
   Dual  29  55  54  168 
   Triple  657  944  870  3101 
   Quadruple +  306  445  369  1356 
   Not known  34  415  148  598 
10000-99999  None  4062  6315  6415  20514 
   Mono  29  42  27  117 
   Dual  33  81  62  206 
   Triple  714  1020  1024  3452 
   Quadruple +  288  431  383  1317 
   Not known  59  713  232  1005 
>100000  None  1256  1955  1738  5997 
   Mono  10  18  20  60 
   Dual  17  38  20  88 
   Triple  425  609  564  1961 
   Quadruple +  171  285  237  837 
   Not known  23  199  96  320 
Not known  None  201  153  168  750 
   Mono  50  19  33  123 
   Dual  69  31  70  198 
   Triple  217  167  180  756 
   Quadruple +  156  89  146  510 
   Not known  58  53  84  206 
Grand Total     16217  26211  25758  86221 
 Source: Personal communication, SOPHID 
Whilst  this  debate  needs  to  continue,  it  also  needs  to  become  more 
sophisticated.    It  is  likely  that  the  risk  of  transmission  cannot  be  eliminated Alison Brown – Chapter Eight 
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through treatment, but this needs to be weighed against the very real reductions 
that  could  be  achieved  through  wide-spread  treatment,  regardless  of  clinical 
need.     Instead debate should focus upon what threshold of transmission risk 
from the treated population is acceptable.  If such a threshold can be agreed 
upon, it is equally important to consider what level of monitoring of viral load 
and  therapy  adherence  would  be  necessary  to  ensure  that  the  risk  of 
transmission remains below this threshold.  Considerations should also include 
the  feasibility  and  cost  benefits  of  implementing  such  a  monitoring  system 
among  the  UK  HIV-infected  population.      In  the  meantime  behavioural 
interventions  should  promote  awareness  of  the  elevated  transmission  risk 
among the untreated, diagnosed population. 
8.6 Thesis conclusions 
The combination of sequence based, laboratory and clinical data can provide 
more  insight  into  HIV  transmission  than  can  be  gleaned  from  each  source 
considered  individually.    The  thesis  has  confirmed  recent  infection  as  an 
important risk factor in causing onward HIV transmission and provided further 
evidence for the debate of whether population level treatment of the diagnosed 
population – regardless of an individual‟s clinical need – should be implemented 
for  public  health  purposes.    There  is  a  very  real  need  for  behavioural 
interventions  targeted  both  at  the  at-risk  HIV  negative  population  (promoting 
awareness of elevated infectivity during seroconversion) and among the HIV 
diagnosed  population  (particularly  emphasizing  the  increased  transmission 
potential among the untreated population).  The phylogenetic approach remains 
in its infancy and it is essential that methods continue to be assessed rigorously 
and results be interpreted with caution. Alison Brown – Appendices 
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10 Appendix B - Consent letter for Brighton dataset 
Lawson Unit 
Department of GU Medicine 
Eastern Road 
Brighton 
BN2 5BE 
 
Study title:   Understanding HIV transmission in men who have sex with men 
 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss 
it with others if you wish. Ask us if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not you wish to 
take part. Thank you for reading this. 
 
1. What is the purpose of the study? 
We are seeing a worrying increase in the number of new cases of HIV infection 
diagnosed in the UK, and the reasons for this are not clear. The aim of this 
study is to find out which factors contribute to this increase, and to use this 
knowledge to help stop more people becoming infected and in turn reduce the 
growth  of  the  HIV  epidemic.  What  we  know  so  far  suggests  that  patients 
recently  infected  with  HIV  (i.e.  within  12  months)  are  much  more  likely  to 
transmit the virus to another person (when there is a much higher level of HIV in 
the semen or vaginal secretions). This perhaps begins a chain of infection that 
grows wider and larger with time. Crucially, most people with early HIV have no 
indication that they are infected and feel perfectly well, and so will not be aware 
of the risk of infecting others. Thus, recognising people who may be at risk of 
early HIV infection may be very useful in preventing the transmission of HIV and 
thus prevent a much larger number of people being infected. 
 
2. Why have I been chosen? 
You are being invited to take part in this study because you are HIV positive, 
over 16 years of age and attend the Lawson Unit regularly. In order to carry out 
this research, we need to take an additional blood sample from you.  
 
3. Do I have to take part? 
It is up to you to decide whether or not to take part. If you decide to take part, 
you will be given this information sheet to keep and be asked to sign a consent 
form. A decision not to take part will not affect in any way the standard of care 
you receive. 
 
4. What will happen to me if I take part? 
If you agree to join the study and sign the consent form at the back of this 
leaflet, the study doctor will then ask you to provide a sample of blood (10 ml). 
The blood sample will be obtained during your clinic visit.  
 Alison Brown – Appendices 
267 
 The  virus  contained  in  this  blood  sample  will  be  analysed*  to  identify  any 
potential resistance you may have to anti-HIV drugs.  This can help in deciding 
the best treatment choice for you, if and when you need to start HIV treatment  
 
We would also like to look for similarities and differences that exist between 
different individuals‟ virus samples.   If viruses from people who were recently 
HIV-infected are very similar, this may show that recently infected people may 
be more likely to infect others.   We should have completed the testing of all 
samples by July 2007.  
 
5. What are the possible disadvantages and risks of taking part? 
The blood samples we ask you to provide, about a couple of teaspoonfuls, may 
cause some discomfort and/or bruising.   
 
6. What if something goes wrong? 
 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements.  If you are harmed due to someone‟s negligence, 
then you may have grounds for a legal action but you may have to pay for it.  
Regardless of this, if you wish to complain, or have any concerns about any 
aspect of the way you have been approached or treated during the course of 
this study, the normal National Health Service complaints mechanisms should 
be available to you. 
 
7. What are the possible benefits of taking part? 
Your participation will increase our knowledge of how HIV is transmitted within a 
population and will help us to develop ways of slowing or halting the epidemic.   
If we find that your virus is resistant to some anti-HIV drugs we will feed this 
back to you and it will help us make better decisions about your future anti-HIV 
treatment. 
 
 
8. Will my taking part in this study be kept confidential? 
 
Yes, we can guarantee that you will remain unidentifiable at any time during the 
study  or  after  study  completion.  Confidentiality  and  anonymity  will  be  highly 
protected, as follows.  
 
Your  blood  sample  will  be  sent  to  the  laboratory  for  genotypic  resistance 
analysis.  The analysis will show whether your virus is resistant to any anti-HIV 
drugs.  The results of this analysis will be fed back to you and will be included in 
your clinic notes.  This will help us make better decisions about your future anti-
HIV treatment. 
 
We will then use the genotypic resistance analysis results for a study to see 
what factors are important in causing HIV transmission.  Before we start this 
study will give your genotypic resistance analysis results an anonymous study 
number and delete any information that identifies you. 
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We will also take some very limited information from your clinic records to help 
interpret  your  resistance  analysis  results  –  no  information  will  be  taken  that 
could identify you directly or indirectly. 
 
The resistance analysis results and the limited clinical data will be sent to an 
independent  centre  (Health  Protection  Agency)  together  with  an  anonymous 
study number.   
 
The Health Protection Agency will examine what factors are shared by viruses 
that are very similar to each other.  It will be impossible to identify any individual 
throughout the duration of the study. 
 
 
9. What will happen to the results of the research study? 
Before the main analysis, your virus will be tested (genotypic resistance testing) 
to see if there are any drugs it is resistant to.  These results will be fed back to 
you. 
 
The main study looking at virus similarity  will  not be feedback to you as an 
individual  since  the  data  are  completely  anonymised  before  the  analysis  is 
carried out.   
 
Similarly, neither Brighton HIV services nor the laboratory will be informed of 
individual results,  
 
The overall results of the study will be made available to you at its conclusion, 
and may be published in a medical journal,  
 
10. Contact for further information 
 
You may ask questions about this study at any time.  If you have any questions 
about  the  informed  consent  process  or  you  require  any  further  information, 
please contact your regular clinic doctor. 
 
Alternatively you can contact Dr Martin Fisher who is the principal researcher 
for this project. 
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Title of Project:   Understanding HIV transmission in men who have sex with 
men 
 
Patient Identification Number for this trial: 
 
Name of Researcher: Dr Martin Fisher 
 
Please initial box 
 
1.  I  confirm  that  I  have  read  and  understand  the  information  sheet 
dated 27th November 02                
  (version 1.1) for the above study and have had the opportunity to ask 
questions.   
 
2.  I  understand  that  my  participation  is  voluntary  and  that  I  am  free  to 
withdraw at any time,                 
  without giving any reason, without my medical care or legal rights being 
affected. 
 
3.  I  understand  that  sections  of  my  medical  notes  may  be  looked  at  by 
researchers                    
  from  the  Lawson  Unit  as  is  relevant  to  my  taking  part  in  research.  I 
understand that my  identity will remain unknown to the researchers at all times, 
up to and including the  conclusion of the research. No data collected from 
the notes will relate either directly or  indirectly  to  my  identity.  I  give 
permission for these individuals to have access to my records. 
 
4.    I agree to take part in the above study.         
                       
       
________________________  ________________ ____________________ 
Name of Patient  Date    Signature 
 
_________________________  ________________ ____________________ 
Name of Person taking consent  Date    Signature 
(If different from researcher) 
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11 Appendix C - Life histories of transmission sources with 
estimated transmission dates 
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